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Su m m a r y
The regulation of monocyte cytokine production is critical to the pathogenesis of 
diseases such as rheumatoid arthritis (RA). In particular, the balance between the 
production of pro- and anti-inflammatory cytokines by mononuclear phagocytes 
within the rheumatoid synovium may modulate tissue degradation and joint 
destruction.
The studies of this thesis have shown that monocyte production of TNFa, IL-6, 
OSM, IL-lp and IL-lra are differentially regulated by intracellular cation levels. 
Inhibition of the Na7K+-ATPase, which in the synovium may be due to oxidative 
damage, has been shown to greatly contribute to the generation of a pro- 
inflammatory cytokine profile from stimulated monocytic cells. The specific Na7K+- 
ATPase inhibitor ouabain has been shown to increase IL-lp processing in monocytes 
stimulated with LPS, or viable activated T cells, and to concurrently down-regulate 
IL-lra production. The mechanism of action of ouabain in these models may well 
involve increased activation of ICE, due to K+ efflux and indeed it has been shown 
that increased concentrations of ouabain can induce both apoptosis and necrosis in 
monocytes
The ability of T cells to regulate production of IL-lp and IL-lra from neighbouring 
monocytes may be an important mechanism in the pathogenesis of RA. The models 
studied here have shown that fixed T cells were able to induce the secretion of both 
IL-lp and IL-lra from resting monocytes, perhaps due to surface CD69 expression, 
but that the balance in cytokine production was not consistently driven in a pro- or 
anti-inflammatory direction. Monocytes stimulated with viable T cells, however, 
produced a markedly increased amount of IL-1 p, implying that T cell derived soluble 
factors may be more important in driving a pro-inflammatory cytokine response from 
monocytes. The balance between production of IL-lp and IL-lra from monocytes 
has also been shown to be differentially regulated by FcR aggregation and LPS 
stimulation. The pathways that are specific to signals induced by these stimuli remain 
to be determined but evidence here supports the involvement of PI3-K in T cell-, 
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This thesis will examine the differential regulation of monocyte-derived cytokines 
and explore pathways of monocyte activation that may be important in the 
pathogenesis of inflammatory diseases such as rheumatoid arthritis (RA). It is now 
more apparent than ever that the outcome of an immune response is not controlled by 
single cytokine signals but the complex orchestration of multiple protein mediators. 
With time, more and more evidence is being gathered to show multiple functions for 
many cytokines, with some clearly having both pro- and anti-inflammatory roles in 
the immune response. Amidst this confusion, however, at the end-point of a 
misdirected immune response, certain monocyte-derived cytokines have been clearly 
identified as being instrumental in the tissue damage and destruction caused in RA. It 
is these mediators that are studied here and this introduction will endeavour to detail 
the current knowledge of their regulation and roles in RA.
1.1: The Monocyte-Macrophage Cell lineage
Originally, monocytes and macrophages were classified as cells of the reticulo­
endothelial system. Van Furth et al. (1972) (1), however, proposed the mononuclear 
phagocyte system, and monocytes and macrophages became basic cell types of this 
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Stem cells committed to differentiation into mononuclear phagocytes pass through at 
least two readily identifiable morphological steps in the bone marrow, namely 
monoblasts and pro-monocytes. These cells undergo a series of programmed
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divisions to form monocytes, which after release from the bone marrow into blood, 
circulate for one to three days before migrating into various extravascular 
compartments. Monocytes do not undergo further division after entering the 
bloodstream. Rather, their emigration into various tissues and organs is marked by 
pronounced morphological and functional differentiation, sometimes characteristic of 
their location. Mononuclear phagocytes are extremely pleiotypic in that they can 
undergo a complex series of differentiation processes in order to adapt to a particular 
environment, e.g. osteoclasts in bone and Kupffer cells in the liver, and be receptive 
to multiple signals from other elements of the host defence system.
Under steady-state conditions of health, traffic of monocytes in and out of the 
circulation occurs at a relatively slow rate. The turnover of mononuclear phagocytes 
increases rapidly when the host encounters an inflammatory stimulus or infectious 
agent. Under these conditions humoral factors are generated which stimulate the 
formation of monocytes in the bone marrow and their release into the bloodstream 
with accumulation at the sites of inflammation and infection occurring within twelve 
to twenty-four hours after the initial influx of neutrophils. The newly recruited 
monocytes undergo rapid differentiation to facilitate the recognition and removal of 
the inflammatory or infectious stimuli.
Once monocytic cells have entered the inflamed tissue it is believed that they do not 
re-circulate. Under conditions of inflammation, therefore, inflammatory mediators 
present in the joint may induce local differentiation and activation of the invading 
monocytes causing increased inflammatory responses and the formation of 
granulomas. In RA granulomas consisting of epitheloid and giant cells are often 
found in the synovial tissues and also in rheumatoid nodules.
Cytokines play critical roles in controlling the differentiation of the 
monocyte/macrophage system. For example, TNFa inhibits differentiation of 
monocytes into macrophages and, together with granulocyte-macrophage colony 
stimulating factor (GM-CSF), directs the precursor cells to differentiate into dendritic 
cells (2-4), which are potent professional antigen-presenting cells (5,6). Another 
branch of the monocyte differentiation system is the formation of osteoclasts, which 
greatly contribute to bone destruction in RA (7).
The presentation of (auto) antigens to synovial T cells could be a major mechanism 
by which cells of the macrophage/monocyte family contribute to the perpetuation of
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inflammatory joint disease. Class II MHC-positive antigen presenting cells may be 
involved in central initiation of auto-immunity due to their ability to educate T cell 
responses in the thymus in the development of self-tolerance (8). Also, there is 
evidence that mononuclear phagocytes are capable of presenting antigen in the 
synovial membrane. Besides the expression of class II MHC molecules, molecules 
such as CD40, CD54, CD80 and CD86 (9-11), and intracellular adhesion molecule 3 
(12) have been detected on synovial monocytes/macrophages. These molecules exert 
important cognate functions in antigen recognition, defined as signal 2, without 
which T cell anergy occurs.
The significance of antigen presentation in the rheumatoid synovium has been 
questioned due to the lack of unequivocal evidence of oligoclonal T cell expansion 
and the failure to detect definitive candidate auto-antigens. On the other hand, it is 
not clear which cell is most relevant for the processing of a putative antigen, since 
synovial fibroblaj^ and chondrocytes are also capable of presenting antigen in vitro 
(13,14). In addition, the specific accumulation of well-differentiated dendritic cells in 
rheumatoid synovium has been recently confirmed (15). Various candidate auto­
antigens have been proposed in RA, including heat shock proteins, cartilage link 
protein and other proteoglycans (reviewed by Moots and Wucherpfennig (16)). The 
most compelling evidence supports the role of type II collagen as a possible auto­
antigen in RA and studies have shown that T cells reactive to type II collagen may 
exist in patients with RA (17).
The precise role played by monocyte/macrophages in the induction of RA remains an 
area of debate. One thing that is certain, however, is that monocyte derived cytokines 
dominate the cytokine profile in inflammatory synovitis. In RA, activated 
macrophages are enriched in the synovium and are also found in strategic sites within 
the destructive pannus tissue (18,19). In addition, macrophages and circulating 
monocytes secrete large quantities of prostanoids and cytokines (20-22), and 
peripheral blood monocytes show increased phagocytic activity (23). The expression 
of CD 14, FcyRI and FcyRII have been shown to be upregulated on the surface of 
peripheral blood monocytes from patients with active RA. Interestingly, FcyRI and 
FcyRII expression on monocytes from RA patients who were in complete remission 
were still seen to be upregulated whereas CD 14 expression had dropped (24).
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To understand the role played by monocytes in the pathogenesis of RA a brief 
description of the disease will follow.
1.2: Rheumatoid Arthritis
Rheumatoid arthritis is predominantly an articular inflammatory disease with 
considerable evidence of abnormal mononuclear cell activity. The inappropriately 
self-directed (autoimmune) inflammatory response results in chronic synovitis, 
infiltration, accumulation and persistent activation of lymphocytes and mononuclear 
phagocytes, which leads to subsequent tissue damage. Breakdown of articular 
cartilage and eventual bone erosion results in crippling deformation of the synovial 
joints. Although the most apparent pathology of RA is seen throughout the synovial 
joint other major organs are affected and systemic features include vasculitis, nodule 
formation and splenomegaly.
The aetiology of RA remains obscure but may involve the inappropriate recognition 
of endogenous self-antigens, such as collagen, mucopolysaccharides and rheumatoid 
factors or exogenous agents such as mycoplasma, mycobacteria and viruses. 
Interestingly, there is a threefold predominance of RA in females, which may 
indicate the involvement of hormonal factors, and there is also a clear genetic 
contribution to the disease contained within the HLA class II locus. There is a shared 
epitope on one side of the peptide binding groove of HLA-DR, comprised of the 
amino acids 70-74 of the P chain, which is conserved between the disease susceptible 
DR1 and DR4 haplotypes (25). Greater than 80% of Caucasian RA patient’s display 
this epitope supporting the concept that T lymphocyte antigen recognition is an 
important factor at some stage in the pathogenesis of the disease. However, the 
involvement of non-genetic factors in RA pathogenesis is undisputed due to the 
discordance in the development of RA in identical twins (26).
Most patients with RA have circulating soluble materials with the characteristics of 
immune complexes and the existence of autoantibodies and immune complexes in 
RA has been recognised for several decades (27,28). Anti-y-globulins of the IgG and 
IgM classes and IgG itself are integral parts of these soluble complexes. Whether 
these immune complexes are responsible for vasculitis or for the other extra-articular 
features or are merely markers for severe disease (29) remains a question for debate.
Chapter 1: Introduction - 5 -
The rheumatoid synovium makes and contains a large amount of immunoglobulins 
(Ig’s) although relatively few plasma cells are present. Plasma cells in the 
subsynovium primarily produce IgG and 20% of the IgG in the synovial fluid is 
produced in the synovium (reviewed by Maini 1987 (30)). The majority of the IgG in 
the synovial fluid is anti-IgG. In most cases the majority of IgM present in the 
synovium is rheumatoid factor (RF). Rheumatoid factors are defined as antibodies 
specific to antigenic determinants on the Fc fragments of human or animal 
immunoglobulin G. In RA the increased Ig production could be a result of B cell 
hyperreactivity due to excessive helper T cell stimulation or due to insufficient 
inhibition by suppressor T cells, either as a result of decreased numbers or 
compartmental exclusion. The IgG-anti-IgG produced by plasma cells form self 
associated intermediate sized complexes which go on to activate the complement 
cascade. These complexes can further stabilise by associating with IgM-RFs and 
other moieties such as anti-f(ab)'2, anti-fibrinogen and collagen-anti-collagen 
complexes. Rheumatoid factors have often been linked with more severe disease, 
sero-negative patients often having characteristics of juvenile RA and more 
asymmetric joint involvement (31,32). In sero-positive RA increased severity of 
disease is also linked to HLA DR4 (33), HLA DR1 (34) or both.
1.2.1: Pathogenesis of RA
The inflammatory response seen in RA is characterised by vasodilatation induced by 
inflammatory mediators such as PGE2, PGI2, the complement component C3a, 
substance P and calcitonin gene-related peptide (CGRP) from sensory C fibres and 
nitric oxide (NO). Endothelial cell damage and increased expression of cell surface 
adhesion molecules such as ICAM-1 and ICAM-2 combined with the release of 
chemotactic factors such as LTB4, IL-8 and C5a leads to vascular leakage and 
oedema. MCP-1 and MIP-la have been identified as likely C-C chemokines 
responsible for the recruitment of mononuclear cells into the inflamed synovium (35- 
37). Immunoreactive MCP-1 and MIP-la were found to be significantly elevated in 
both synovial fluid and serum of patients with RA. Immunolocalisation showed that 
both synovial tissue fibroblasts and macrophages constitutively expressed MCP-1 
and MIP-la. Both chemokines were expressed by cells of the macrophage-rich 
synovial lining layer from patients with RA, whereas normal synovial tissue
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displayed little expression. Macrophages within the subsynovial lining of patients 
with RA were also highly immunopositive for both MCP-1 and MIP-la. Additional 
studies demonstrated that cultured synovial fibroblasts constitutively expressed 
MCP-1, which was markedly enhanced by the addition of IL-1, IL-4 or IFNy (38). 
The chemotactic gradients generated favour the infiltration of PMNs initially but 
changes in endothelial adhesion molecule expression and mononuclear cell surface 
integrin expression then favour the infiltration of mononuclear cells. Accumulating 
monocyte/macrophages maintain the inflammatory reaction due to the release of 
powerful pro-inflammatory cytokines such as IL-lp and TNFa. The normally 
acellular synovial fluid becomes predominantly enriched with neutrophils, but T 
lymphocytes, mononuclear phagocytes and dendritic cells are also found. The 
increased accumulation of cells is most obvious in the synovial membrane, where an 
increase from 1-2 cells to 6-8 cells is seen in the thickness of the joint lining layer, 
with activated resident monocyte/macrophages (often referred to as type A 
synoviocytes) and T cells predominating. Plasma cells, dendritic cells and activated 
fibroblasts are also found in abundance in the inflamed synovium and the cell surface 
phenotypes found favour antigen presentation. Synovial hyperplasia and pannus 
formation, which is characterised by extending villi of inflamed synovium that 
intrude upon the articular cartilage, involves many cytokines and growth factors 
provided by the ongoing inflammatory reaction within the joint, and it is at this 
junction between the pannus and the articular cartilage that the most tissue 
destruction occurs. The type A synoviocytes, present in the invading pannus, have 
numerous lysosomes and vacuoles with relatively small amounts of endoplasmic 
reticulum, resembling monocyte/macrophage-like cells that are active in both 
phagocytosis and secretion of proteolytic enzymes. Activated neutrophils and 
macrophages that infiltrate the joint release enzymes that lead to cartilage 
destruction. Inappropriate activation of osteoclasts can then lead to destruction of the 
bone (39).
The destruction of cartilage seen in RA is now considered to be mostly due to the 
activity of matrix metalloproteinases (MMP’s), enzymes produced by activated 
macrophages and fibroblasts in response to pro-inflammatory cytokines such as IL-1 
and TNFa. These enzymes are synthesised and secreted as latent molecules, with 
activation induced by the proteolytic cleavage of a regulating pro-peptide domain. In 
RA two of the principal MMP’s involved, whose production has been shown to be
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increased, are collagenase (MMP-1) and stromelysin (MMP-3) (40). The tissue 
inhibitors of metalloproteinases (TIMP’s), that irreversibly bind the active MMP 
forming an inactive heterodimer provide further regulation of the MMPs. 
Interestingly, TIMPs are produced by the same cells that produce MMPs indicating 
the fine balance that their regulation must depend upon. The competition between the 
production of MMPs and TIMPs could be critical in the regulation of matrix turnover 
and the outcome of diseases such as RA. It has been shown that certain 
immunomodulatory and anti-inflammatory cytokines such as transforming growth 
factor p (TGFP) and IL-10, not only depress the production of certain pro- 
inflammatory cytokines that induce MMPs, but also induce the production of TIMPs 
(41).
Rheumatoid synovitis is thus characterised by an exudative phase, involving the 
microcirculation and lining cells of the synovium, that allows an influx of plasma 
proteins and cellular elements into the joint and a chronic inflammatory phase 
featuring mononuclear cell infiltration into the subsynovium. The exact role of T 
lymphocytes and monocyte/macrophages in the initiation and progression of 
synovitis remains somewhat unclear (42,43). The involvement of monocyte derived 
cytokines, such as IL-1, granulocyte/macrophage-colony stimulating factor (GM- 
CSF), IL-8, platelet derived growth factor (PDGF), transforming growth factor a  
(TGFa), TGFp, IL-6 and TNFa, however is undisputed. Local synthesis of IL-la, 
IL-lp and TNFa in rheumatoid synovium as well as increased levels of these 
cytokines in the synovial fluid has been well documented in RA (22,44-46). These 
cytokines are just a few among the many that are important in regulating the immune 
response but their powerful pro-inflammatory activity and undoubted involvement in 
inflammatory disease make them the focus of much research.
1.2.2: Pro-inflammatory cytokines
Many pro-inflammatory cytokines are involved in the control of inflammatory 
reactions and the pathogenesis of chronic inflammation but perhaps the most relevant 
to RA are TNFa and IL-1 p. Consequently, TNFa and IL-ip will be discussed in 
greater detail in following sections but here the intention is to introduce other pro- 
inflammatory cytokines that play a part in the pathogenesis of RA.
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IL-1 p and TNFa protein is readily detected in the rheumatoid synovial fluid (45,47- 
50). These cytokines can also be detected at the mRNA level in the synovial 
membrane using in situ hybridisation (22,51) and blotting (52). 
Immunohistochemical localisation of these proteins has demonstrated predominant 
expression in macrophages (22,44). These proteins were also detected in short-term 
in vitro cultures of enzymatically disaggregated synovial membrane samples (52,53). 
Of importance was the observation that IL-lp and TNFa could be detected by 
bioassay of synovial membrane cultures, and hence were present in quantities able to 
signal effectively.
Subsequently, as other cytokine and growth factor cDNAs were cloned, their mRNAs 
and proteins were also detected in RA synovial tissue. These cytokines include IL-6 
(54-57), interferon a  (IFNa) (50), granulocyte macrophage colony stimulating factor 
(GM-CSF) (58-60), macrophage stimulating factor (M-CSF) (61), and leukocyte 
inhibitory factor (LIF) (62-64).
The growth factors identified as major contributors in the pannus formation and 
synovial hyperplasia seen in RA include platelet-derived growth factor (PDGF) (65), 
fibroblast growth factor (FGF) (65-67), and transforming growth factor p (TGFP) 
(65,67-70).
1.2.3: Anti-inflammatory cytokines
Immunoregulatory and anti-inflammatory cytokines were generally discovered and 
cloned after the pro-inflammatory cytokines. These cytokines include IL-lreceptor 
antagonist (IL-lra), TGFp, IL-4, IL-10 and IL-13. A number of studies from different 
groups have demonstrated that TGFp is abundant in both the precursor inactive form 
and the active form in rheumatoid joints (68,71-74). Whether this cytokine functions 
as an anti-inflammatory mediator in RA, however, remains an area of debate. TGFp 
can have pro-inflammatory effects such as acting as a monocyte chemoattractant (75) 
and causing synovial hyperplasia (67-70). On the other hand, TGFp is likely to be a 
key cytokine that is involved in tissue repair and fibrosis in the joint. For example, 
whilst inhibiting production of MMPs such as collagenase (71) and inducing TIMP 
(41), TGFP also stimulates the production of type I and type XI collagen (76).
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However, whilst locally promoting tissue repair, overproduction of TGFp in chronic 
lesions may lead to tissue destruction via recruiting inflammatory monocytes and 
fibroblasts and promoting synovial hyperplasia.
In common with TGFp, IL-4 also displays some immunoregulatory effects such as 
inhibition of LPS-induced IL-lp, TNFa, PGE2 and 92-kDa gelatinase production in 
human monocytes (68,77-79). However, IL-4 is not highly expressed in rheumatoid 
synovial tissue cultures (80) or in T cells cloned from RA synovial biopsies (81). The 
major source of IL-4 is T cells of the helper type two phenotype and the decreased 
expression of IL-4 in the rheumatoid synovium may be due to the predominance of T 
cells of the type 1 helper phenotype (82). IL-4 production may well be defective in 
RA joints and there is also a report showing that the incidence of allergies is lower in 
RA patients (83).
IL-10 also has profound anti-inflammatory effects. Its presence has been well 
documented in RA peripheral blood (84) and synovial joints (85,86). Blocking IL-10 
activity with neutralising antibodies has been shown to enhance the production of IL- 
ip and TNFa in synovial cell cultures (85). Conversely, addition of IL-10 to these 
cultures inhibited production of IL-lp and TNFa by approximately 50%.
IL-lra expression may also be relevant to the outcome of the inflammatory condition 
in RA. Along with decoy soluble IL-1 receptors, IL-lra plays a key role in regulating 
the action of IL-1 p. The expression of IL-lra has been analysed in RA joints and 
both an upregulation of mRNA and protein has been observed in synovial fluid and 
joint cell cultures (87-90). The balance between IL-lra and IL-lp production in RA 
however still favours the effects of IL-lp as levels of IL-lra are insufficient to 
neutralise IL-ip bioactivity. IL-lra does have high affinity for membrane type I and 
II IL-1 receptors but due to the ability of IL-1 to activate cells at very low receptor 
occupancy, a considerable molar excess (approx. 100:1) of IL-lra is required to 
inhibit IL-lp effectively. Normal joint tissues express very little IL-lra, so IL-lra 
production is upregulated in the disease process but not sufficiently to neutralise IL- 
1. It is of interest that a study of the ratio of IL-lra:IL-lp in synovial fluid of patients 
with Lyme arthritis indicated that the patients with the most favourable outcome had 
the highest ratio (91).
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In this thesis the emphasis of the research is on the regulation of monocyte derived 
cytokines and as a result the next section will detail more about their roles in 
inflammation.
1.3: Monocyte-derived Cytokines 
1.3.1: Interleukin 1 and its receptors
IL-1 was one of the first cytokines described. It was studied for many years for its 
ability to induce fever, stimulate hepatic acute-phase protein synthesis, augment 
lymphocyte responses, induce joint degeneration and cause proliferation of bone 
marrow cells. Although mainly studied as an element of host defence and disease 
there is also evidence for a role of IL-1 in normal health. For example, IL-1 
expression is seen in the placental trophoblast and there may be a role for IL-1 in 
embryonic development, implantation and birth. However, studies carried out using 
gene deletions in mice have shown normal ovulation, fertilisation, implantation and 
parturition regardless of IL-ip, IL-lp converting enzyme and IL-1RI knockouts 
(reviewed in (92)). As a result it is no surprise that attention has focused on the role 
of IL-1 in disease. IL-1 is a potent inflammatory cytokine and the production and 
activation of IL-1, especially IL-lp, is tightly regulated. In addition to controlling 
gene expression, synthesis, and secretion, this regulation extends to surface receptor 
expression, soluble (decoy) receptors and a receptor antagonist protein (92).
The IL-1 gene family is composed of IL-1 a, IL-lp and II-Ira and is found, in 
humans, on the long arm of chromosome 2 (93). They are first synthesised as 
precursor proteins with pro-IL-la and pro-IL-ip each having a molecular mass of 
31kDa. Both pro-IL-la and mature 17kDa IL-la are biologically active (94) in 
contrast however, pro-IL-ip is relatively inactive and needs cleavage to a 17kDa 
peptide for optimal activity. The IL-lra precursor has a leader sequence, is cleaved to 
its mature form and is secreted like most proteins.
The IL-1 receptor family is comprised of four members: IL-1RI, which is found in 
low numbers on nearly all cells; IL-1RII, which is primarily found on neutrophils, 
monocytes, and B-lymphocytes; IL-1 accessory protein (IL-1 AcP); and the 
Tl/ST2/Fit-1 receptor. The gene for IL-1RI has no TATA box in its promoter and 
thus this receptor is constitutively expressed, falling into the category of the
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housekeeper gene promoters (95). Various stimuli, such as PGE2, phorbol ester, IL-1, 
IL-2 and IL-4 have been shown to increase the numbers of cell surface IL-1RI (96), 
but in some cell types IL-1 down regulates the number of its own receptors (97) by a 
decrease in mRNA half-life.
The IL-1RII has a cytosolic domain of only 29 amino acids and does not transduce a 
signal (98). The type II receptor may act as a decoy receptor, competing with the 
signal transducing type I receptor on the cell surface and also possibly as a shed 
receptor in the circulation. Soluble IL-1RII may serve as a natural antagonist to the 
effects of IL-1. It is worth noting however that very few IL-1RI need to be occupied 
for a committed biological effect due to a very efficient and greatly amplified signal 
transduction mechanism. IL-1 AcP has recently been shown to play a part in IL-1 
signal transduction by increasing the affinity of IL-1 RI for IL-lp (99-102). In general 
IL-1 a  and IL-lra have a higher affinity for IL-1RI whereas IL-lp has a higher 
affinity for IL-1RII (97).
1.3.1.1: Genetic Regulation of IL-1
The genes for IL-la, IL-ip and IL-lra are differentially expressed (103,104) The 
promoter for IL-la does not contain a TATA box but the IL-lp promoter does (104). 
The gene for IL-lra is predominantly inducible in most cell types but the intracellular 
isoform of IL-lra (icIL-lra) is constitutively expressed in keratinocytes and intestinal 
epithelial cells (105). The gene encoding for IL-lp is not spontaneously expressed in 
mononuclear cells from the blood of healthy humans, but upon stimulation with 
bacterial endotoxin, mRNA for IL-la and IL-lp is present within 15 minutes. IL-lp 
mRNA accumulates for 4 hours followed by a rapid fall that results in part from the 
synthesis of a transcriptional repressor as well as a decrease in mRNA half-life (106). 
The regulation of IL-lp transcription in monocytes has been most extensively 
studied in response to LPS (92,107,108). Several transcription factors have been 
identified including NF-IL6, cAMP-response element binding protein (109), NF-kB 
(110) and a STAT-like factor (111) that bind an upstream induction sequence. A 
promoter-proximal sequence has also been studied and shown to bind NF-IL6 
(112,113) and a B-cell and myeloid-specific transcription factor PU.l (114,115). 
Recent studies have also shown that IL-lp induced IL-ip mRNA involves the
Chapter 1: Introduction - 1 2 -
induction of multiple protein complexes that incorporate the nuclear factor Oct-1 
(116). In addition to transcriptional regulation, the stability of IL-1 mRNA can be 
selectively modulated by various stimuli (108).
Various other stimuli, such as blood clotting or complement components induce the 
synthesis of IL-1 p mRNA in monocytic cells without significant translation into 
protein (117). Without translation most of the mRNA is degraded. This translational 
block, however, can be removed by stimulating the IL-lp-transcribing cells with 
bacterial endotoxin or IL-1 itself. Stabilisation of the AU-rich 3’ untranslated region 
is thought to promote translation, but other mechanisms may be involved.
However, in contrast to IL-lp even under conditions of cell activation human 
monocytes do not readily process or secrete mature IL-1 a  (118,119). The lack of 
leader peptide means that IL-1 a  and p remain in the cytosol soon after translation 
and indeed IL-1 a  remains cytosolic, not usually being found in the circulation or in 
inflammatory body fluids except during severe disease, which may be as a result of 
release from dying cells (120) or as a consequence of calpain-mediated cleavage of 
membrane bound IL-la (121). IL-la may in fact act as an autocrine, intracellular 
messenger in some cells.
After synthesis, proIL-lp remains primarily cytosolic until it is cleaved and 
transported from the cell. In mononuclear phagocytes, some of the proIL-lp is 
secreted from intact cells in a manner distinct from the secretion of the mature form 
of the peptide. ProIL-lp requires cleavage by an intracellular cysteine protease that is 
highly specific for cleaving at the aspartic acid-alanine (amino acids 116-117) 
position (122). This enzyme, known as interleukin-1 p converting enzyme (ICE) is 
constitutively expressed as an inactive precursor requiring two cleavages itself for 
enzymatic activity. The cleavage of proIL-la appears to be carried out by several 
enzymes that are less specific than ICE. The IL-ip pro-piece (amino acids 1-116) is 
myristoylated on lysine residues, as is proIL-la (123), but, unlike IL-la, proIL-ip 
has no membrane form and proIL-lp is only marginally active (124).
Chapter 1: Introduction - 13-
1.3.1.2: Interleukin 1 Converting Enzyme (ICE)
Apart from the specific role of ICE in cleaving the mature form of IL-1 p from pro- 
IL-lp a great deal of evidence is emerging for more general roles of ICE in general 
physiology and pathology. ICE is also known as Caspase 1 and is thought to play a 
role in the activation of a cascade of intracellular proteases leading to programmed 
cell death (apoptosis). At least ten members of the caspase family have been 
identified to date (125). Each is capable not only of degrading key cytostructural and 
reparative proteins but also of activating other caspase family members by cleaving 
the pro forms of the enzymes at aspartic acid residues. Caspase 1 was identified on 
the basis of its sequence homology to the pro-apoptotic Caenorhabditis elegans gene 
product, ced-3 (126). In the nematode Caenorhabditis elegans, genetically 
determined cell death has an essential requirement for the ced-3 gene (127). 
Consequently, caspase-1 (ICE) may have divergent effects on cell survival, 
depending upon which of its substrates is preferentially processed.
1.3.1.3: Physiological Regulation of IL-1 Activity
Structurally, the two agonists, IL-la and IL-lp are very similar, being comprised of 
12-14 p sheets in a barrel conformation (128,129). However, when examining 
regulation of gene expression, mRNA stability, translation, processing and secretion 
the two proteins are considerably different. Once released from cells, mature IL-ip is 
regulated by two antagonistic molecules: the soluble form of the type II receptor, 
which binds IL-lp with high affinity, and sIL-lra, which competes with IL-lp for 
occupancy of cell surface expressed receptors.
1.3.1.4: IL-lra
IL-lra is the first described naturally occurring specific receptor antagonist of any 
cytokine or hormone-like molecule. Several groups were involved in the discovery of 
IL-lra with Arend et al. describing IgG driven IL-lra production by human 
monocytes in 1985. A cDNA for a secreted form of IL-lra (sIL-lra) was cloned from 
a human monocyte library (130) and synthesised as a 177 amino acid protein, with 
cleavage of a 25 amino acid leader sequence prior to secretion as a variably 
glycosylated 152 amino acid protein. A second cDNA for an intracellular form of IL-
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Ira (icIL-lra) was subsequently cloned and expressed as an 18 kDa, 159 amino acid 
protein (105). sIL-lra protein is produced by virtually any cell that is capable of 
synthesising IL-1, with the possible exception of endothelial cells and hepatocytes. 
icIL-lra is found constitutively expressed in keratinocytes and other epithelial cells 
but is also a delayed product of stimulated monocytes and macrophages (131,132).
A smaller isoform of IL-lra was recently described by Malyak et al. as a major 
cytoplasmic constituent of LPS-stimulated human neutrophils (133). This 16 kDa 
protein was also detected in monocytes and the human hepatoma cell line HepG2 
(134). This isoform bound less well to IL-1 receptors in comparison to the original 
two isoforms of IL-lra (135) and the origin of this low molecular weight isoform of 
IL-lra appears to be by alternative translational initiation. Thus, IL-lra appears to be 
a family of proteins and is similar to fibroblast growth factor in possessing both 
secreted and cytoplasmic forms.
Elevated blood levels of IL-lra have been described in patients with juvenile chronic 
arthritis (136,137), polymyositis (138), systemic lupus erythematosus (139-141) and 
RA (141,142). RA patients exhibited a lower ratio of IL-lra to IL-ip in plasma both 
at baseline and following surgery in comparison to patients with OA or osteomyelitis 
(142). This observation suggests that IL-lra production may be relatively deficient or 
inadequate in RA patients. Furthermore, IL-lra production was enhanced, and the 
ratio of IL-lp to IL-lra was decreased, in peripheral blood monocytes form patients 
with RA after clinical response to treatment with methotrexate (143,144) or gold 
injections (145).
In rheumatoid synovial fluid IL-lra levels have been shown to be elevated (146-148), 
although soluble type I IL-1 receptors in these fluids may have obscured accurate 
measurement of IL-lra by ELISA (146). The major source of IL-lra in synovial fluid 
is the neutrophil (147), even though these cells produced relatively less IL-lra and 
more IL-lp in comparison to peripheral blood neutrophils (148). In patients with 
acute arthritis speed of recovery has been correlated with the balance between IL-lra 
and IL-ip levels in synovial fluid (91). In the case of chronic RA, although levels of 
IL-lra are elevated in the synovial fluid and tissues this may not be sufficient to 
overcome the locally produced IL-lp.
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The gene for the human secreted form of IL-lra contains three LPS-responsive 
promoter elements, one of which was identified as an NF-kB binding site (149). A 
second of these three sites has been recently identified to bind PU. 1 (34). However, 
in contrast to the role of PU.l in the regulation of many other myeloid genes, the 
binding of PU.l to the sIL-lra promoter does not significantly regulate basal activity 
in macrophages. The binding of PU.l does, however, appear to be essential for LPS 
induced IL-lra secretion (34) and also for LPS induced IL-lp (150). Interestingly, a 
second PU.l binding site has been identified which overlapped with the NF-kB site 
and is also a recognition sequence for the transcription factor GABP (34). The crystal 
structures of the three transcription factors, NF-kB, PU.l and GABP suggest that 
they would not bind together and would in fact compete for the same site (151-154).
1.3.1.5: Biological Effects of IL-1
The biological effects of IL-1 are very diverse but generally involve the induction 
and suppression of various genes. For instance, IL-1 induces a variety of non- 
structural, function-associated genes that are characteristically expressed during 
inflammation, particularly other cytokines such as IL-6 and the entire chemokine 
family. The constitutive expression of housekeeping genes such as albumin, 
lipoprotein lipases and cytochromes, however, is somewhat suppressed. These 
divergent effects on gene expression may represent an attempt by IL-1 to increase the 
efficiency of the host’s immune system in dealing with attack. In disease however, 
excessive IL-1 induction of genes such as inducible nitric oxide synthase, soluble 
type 2 phospholipase A2 and type-2-cyclooxygenase lead to chronic inflammation. 
Potent induction of MMP synthesis and inhibition of TIMP synthesis contributes to 
local tissue damage in the inflammatory tissues.
Levels of IL-1 p in the circulation of animals or humans correlate with the severity of 
some disease states (155). Although this does not necessarily implicate IL-1 as being 
causative in the pathogenesis of the disease, there is convincing data to suggest this 
in some cases. IL-lra, sIL-lRII, neutralising anti-IL-1 antibodies, antibodies to the 
IL-1RI and antisense oligonucleotides to IL-1RI have been used to show an 
important contributory role for IL-1 in several disease states reviewed in (156).
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Bone is one of the most sensitive tissues to the actions of IL-1 (157). It regulates not 
only bone formation but also bone resorption (158) and is believed to have an 
important role in the pathogenesis of bone lesions associated with RA (159) and 
osteoporosis (160). Bone resorption is regulated by at least three events; osteoid 
degradation mediated through collagenase produced by osteoblasts (161), recruitment 
of new osteoclasts from their progenitors and activation of pre-formed and newly 
developed osteoclasts (162). IL-1 exhibits potent bone-resorbing activity by 
stimulating these three steps independently. IL-1 induces osteoclast formation by a 
mechanism involving PGs and, as in the case of TNFa, direct interaction between 
osteoclast progenitors and osteoblastic cells is required in the osteoclast recruitment 
induced by IL-1 (163). IL-1 also has potent bone resorbing activity, which can be 
attributed to its role as a stimulator of PGE2, as demonstrated by partial inhibition of 
in vitro bone resorption in the presence of indomethacin. IL-1 can also act in synergy 
with other cytokines with bone resorbing activities such as TNFa and TNFp. 
However, even with optimal synergy, IL-1 is considerably more potent than these 
cytokines in inducing bone resorption (164-166).
1.3.2: TNFa
Tumour necrosis factor a  is a 17kDa polypeptide that exists in multimers of three 
identical subunits that contain several potential glycosylation sites. TNFa is a potent 
inducer of IL-1 and it often has synergistic effects with those of IL-1. On the 
endothelium TNFa induces prostacyclin release, expression of adhesion molecules 
and synthesis of other cytokines. TNFa also induces expression of adhesion 
molecules on, and is chemotactic for, neutrophils and macrophages; activates 
fibroblasts, osteoclasts and chondrocytes; induces fever and release of acute phase 
proteins. Increased efficiency of antigen presentation may also result from TNFa 
induced expression of HLA-DR antigens and increased IL-2R expression on T 
lymphocytes. In RA TNFa activates synovial fibroblasts, inducing increased 
collagenase and prostaglandin release and osteoclasts, resulting in increased bone 
resorption (167).
It has been proposed that TNFa plays a pivotal role in the pathogenesis of RA. In RA 
TNFa has been shown to be critical in driving the production of IL-1 in synovial
Chapter 1: Introduction - 17 -
membrane cultures (168). Using TNFa neutralising antibodies Brennan and 
colleagues have shown that within three days IL-1 bioactivity had virtually 
disappeared. TNFa has also been shown to be a critical regulator of GM-CSF (59), 
IL-6 and IL-8 (169). The dominance of TNFa in the development of pro- 
inflammatory cytokine profiles in RA was first demonstrated using dissociated 
rheumatoid cell cultures (52,53,170). These findings were complemented by animal 
model data that showed TNFa to be critical in the development of arthritic pathology 
(171,172) and then finally proven with clinical data on the efficacy of anti-TNFa 
antibody (173-176) and TNF receptor-Ig fusion proteins (177).
Transcription of the TNFa gene is complexly regulated and the promoter region 
contains binding sites for multiple transcription factors including NF-kB, AP-1, NF- 
IL6 and NF-AT (178-180). The p38 MAPK signalling pathway has also been shown 
to play a role in controlling translation via possible effects on the 3' untranslated 
region (181). In the murine macrophage cell line, RAW 264, NF-kB was shown to be 
essential for induction of TNFa production (178,182) but in human lymphoid cell 
lines NF-AT rather than NF-kB was required for TNFa production (179,180). 
Recent work published by Foxwell et al. (1998), using adenoviral infection with 
hcBa, has shown that LPS induced TNFa production in human monocytes is NF-kB 
dependent (183).
In general, the majority of biological functions that can be attributed to TNF are 
shared by IL-1. Indeed, IL-1 and TNF often act in concert with one another, 
synergistically amplifying their solitary effects. For the purposes of this report the 
actions of TNF have not been specifically outlined in great detail, because of the 
similarities with IL-1 actions and because of the fact that the main focus of this thesis 
is on the balance between IL-ip and IL-lra production.
1.3.3: Interleukin-6 and Oncostatin M
The biology of IL-6 has been reviewed in detail recently by Toshio Hirano (184). 
Consequently, what is given here is an overview of those aspects of IL-6 biology that 
are relevant to its role in health and disease. For the sake of this thesis, IL-6 was
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mainly considered due to the fact that its production by PBMCs may be differently 
regulated compared to that of IL-1 and TNF.
IL-6 is a typical example of a pleiotropic cytokine that acts on various cells: IL-6 
induces the differentiation of B cells to antibody producing plasma cells, T-cell 
growth and differentiation, the differentiation of myeloid leukemic cell lines into 
macrophages, megakaryocyte maturation, the neural differentiation of PC 12 cells, the 
development of osteoclasts, and acute-phase protein synthesis in hepatocytes. IL-6 
acts as a growth factor for myeloma/plasmacytoma, keratinocytes, mesangial cells, 
renal cell carcinoma, and Kaposi's sarcoma, and promotes the growth of 
hematopoietic stem cells. In addition, IL-6 inhibits the growth of myeloid leukemic 
cell lines and certain carcinoma cell lines (185-187).
Human IL-6 is a variably glycosylated, 22-27kDa secreted glycoprotein that serves 
as a prototype for a family of molecules including leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotropic factor (CNTF), cardiotrophin-1 (CT-1) and 
IL-11. These cytokines constitute the IL-6 related cytokine subfamily because of 
their functional redundancy, structural similarity, and sharing of a receptor subunit. 
OSM was identified by its ability to inhibit the growth of human melanoma cell line 
A375 (188,189). OSM is also a potent growth factor for AIDS-related Kaposi's 
sarcoma (AIDS-KS) (190,191) and enhances the secretion of IL-6 by AIDS-Ks 
cells. The functional redundancy that occurs among these cytokines is very broad. In 
particular, IL-6, LIF, OSM, and CT-1 induce macrophage differentiation in a 
myeloid leukemic cell line, Ml (187,192,193). IL-6, IL-11, LIF, and OSM all induce 
the growth of myeloma cells (194,195). IL-6, LIF, and IL-11 enhance IL-3- 
dependent colony formation of primitive blast colony-forming cells (187,196,197). 
IL-6, LIF, IL-11, and OSM stimulate the biosynthesis of acute-phase proteins in 
hepatocytes (46,186,198-200). IL-6, LIF, OSM, IL-11, CNTF, and CT-1 all act on 
the nervous system (201). The functional redundancy observed among the IL-6- 
related cytokine subfamily is largely explained by the sharing of the receptor subunit, 
gpl30.
Of the IL-6-type cytokines, IL-6 is best characterised as being involved in the acute- 
phase response in RA. IL-6 is produced mainly by fibroblast-like cells in the 
synovium (22,202) and is found at high levels in synovial effusions (55,97,203). 
Levels of circulating IL-6 in the blood have been shown to correlate with serum
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levels of CRP and other APP in RA patients (55). Recent studies have shown that IL- 
6, IL-11, LIF and OSM are all produced in large amounts at the site of disease 
activity, but IL-6 derived from synovial fibroblasts may be the major hormone-like 
mediator that induces the hepatic synthesis of acute-phase proteins in RA (204).
1.4: Regulation of Monocyte Activation
The balance between the production of pro- and anti-inflammatory cytokines is 
critical to the outcome of immune responses. Factors that regulate monocyte 
activation may well determine the outcome of an inflammatory response and define 
the perpetuation of inflammatory diseases such as RA. Although inappropriate 
activation of mononuclear phagocytes is not necessarily causative in the initiation of 
autoimmune responses, it is at least highly likely to contribute to the progression and 
severity of disease (42). Thus, this section will discuss factors that are important in 
regulating monocyte activation in RA. Monocytes play a central role in both the 
innate and adaptive inflammatory responses and thus the areas considered here will 
be loosely separated into immunologically non-specific activation mechanisms, such 
as LPS and biochemical modulation, and those that may be involved in the specific 
immune response, such as stimulation with immune complexes and T cells. Of the 
multitude of possible innate activation mechanisms that can drive 
monocyte/macrophage functions particular emphasis will be given to bacterial LPS 
stimulation as this is a classical stimulator of IL-1 secretion. In addition, biochemical 
modulation will be considered as an innate, possibly environment-dependent 
stimulator of monocyte function.
Of particular interest to our group has been the exploration of Na+/K+ATPase 
expression in rheumatoid mononuclear cells, how this may vary with disease and 
how this may contribute to monocyte activation. Consequently, the biochemical 
modulation of mononuclear cells used in this thesis is focused on manipulations of 
the Na+/K+ATPase and hence the effects of downstream alterations in intracellular 
cation concentrations.
Immunologically specific modulation of monocyte/macrophage function involves 
interactions with antibody-coated pathogens or immune complexes, and intercellular 
interactions with other cells of the immune response, such as lymphocytes. 
Consequently, as immune complex and T cell interactions with monocytes might
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play an important role in RA, IgG stimulation of monocytes through FcR and T cell- 
derived soluble mediator and membrane bound interactions with monocytes are 
considered here.
1.4.1: Innate Regulation of Monocyte Activation 
1.4.1.1: Biochemical Modulation of Monocytes
The main biochemical manipulation used in these studies to regulate monocyte 
activation is the modulation of the Na7K+-ATPase. The Na7K+-ATPase (EC 3.6.1.3) 
is an integral heterodimeric membrane protein found in the cells of all higher 
eukaryotes and is responsible for translocating sodium and potassium across the cell 
membrane utilising ATP as an energy source. The enzyme was first described by 
Jens Skou in 1957 but it was not until 1966 that Oleg Jardetzky (205) proposed a 




The Na7K+-ATPase can operate at a rate of 100 molecules of ATP per minute, each 
cycle expelling 3Na+ ions and importing 2K+ ions. In the model, shown 
diagrammatically above, the enzyme (El) binds 3Na+ ions and one ATP molecule on 
its intracellular surface. El is phosphorylated on an aspartate residue (Asp 369), 
when both sodium and magnesium are present, which allows a conformational 
change in the protein structure resulting in a flip that exposes sodium to the outside 
of the cell. In this form the enzyme has increased affinity for K+ ions. Two K+ ions 
bind to the extracellular surface and upon dephosphorylation become internalised. As 
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The Na+/K+-ATPase is composed of two subunits, an a  unit of approximately 
113kDa molecular mass and a P unit of approximately 55kDa molecular mass. The 
a  subunit contains the ATP binding site, the phosphorylation site, and amino acids 
essential for the binding of cations and cardiac glycosides, which suggests that this 
subunit plays a major role in the catalytic function of the enzyme. The p subunit 
appears to be involved in maturation of the enzyme, localisation of the ATPase to the 
plasma membrane, and stabilisation of a K+-bound intermediate form of the protein 
(206-209).
The ion gradients formed by this enzyme are essential for the Na+-coupled transport 
of various nutrients, including glucose and amino acids, into cells (210), movement 
of such ions as Ca2+ (211,212) and H+ (213) across the membrane, and osmotic 
balance and cell-volume regulation (214). Protein synthesis and receptor-mediated 
endocytosis and recycling also depend on the resulting ion gradients. These ion 
gradients also cause an electrochemical gradient which regulates the cellular 
membrane potential and thus plays a role in cell activity, muscle contraction and 
nerve activity (215). The importance of this enzyme cannot be overstated, and it has 
been estimated that approximately 25% of the ATP catabolised by an individual at 
rest is used by this enzyme.
Na7K+-ATPase is the receptor for the cardiac glycosides, which were first described 
as therapeutic agents by William Withering in 1785 (216). Ouabain, as well as other 
members of the digitalis family, compete for the potassium binding site on the cell 
surface and inhibit the dephosphorylation of E2. Affinity labelling has shown that 
the site of interaction is primarily the a  subunit but that some p subunit labelling also 
occurs (217). In the heart, ouabain has been shown to inhibit the Na+/K+-ATPase 
resulting in an increase in intracellular Na+ and membrane depolarisation, which in 
turn results in an increase in intracellular Ca2+ via Na+/Ca2+ exchange. The elevated 
calcium concentration subsequently causes an increase in the force of contraction.
Within the immune system ouabain has been shown to suppress T and B lymphocyte 
activation in vitro (218) and to induce IL-lp production by human monocytes (219). 
Such T cell hyporesponsiveness is indeed a feature of RA, where decreased release of 
T cell derived anti-inflammatory cytokines such as IL-4, IL-10 and IL-13 contribute 
to chronic inflammation (78,220-229) and a state of frustrated activation is seen
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(230). Also in RA PBMCs show increased release of IL-lp /TNFa and decreased 
IL-6, whereas synovial fibroblasts show increased IL-6 with negligible IL-1 release. 
Recent studies by Matsumori et al. (231) have shown that various drugs used to treat 









Research previously carried in our laboratory by A. Foey has centred upon the effects 
of ouabain in regulating the cytokine profile generated from healthy and rheumatoid 
inflammatory cells. In preliminary studies he showed that ouabain mimics the 
increase in IL-lp and TNFa production seen in rheumatoid monocytes (232) as does 
the calcium ionophore A23187 (233). The specific sodium ionophore monensin also 
stimulates the generation of a similar cytokine profile to ouabain in PBMCs (232) 
suggesting that ouabain may exert its effects initially via an increase in intracellular 
sodium. Evidence from Perregaux (1992) and later by Walev (1995) has also shown 
potassium regulatory effects on IL-lp processing in human monocytes. Using agents 
such as staphylococcal a-toxin and gramicidin, both of which selectively 
permeabilise plasma membranes for monovalent ions, the ionophores nigericin and 
valinomycin, and the Na+/K+ATPase inhibitor ouabain they demonstrated that K+ 
depletion triggered processing of proIL-lp (234,235). The central role of K+ 
depletion for inducing IL-lp maturation was demonstrated in cells permeabilised 
with a-toxin: processing of proIL-lp was totally blocked when cells were suspended 
in medium that contained high K+, but could be induced by replacing extracellular K+ 
with Na+, choline+ or sucrose. Walev et al. (1995) hypothesised that the activity of
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ICE was linked directly or indirectly to potassium flux across the cell membrane or 
to local concentrations of potassium ions.
Elevation of intracellular Ca2+ could also play a role in the regulation of cytokine 
production through effects on gene transcription. The calcium/calmodulin-regulated 
protein phosphatase, calcineurin (PP2B), plays a critical role in the coupling of Ca2+ 
signals with cellular responses (236-238). Activated calcineurin regulates the activity 
of the nuclear transcription factor NF-kB via modulation of IkB degradation (239- 
242).
This compelling evidence, of ouabain induced pro-inflammatory cytokine induction 
and suppression of immuno-regulatory mechanisms, coupled with evidence of 
decreased Na+/K+ATPase activity in rheumatoid mononuclear cells demonstrated by 
K. Maubach and A. Foey (243) provided the impetus for the work presented here.
The decrease in rheumatoid mononuclear cell Na+/K+ATPase activity was assayed 
both functionally, with a histochemical assay, and by 3H-ouabain binding studies. In 
the present studies, however, there was a need for a more quantitative ATPase assay 
and for a larger group of patients to be studied.
The functional consequences of decreased Na+/K+ATPase activity undoubtedly 
include altered processing of various cytokines, as shown with ouabain. However, 
the reason for this enzymatic abnormality is still an area for debate. One possible 
explanation for the impairment of Na+/K+ATPase activity in RA is oxidation and 
blockade of surface SH groups (243) by peroxides released during the inflammatory 
process. Studies in Jurkat T cells have shown that SH blockers induce membrane 
depolarisation and impair receptor mediated Ca2+ influx (244). Sulphydryl blockade 
with pHMPSA results in decreased ouabain binding ability.
Another explanation for the decreased Na+/K+-ATPase activity in rheumatoid 
mononuclear cells may lie in the discovery of an endogenous ouabain-like substance 
in mammals. The existence of a mammalian counterpart to the digitalis glycosides 
has been postulated for over a century (245). Hamlyn et al. reported in 1991, 
however, that one (perhaps the only) endogenous digitalis-like factor in human 
plasma was ouabain or a closely related isomer (246) secreted by the adrenal cortex
(247). Whether the existence of this endogenous ouabain has any relevance to 
inflammatory diseases such as RA remains to be seen as most of the research so far
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has centred upon cardiovascular conditions. Indeed, significant relationships 
between plasma ouabain concentration and cardiac index and mean arterial pressure 
imply that endogenous ouabain may be an important homeostatic factor in humans
(248).
To date investigations into the role of intracellular cations in the regulation of 
monocyte cytokine secretion have not commented upon the balance between 
secretion of pro- and anti-inflammatory cytokines such as IL-lp and IL-lra. 
Although there is now an expanding amount of literature on the role of cations, 
especially K+, in the activation of ICE (234,249,250) and the processing of IL-lp at 
the time of these studies little was known about the effects of Na7K+-ATPase 
modulation on the induction of monocyte secretion of IL-lp and IL-lra.
1.4.1.2: Lipopolysaccharide (LPS) Stimulation of Mononuclear Cells
LPS of gram-negative bacteria induces a diverse array of biological responses in 
mammalian cells and initiates inflammatory, complement and coagulation cascades. 
The response of mononuclear phagocytes to LPS may be more relevant to reactive 
arthritis than RA but in this thesis LPS was mainly used due to its ability to stimulate 
IL-1 synthesis. Variations in responses to LPS between RA and normal monocytes 
were not the issue in question, rather the effects of LPS on other modulations of 
monocyte function, such as ouabain and T cell stimulation.
LPS has the ability to stimulate mononuclear phagocytes directly via cell surface 
receptors and indirectly via products of the complement cascade. By activating the 
alternative complement cascade LPS can initiate the innate inflammatory response 
via production of the opsonin C3b and the chemoattractant C5a. Mononuclear 
phagocytes express specific complement receptors, such as CR3, ligation of which 
facilitates phagocytosis of the C3b labelled organisms/tissue and release of 
lysosomal enzymes. The direct, most sensitive actions of LPS are mediated by CD 14 
and LPS binding protein (LBP). CD14 is a 55kDa glycoprotein that is found as a 
glycosylphosphatidylinositol (GPI)-anchored membrane protein (mCD14) on the 
surface of PMNs and monocytes and as a soluble protein (sCD14) in plasma. LBP is 
a 60kDa plasma protein that binds LPS (251). LBP has structural homology with 
plasma lipid transfer proteins and acts catalytically to accelerate the binding of LPS
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to CD 14 (252,253). While LBP was originally thought to play a direct role in 
inducing functional responses to LPS by acting as a coligand for mCD14, recent 
studies have shown that monomeric LPS presented as sCD14-LPS complexes is 
sufficient to trigger sensitive responses from endothelial cells (254,255), PMNs and 
monocytes (256), and the role of LBP appears limited to facilitating the translocation 
of LPS to CD 14.
The precise role of CD 14 in mediating LPS responses remains unclear, however, as it 
is thought to be unable to transduce signals across the plasma membrane (257-260). 
It is possible that CD 14 plays a role in the internalisation of LPS from where LPS 
can then move into acidic intracellular compartments where the lipid A moiety may 
be partially degraded in ways that modify its biological activity (261-263). While 
some evidence suggests that LPS must be internalised before certain signals are 
transduced (264-266), other data argue that intracellularly processed LPS is not 
involved in signalling (267). Results presented by Vasselon et al. (1997) (268) 
suggest that one or more trypsin-sensitive cell surface proteins distinct from CD 14 
participate in both the uptake of LPS and the initiation of signalling (269). A member 
of the Toll-like receptor family (TLR4) has recently been suggested as a cell-surface 
co-receptor for CD14/LPS complexes and has been implicated in LPS stimulation of 
NF-kB activation (270).
Although definitive knowledge of the functional components of the LPS receptor is 
incomplete, it has been possible to analyse the intracellular signalling pathways 
induced by LPS-CD14 interactions (271). Weinstein et al first showed that LPS 
stimulated an increase in protein tyrosine phosphorylation in monocytes and 
identified MAP kinase (MAPK) isoforms as well as other proteins as targets 
(272,273). Using cells stably transfected with human CD 14, LPS binding has been 
shown to induce rapid protein tyrosine phosphorylation of a 38kDa protein, termed 
p38, that is distinct from the 44- or 40kDa isoforms of MAPK (274). Other MAPKs 
activated by LPS-derived signals include the ERK family and JNK (275-277). The 
protein p38 is a kinase that is most closely related to the product of the HOG1 gene 
of Saccharomyces cervisiae (277,278). Both p38 and HOG1 are members of the 
MAPK family and define a new group of MAPKs with distinctive structural features 
(277). MAPKs require dual phosphorylation on threonine and tyrosine residues to 
achieve enzymatic activity. These phosphorylations are catalysed by dual specificity
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protein kinases known as MAP kinase kinases or MEKs (279,280). LPS induced IL- 
lp and TNFa release from monocytes has been shown to involve p38 (181). p38 
activation has been shown to be regulated by the small GTP-binding proteins Rac 
and Cdc42 and by p21-activated kinase-1 (Pakl) (281). MAPK-activated kinase-2 
(MAPKAPK-2) is an in vivo substrate for p38, which in turn phosphorylates the 
small heat-shock protein Hsp27 (282,283). Other substrates for p38 include 
MAPKAPK-3 (284), MEF2C (285), Elkl (286) and Max (287).
In addition to regulating the production of IL-lp and TNFa by monocytes, p38 also 
controls several other cellular responses. For example, p38 plays an essential role in 
IL-10 and prostaglandin H synthase-2 (PGHS-2) production by monocytes 
(288,289), and the production of PGHS-2, MMPs and IL-6 from fibroblasts and 
endothelial cells (290,291).
Signalling cascades initiated by LPS stimulation of monocytes have been shown to 
result in activation of several transcription factors, including NF-kB, NF-IL6 
(C/EBPp), AP-1, and members of the Ets family including Ets-2, Elk-1 and most 
recently PU.l (292). In resting cells, NF-kB is complexed in the cytoplasm by an 
inhibitory protein, IkB. Signal-induced phosphorylation and subsequent proteolytic 
degradation of IkB frees NF-kB from such complexes. Following this, NF-kB 
rapidly translocates to the nucleus, binds to the kB element of target genes, and 
activates the expression of previously quiescent genes, such as IL-1, IL-6, TNFa, 
lymphotoxin and IFNy. Many of the acute phase proteins also have kB sites in their 
promoters or enhancers and are produced as a result of NF-kB activation. These 
include serum amyloid A protein 1, a l  acidic glycoprotein, angiotensinogen, 
complement factor B and the C3 component of complement (293,294). Interestingly, 
anti-inflammatory drugs such as NSAIDs and dexamethasone inhibit NF-kB 
activation in cultured cells, suggesting that NF-kB may be a good target for potential 
therapies against chronic inflammatory diseases (295-298).
Quite how LPS initiates specific signalling in mononuclear phagocytes remains to be 
clarified. One thing that is clear, however, is that CD 14 dependent pathways are 
involved in LPS induction of many pro-inflammatory functions. Of particular interest 
here is the ability of LPS to induce the production of pro-inflammatory cytokines,
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such as IL-lp, TNFa and IL-6. LPS is also known to modulate IL-lra production but 
to a lesser extent than IL-lp. In the case of IL-lp, LPS triggers transient transcription 
and steady state levels of IL-lp mRNA, which accumulates for four hours followed 
by a rapid decrease due to the synthesis of a transcriptional repressor (106,299). In 
contrast, stimulation with cAMP-inducing agents, such as PGE2 or IL-1 itself, 
induces mRNA levels that are sustained for over twenty-four hours in human blood 
monocytes (300,301). Inflammatory effects of prostaglandins, such as PGE2, may 
well involve regulation of IL-1 induced IL-1 release via modulation of cAMP levels. 
Interestingly, however, elevation of cAMP levels inhibits LPS induced IL-ip mRNA 
(302).
1.4.2: Immune Activation of Monocytes
As part of the adaptive immune response mononuclear phagocytes have the ability to 
interact specifically with immune complexes and lymphocytes. Immune complexes 
consisting of antibody and antigen interact with monocyte/macrophage Fc receptors 
facilitating inflammatory functions and phagocytosis. The interactions between 
mononuclear phagocytes and T lymphocytes are of a more complex nature. The 
classical scenario of antigen presentation to T cells is just one aspect of this 
interaction in which monocyte derived APCs regulate immune function. It is now 
known that T cells also regulate monocyte/macrophage functions via direct cell-cell 
interactions and via the secretion of immunomodulatory cytokines.
1.4.2.1: FcR Driven Monocyte Activation
Fc receptor biology has recently been reviewed extensively by Daeron (303). 
Consequently, what follows here is an overview of FcR functions that may be 
relevant to the regulation of monocyte activation.
Receptors involved in antigen (Ag) recognition include the B cell receptors (BCR), T 
cell receptors (TCR) and Fc receptors (FcR). FcR do not recognise Ag but the Fc 
portion of Ab’s and can bind either Ab-Ag complexes or free Ab. Many FcR share 
activation motifs with BCR and TCR and may share similar signalling pathways.
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FcR exist as membrane and soluble forms. Most human and murine FcR belong to 
the immunoglobulin superfamily (IgSF) with others belonging to the lectin family. 
FcR capable of triggering cell activation possess one or several intracytoplasmic 
activation motifs, which resemble BCR/TCR activation motifs (304). These motifs 
consist of twice repeated YxxL sequences flanking seven variable residues and are 
now designated as immunoreceptor tyrosine based activation motifs (ITAMs) (305).
Receptor aggregation, after ligand binding, is the first step in FcR signalling (306- 
308) and may involve the transphosphorylation of co-localised receptor chains (309). 
FcR aggregation may occur under two conditions, depending upon the affinity of the 
receptor for its ligand. High affinity receptors can bind monomeric Ig (non- 
complexed) with, for example, an affinity of 108M_1 for macrophage FcyR (310). Low 
affinity FcR fail to bind monomeric Ig with a measurable affinity but do bind Ig 
aggregates or Ag-Ab complexes. All low affinity FcR belonging to the IgSF are IgG 
receptors. Interestingly, both low and high affinity receptors trigger cell responses 
with similar efficiency, the difference being in the number of events required for 
receptor aggregation. Monomeric antibodies bind to high-affinity FcR before 
forming complexes with multi-valent antigens, whereas antibodies are complexed to 
antigen before they bind to low-affinity FcR. By convention high affinity FcR are 
termed FcRI and low-affinity FcR are termed FcRII, with a subclass of the low 
affinity family being termed FcRIII.
Ligand binding FcRa subunits of multichain FcR are transmembrane molecules with 
2 or 3 extracellular Ig-like domains of the V-type (311), rather than the C2-type as 
originally thought (312). They associate with a common FcRy subunit (312) which 
has one ITAM motif in the intracellular domain. Association of the subunits is 
enabled via the interaction of a basic residue of the FcRa chain with an aspartic 
residue in the trans-membrane domain of FcRy (313).
FcRy are not members of the IgSF. They are related to TCR£ (314) and are encoded 
by related genes on chromosome 1 in both humans and mice (315). y chains form yy 
and C& homodimers, and sometimes y£ heterodimers, which can each associate with 
FcR and TcR.
FcRa genes are mainly expressed by myeloid cells and only FcyRIIIA are also 
expressed by sub-populations of lymphoid cells (312). FcyRI are expressed by
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macrophages, monocytes and neutrophils. FcyRIIIA are expressed by macrophages, 
activated monocytes, NK cells, pre-B cells and T cells, notably of the y/5 subset 
(316,317).
After aggregation of FcR it has been shown that signalling events occur within just a 
few seconds. In mast cells, FcsRl aggregation has been shown to result in tyrosine 
phosphorylation of the FcRy and FcRp IT AMs within 15 seconds (318). TCR^ 
IT AMs are phosphorylated after aggregation of FcyRIIIA in NK cells (319) and FcRy 
ITAMs are phosphorylated after aggregation of FcyRI in macrophage cell lines (320) 
and after FcaRI aggregation in U937 cells (321). Likewise, aggregation of FcyRIIA 
induces phosphorylation of their ITAMs in the monocytic cell line THP-1 (322,323).
Phosphorylation of ITAMs is correlated with the activation of several sets of 
cytoplasmic protein tyrosine kinases. The src family kinases have been shown to be 
activated by the aggregation of several FcR. FcyRIIIA activate lck in NK cells (324). 
FcyRI activate lck, lyn and hck in U937 cells treated with IFNy (325). FcyRIIA 
activate lyn and hck in the monocytic cell line THP-1 (322). Lyn and hck also co­
precipitate with FcyRIIA following its aggregation in THP-1 cells (322,323). 
Another set of kinases that become activated are the Syk family. Syk was found to be 
activated in human cultured monocytes triggered by FcyRIIIA (326), in THP-1 cells 
(327) and IFNy-treated U937 cells (328) triggered via FcyRI and in THP-1 cells 
triggered via FcyRIIA (327). Syk was co-precipitated with FcRy in macrophages 
following FcyRIILA (326) of FcyRI (328) aggregation, and with FcyRIIA in THP-1 
cells (329).
Tyrosine kinases phosphorylate various intracellular substrates including enzymes 
such as phospholipid kinases and phospholipases, adaptor molecules and proteins 
associated with the cytoskeleton. PI3-K is activated in various cell types, associated 
with the aggregation of various FcR including in U937 cells triggered via FcyRI or 
FcyRIIA (330). PLCy-1 and PLCy-2 have also been shown to be phosphorylated after 
the aggregation of various FcR in different cells including after FcyRI and FcyRIIA 
activation in THP-1 (327).
Signals induced by the aggregation of FcR with ITAMs join major biochemical 
pathways where they merge with signals generated by other receptors. These include
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pathways leading to the increase in intracellular calcium, pathways leading to the 
activation of PKC and the ras pathway that results in the translocation of various 
transcription factors to the nucleus.
Once activated by syk, PLCy generates metabolites that activate PKC and the 
inositide phosphate cycle. IP3 triggers the mobilisation of Ca2+ from the endoplasmic 
reticulum, which leads to a transient increase in intracellular calcium which in turn 
results in the opening of calcium channels in the plasma membrane and a sustained 
rise in Ca2+ concentration.
The FcyRIIIA has been shown to activate the ras pathway via the exchange factor sos 
(331), bound to the adaptor Grb2 that is recruited upon phosphorylation of she. Ras 
phosphorylates raf, which in turn phosphorylates the MEK kinases which results in 
the phosphorylation of MAP kinase. MAP kinase activation has also been 
demonstrated after aggregation of FcyRI (325). MAP kinase activation leads to the 
activation of transcription factors such as NF-kB and NFAT.
The biological responses generated by FcR with ITAMs are cell type specific rather 
than receptor specific. FcyRI trigger super-oxide production and the secretion of 
inflammatory cytokines by macrophages and monocytes (332) via a mechanism that 
involves NF-kB. Also in human monocytes FcaRI induces the release of 
inflammatory cytokines (333), super-oxide, leukotrienes and prostaglandins.
Besides triggering cell activation, FcR with ITAMs internalise their cross-linking 
ligands. These can be either soluble immune complexes that are endocytosed in every 
cell type, or particulate immune complexes that are phagocytosed only by 
phagocytes. FcyRI and FcyRIIIA (334) as well as FcaRI (335) and FceRI (336) 
mediate phagocytosis.
In summary, FcR ligation results in the activation of multiple signalling cascades. 
Through activation of PLCy, PI3-K and ras signals from FcR have the capacity to 
modulate the translocation of multiple transcription factors. Which of these 
signalling cascades predominates during the activation of monocytes by IgG and how 
it regulates cytokine production is yet to be determined. The role of FcR aggregation 
in the interactions of immune complexes and monocytes in the rheumatoid synovium 
is also an area that has not yet considered the balance of pro- and anti-inflammatory 
cytokine production.
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1.4.2.2: T cell Stimulation of Monocytes
Mononuclear phagocytes are capable of mediating tissue destruction via the direct 
secretion of MMPs (337) and indirectly by releasing cytokines such as IL-lp and 
TNFa which stimulate MMP release from connective tissue cells (338) and 
perpetuate inflammation. It is currently believed that chronic inflammation in 
diseases such as RA and MS is fostered by an imbalance between the production of 
pro-inflammatory cytokines and their inhibitors (339,340), e.g. IL-lra production is 
deficient relative to IL-lp production in synovial tissue explants of patients with RA 
or OA (87,341). Although IL-lp and IL-lra are produced by the same cell types 
(131), they are regulated differentially by a number of inducers. The critical events in 
the control of the balance between IL-ip and IL-lra production have not yet been 
elucidated.
T lymphocytes are likely to play a central role in the pathogenesis of chronic 
inflammatory diseases such as RA. In the rheumatoid joint T cells that display a 
mature helper phenotype (i.e. CD3/CD4 positive) are the main infiltrating cell type in 
the pannus (342-344) and as they migrate through the synovium they become 
activated. Activated T cells bind to matrix proteins and fibroblasts in the perivascular 
space (345) and tissue damage occurs in areas where T cells are co-localised with 
monocytes. The ability of T cells to modulate monocyte activation has been an area 
of intense interest recently and will be discussed further here.
T lymphocytes are potent activating cells since they can release cytokines that 
stimulate B cells, monocyte-macrophages and fibroblasts (346). T cells regulate the 
inflammatory process by releasing cytokines or other soluble mediators that have 
pro- or anti-inflammatory properties. T helper cells are separated into Thl and Th2 
subsets based on their preferential production of EFNy and lymphotoxin for Thl cells 
and IL-4, IL-5, IL-10 and IL-13 for Th2 cells (347,348). IFNy activates and primes 
macrophages to produce IL-1 in response to triggering events (349). In contrast, IL-4, 
IL-10 and IL-13 induce IL-lra while down-regulating IL-lp production by 
macrophages (78,220-229).
Stout and Shuttles (1993) (350) demonstrated that T cells may trigger cytostatic and 
cytotoxic activity as well as the production of reactive nitrogen intermediates by 
macrophages (351) during direct cell-cell contact. Studies carried out by J-M Dayers’
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group have complemented these data showing that direct cell-cell contact with 
stimulated T cells is a potent mechanism which induces the production of pro- 
inflammatory factors by monocyte-macrophages, including IL-lp, TNFa, IL-6 and 
MMP-1 and MMP-9 (352-354).
IL-lp secretion can be regulated by a variety of T cell derived cytokines, including 
IL-2, IL-4, IL-10, IFNy and GM-CSF (78,355,356). However, little is known about 
the T cell-derived membrane signal which induces the production of IL-1 p mRNA. 
The IL-lp mRNA inducing molecules are acquired by T cells rapidly after activation 
and are expressed independently of protein synthesis suggesting that the induction of 
monocyte IL-1 mRNA is mediated by a pre-existing T cell surface molecule that 
undergoes a change in either its expression and/or function following activation.
A number of T cell surface molecules are known to undergo rapid changes in 
function or expression following T cell activation, including CD 11a, CD2, CD25, 
CD28, CD95 and CD69. Both CD lla and CD2 undergo a rapid and transient 
increase in binding affinity for their respective ligands, CD54 (ICAM-1) and CD58 
(LFA-3), following engagement of the TCR (357-360). Although the role of such 
affinity changes in regulating the functions of ligand-expressing cells remains 
unknown, studies by Webb et al. (1990) have shown that the expression of IL-1 p 
mRNA in human monocytes can be induced by either anti-CD58 or purified 
recombinant CD2 molecules immobilised to plastic (522). The CD40-CD40L 
interaction is also relevant to the contact-dependent induction of IL-1 and, in mice, 
nitric oxide synthesis by monocytes (362-364). The human lymphocytic cell line 
HUT-78, however, does not express CD40L (365) even though it is a potent 
stimulator of THP-1 cytokine production, as will be detailed later. Also, THP-1 cells 
do not express CD40. By interacting with CDllb-CD18 and CDllc-CD18, CD23 
also regulates monocyte activation and production of IL-lp, IL-6 and TNFa (363). 
Similarly, anti-CD 11a and anti-CD lib  mAb partially inhibit IL-lp production 
induced upon contact with T cells (354,366). In addition, anti LFA-1 and anti-CD69 
mAb have inhibitory activity (354). Previous work carried out by Landis et al. (1991) 
has also shown that the induction of IL-lp mRNA in monocytes during immune 
activation is regulated by direct contact with activated T cells (367). In later studies 
(368), anti-CD3 alone (in the absence of CD80/86) was used to stimulate T cells,
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which then drove monocyte IL-ip mRNA in a CD2 dependent manner. Only anti- 
CD2 mAbs that inhibited the interaction between CD2 and CD58 (monocyte ligand) 
affected IL-ip mRNA production. As CD2 ligation by CD58 provides a co­
stimulatory signal to T cells that promotes activation (369) to confirm that the anti- 
CD2 mAb was not simply reducing the activation of the T cells they were activated 
on plastic bound anti-CD3 prior to culture with the monocytes. The relevance of 
using T cells that had been activated by anti-CD3 alone to stimulate monocyte 
cytokine production is questionable, however, as various studies have shown that 
without co-stimulation through CD28 T cells do not display full activation 
characteristics (370).
In these studies McAllister et al. have also shown that anti-CD69 mAb significantly 
inhibited T cell induced IL-lp secretion by monocytes during anti-CD3 mitogenesis 
(52.1% inhibition). Anti-CD2 inhibited by 66% and combination inhibited by 83.8% 
(368). Interestingly, although blocking Abs against CD2 and CD69 inhibited T cell 
driven monocyte release of mature IL-lp protein the accumulation of IL-1 p mRNA 
was not affected. Similarly, neutralising Abs against CDlla, CD 18 and CD28 also 
had no effect upon production of IL-lp mRNA.
Upon activation, CD2 has been shown to undergo conversion to a form which binds 
CD58 with higher affinity (358,371). This conformational change has been suggested 
to allow triggering of monocytes through CD58 (372) and increased affinity for 
LFA-3 has been reported within fifteen minutes of T cell activation (371). However, 
in these studies agents that are reported to directly induce the change in T cell CD2 
(i.e., forskolin and dibutyryl cyclic AMP) were unable to induce IL-ip mRNA 
production in monocytes. In fact, the ability of CD2 to undergo transformation is 
itself controversial.
CD69 is expressed within hours of T cell activation (373-375) and can be expressed 
independently of de novo synthesis via mobilisation of pre-existing intracellular 
molecules to the membrane (376). Previous reports (367) have shown that the 
induction of IL-1 secretion following contact mediated signalling was regulated 
largely by T cell cytokines. McAllister has shown, however, that membrane contacts 
are critical for the induction of IL-1 p mRNA and that CD69 modulates the secretion. 
In addition mAb against CD69 have also been shown to prevent the induction of IL-
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1P secretion in a number of monocyte cell lines when cultured with activated T cell 
lines (354,366).
The balance between TIMPs and MMPs has also been shown to be regulated by T 
cell cytokines and may be critical to the degree of tissue destruction in chronic 
inflammation (377). Shapiro (1990), Lacraz (1992) and Corcoran (1992) have 
observed that IFNy, IL-4 and IL10 suppress MMP production whereas IL-6 and IL- 
10 increase TIMP expression (378). Through the release of soluble mediators and 
direct cell-cell contact with mononuclear phagocytes T cells may play a critical role 
in the regulation of extracellular matrix turnover.
Lacraz (1994) has presented evidence that a cell surface glycoprotein that is 
synthesised and presented on the surface membrane of stimulated T cells triggers the 
expression of MMPs in monocytes (379). Freshly isolated T cells as well as T cell 
lines induced, by direct contact, the production of two major MMPs, interstitial 
collagenase and 92kDa gelatinase. Fixed PMA/PHA treated T cells, J16 cells and 
Hut78 cells as well as membrane preparations from these cells induced production of 
the above mentioned MMPs in undifferentiated THP-1 cells. A marked synergistic 
response was also seen when a combination of LPS and activated T cells was used to 
stimulate THP-1 production of IL-lp and TNFa. PHA treatment of the T cells was 
insufficient to induce monocyte activation, negating the possibility of carryover and 
PMA carryover was also ruled out by substituting T cells with red blood cells. Using 
the THP-1 cell line Vey et al. have also shown that activated HUT-78 cell 
membranes induced IL-ip and IL-lra production from THP-1 cells. IFNy did not 
affect THP-1 response whereas differentiation with D3 increased IL-ip by 2.3-fold 
and IL-lra by 1.6-fold (352).
Lacraz et al. (1994) challenged the ability of activated T cells to induce monocyte 
cytokine production using various methods. T cells treated with trypsin lost most of 
their capacity to induce 92-kDa gelatinase and IL-lp synthesis, whereas TIMP 
production was somewhat less affected (380). To test whether this protein was 
glycosylated, HUT 78 were treated with tunicamycin during activation. Tunicamycin 
treated Hut 78 cells were unable to induce THP-1 production of MMP, TIMP and IL- 
lp. Care should be taken when interpreting these data however due to the possible 
toxic effects of tunicamycin.
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Peripheral T cells became fully competent to induce MMP release from THP-1 cells 
after 2 hours incubation with PMA/PHA. The ability to induce IL-lp was not 
maximally achieved until 48-72 hours culture, with initial responses seen at about 4 
hours. Interestingly, J16 cells acquired the ability to induce MMP release from 
monocytes more rapidly than T cells (within lhour). Also, induction of IL-lp release 
maximised after 1-4 hours of J16 activation and dropped with further J16 activation. 
The data suggest that the glycoprotein responsible for the induction of MMPs is 
expressed early and that the molecule responsible for cytokine induction is more 
variably expressed.
Lacraz et al. also found that T cell activated IL-lp release from THP-1 cells was 
suppressed by anti-CDllb and CD11C and CD69 (380). None of the these Abs 
inhibited MMP induction.
Activation of T cells may induce a conformational change in the membrane- 
associated protein. Alternatively modification of an existing membrane protein, e.g. 
by phosphorylation or proteolysis, may be required for activity. Also, activation may 
prompt the translocation of an already existing pool of proteins to the membrane. The 
persistent capacity of activated T cells to function on monocytes implies that de novo 
synthesis of the operative glycoprotein also occurs during prolonged T cell 
activation.
Conclusive evidence remains to be found as to which T cell membrane proteins and 
monocyte ligands are critical for the induction of contact-driven monocyte cytokine 
production. In spite of this confusion, however, recent evidence has been reported by 
Vey et al. on the signalling cascades that are activated within THP-1 cells upon 
stimulation with T cell membranes. Staurosporine, genistein, calyculin A, calphostin 
C, tryphostins, phenylarsine oxide, vanadate and okadaic acid (inhibitors of 
phosphorylation and dephosphorylation) were tested against HUT-78 membrane 
induced THP-1 cytokine production (381). Only okadaic acid, an inhibitor of 
serine/threonine phosphatases, dissociated IL-lra and IL-ip production (Okadaic 
acid does not inhibit the PP2B-calcineurin). 50nM okadaic acid markedly inhibited 
secreted and cell associated IL-lra, whereas secreted and cell associated IL-lp was 
increased. Okadaic acid did not induce IL-lp secretion from THP-1 cells in the 
absence of stimulation with HUT-78 membranes. This demonstrates that IL-ip and 
its inhibitor IL-lra are inversely regulated by serine/threonine phosphatases upon
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contact with stimulated T cells, IL-lp being down-regulated while IL-lra is up- 
regulated.
Further results demonstrated that okadaic acid-sensitive serine/threonine 
phosphatases specifically modulate the production of IL-lp and IL-lra by regulating 
the expression of their respective mRNA in THP-1 cells (381).
Little is known about the intracellular signals induced by direct cell to cell contact 
that regulate the production of the pro-inflammatory cytokine IL-ip, and its inhibitor 
IL-lra. The identity of specific IL-1 inducing surface interactions is also questionable 
but probably involves both adhesion molecules and T cell activation molecules. In 
fact, antibody cross-linking of ICAM-1 (CD54) in a rheumatoid synovial cell line 
(E ll) has recently been shown to induce activation of the transcription factor AP-1 
and promote IL-lp gene transcription (382). Whether ICAM-1-induced signals can 
be replicated in normal monocytes remains to be seen, as does whether physiological 
ligation of ICAM-1 is sufficient for signal induction. The convergence of several 
signalling cascades may be necessary to initiate IL-1 induction following T cell- 
monocyte interaction. It has been shown that phosphatase inhibitors such as calyculin 
A (373) or cyclosporin A (383) decrease the production of pro-inflammatory 
cytokines by LPS-stimulated macrophages. In contrast, from recent studies it appears 
that okadaic acid potentiates PMA-induced IL-ip by increasing IL-lp mRNA and 
protein expression via effects on AP-1 binding (384,385).
In RA monocytes receive activating stimuli from interactions with T cell membranes, 
T cell-derived soluble factors, inflammatory mediators such as PGE2 and PGI2, and 
the oxidative environment. This fascinating milieu somehow converges in a signal 
that favours the production of pro-inflammatory cytokines from the 
monocyte/macrophages that encounter it. Whether T cell-derived stimulation of 
monocytes, which occurs in the rheumatoid synovium, can individually dominate the 
induction of pro- or anti-inflammatory cytokine secretion remains to be determined. 
Also, the level at which T cells can regulate monocyte cytokine production, whether 
it be increased transcription, translation or processing of cytokines remains to be 
determined.
RT-PCR analysis has shown that IL-lra mRNA was present in unstimulated THP-1 
cells which did not produce IL-lra protein. Upon contact with activated HUT-78
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cells, IL-lra production was strongly induced, with no change in mRNA expression. 
Thus the modulation of IL-lra production by membranes of stimulated HUT-78 cells 
may occur at a post-transcriptional level by stabilisation of mRNA, or at a 
translational level by derepression of IL-lra mRNA translation. Both phenomena 
have been previously reported in different systems (108,386), but the mechanism 
involved in IL-lra mRNA expression may be different since the 3’ UTR of IL-lra 
mRNA lacks the AUUUA sequence involved in the mRNA half-life and derepression 
processes (387).
IL-ip production depends on newly synthesised mRNA whose expression is 
inhibited by okadaic acid-sensitive serine/threonine phosphatases, and IL-lra 
production depends on the derepression of pre-existing mRNA whose expression is 
triggered by dephosphorylation catalysed by serine/threonine phosphatases. The 
question as to whether similar phosphatases are responsible for both phenomena as 
well as the identity of these phosphatases and the nature of their substrates remain to 
be elucidated. However, such observations could imply that pharmacological 
intervention at the level of serine/threonine phosphatases might reverse the 
imbalance between pro-inflammatory IL-lp and its inhibitor IL-lra which occurs in 
chronic destructive inflammatory diseases.
1.4.2.3: Differential Regulation of Monocyte Activation by Thl and Th2 Cells
Vey et al. (1997) have shown that when monocytes were activated by factors secreted 
by stimulated T cells in the absence of cell contact, production of IL-lra was 60 
times that of IL-ip (381). Since the inhibition of IL-ip-mediated effects requires 
approximately 100 fold excess of IL-lra over IL-ip (340) soluble factors from 
stimulated T lymphocytes may stimulate the generation of a monocyte cytokine 
profile in which the effects of IL-lp are regulated by IL-lra. However, when 
stimulated T cells are in direct contact with monocytes, as is likely to be the case at a 
site of inflammation, the production of IL-ip overwhelmed the inhibitory 
concentration of IL-lra. Among the soluble factors produced by T cells, Th2 
cytokines such as GM-CSF, IL-4, IL-10 and IL-13 have been shown to favour IL-lra 
production in several biological systems (224,225,388-390). Interestingly, Thl but 
not Th2 lymphocytes are involved in mechanisms of chronic inflammatory diseases
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such as RA and MS (391), whereas Th2 type cytokines display anti-inflammatory 
activities in these diseases (340).
Work performed using murine cells has provided evidence that upon contact with 
plasma membranes of antigen activated Thl cells, macrophages rapidly acquire the 
capacity to produce TNFa and nitric oxide (351,392). The contact dependent 
activation of macrophages is partly due to membrane-associated TNFa, but other 
factors, such as CD40-CD40L interaction, are involved (392-395).
IL-ip mRNA but not IL-lp protein is produced upon contact of human monocytes 
with paraformaldehyde fixed T cells, unless soluble factors are added to the co­
culture (367). Similarly, intact CD4+ T cells activated by purified protein derivative 
of Mycobacterium tuberculosis (PPD) induce IL-ip production by peripheral blood 
monocytes (396). Ag (PPD or TT) activated T cell membranes induced THP-1 IL-lp 
production. T cell activity peaked at six hrs and was Ag-concentration dependent. TT 
stimulation led to Th2 cell phenotype (IL-4 producers) whereas PPD stimulation led 
to Thl phenotype (IFNy producers).
Thl clones strongly induced the production of IL-ip by THP-1 cells (4 out of 4 
clones tested) with levels ranging between 484 and 806 pg/ml (IL-lra 0.9-7.8ng/ml). 
Th2 clones showed less induction of IL-lp, with levels ranging from 21-114pg/ml 
(IL-lra 7.0-49.6ng/ml) (397).
Overall, the ability to induce IL-ip production by THP-1 cells was directly correlated 
with the production of IFNy by T cells (p<0.001), and was independent of their IL-4 
production. Conversely, IL-lra production was directly correlated with the 
production of IL-4 by T cells (p=0.003), but inversely with their production of IFNy 
(p=0.001). No clear relationship between the T cells capacity to produce IL-10 and 
THP-1 responses was seen.
In these studies reported by Chizzolini, Ag was presented to T cells on autologous 
APCs, therefore anti-CD3 and anti-CD28 combination was also used to activate T 
cells. Again, the same correlation was seen with the T cell cytokine secreting 
capacity. Soluble cytokines were used to stimulate THP-1 cells. IFNy had no effect 
(5-5000U/ml) whereas IL-4 gave low IL-lra (but no IL-lp). When assayed T cell 
membranes were found to contain 0.37 ± 0.15ng/ml IL-4. When equivalent amounts
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of membrane associated and soluble IL-4 were used to stimulate THP-1 cells, higher 
IL-lra production was seen in the first group.
These results are in agreement and extend those of Landis, C.R. et al (1991) showing 
that activity exists predominantly within the CD4+ Thl group.
Th2 activity may lie in membrane associated IL-4. Increased activity of membrane 
bound IL-4 could be due to changes in steric conformation or more likely synergy 
with other membrane molecules. Thl cell induction of monocyte activation may also 
be due membrane-associated cytokines, in this case IFNy, and recent evidence has 
been published to support the existence of membrane bound IFNy. The expression of 
IFNy has been shown to be detectable by enhanced fluorescence cytometry on 
activated T cells (398).
Of all the T cell surface antigens considered here as being relevant to activation of 
monocytes, no evidence supports a difference between expression levels on Thl and 
Th2 cells. As the Thl subset is the predominant population in the RA synovium (82) 
it would be interesting to observe whether rheumatoid T cells regulate the balance of 
monocyte IL-lp and IL-lra production in a similar way to the T cell clones used by 
Chizzolini above. The recruitment of Thl cells to sites of inflammation may well be 
as a result of differential chemokine receptor expression. Thl cells show marked 
staining for CCR5 and CXCR3, and are only occasionally positive for CCR3 (399). 
It appears that CCR5 is highly expressed on Thl cells and rarely present on Th2 
cells, whereas CCR3 is found almost exclusively on Thl cells. CXCR3 is highly 
expressed on both subsets (399,400). MEP-lp appears to be a selective ligand for 
CCR5 (401,402), eotaxin for CCR3 (403-405) and IP10 for CXCR3 (406).
Upon activation within the inflamed synovium Thl cells may modulate monocyte 
cytokine production via a complex interaction of surface expressed cytokines, such 
as IFNy, adhesion molecules and activation markers such as CD69. Which membrane 
interactions are critical to T cell stimulation of monocyte IL-lp and IL-lra 
production remains to be seen. It is possible that T helper cell subset-specific surface 
molecules favour the induction of monocyte IL-ip or IL-lra production. From the 
evidence presented here, however, it is most likely that the surface phenotype of T 
helper cells simply governs their recruitment to the rheumatoid joint and that once
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they interact with resident mononuclear phagocytes the key interactions are those of 
adhesion molecules and surface bound cytokines. T cell induced monocyte cytokine 
production is dependent upon the state of T cell activation therefore activation 
induced surface markers may play a critical role.
1.4.3: Summary of Signalling Events Involved in IL-1 Gene 
Regulation
Thorough discussion of the signalling cascades involved in regulation of the IL-1 
family genes is beyond the scope of this introduction. A diagram summarising the 
data presented in the previous sections, however, is shown in figure 1. Possible 
signalling cascades initiated by ouabain, LPS stimulated CD 14 and FcyR ligation are 
shown in the upper part of the diagram. The contributions from T cell membrane 
interactions and secreted cytokines are shown in the bottom half of the diagram.
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Figure 1: Summary of signalling molecules involved in regulation of IL-1 
induction.
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1.5: AIMS OF THIS STUDY
Despite intensive research efforts the factors that regulate monocyte cytokine 
production in rheumatoid arthritis remain unclear. Pro-inflammatory cytokines such 
as IL-ip have been identified as critical regulators of the pathogenesis of RA yet the 
conditions that govern their synthesis, secretion and biological activity remain 
somewhat elusive. Upon secretion the activity of IL-lp is controlled by the decoy 
type II IL-1 receptor and perhaps more importantly by the specific receptor 
antagonist protein IL-lra. An understanding of the factors that determine the balance 
between IL-lp and IL-lra production by monocytes would be greatly beneficial for 
the development of treatments for RA and indeed many other inflammatory 
conditions. Thus it was the primary aim of this thesis to identify features that 
differentially regulate the production of monocyte cytokines and in particular alter 
the balance between IL-1 P and IL-lra production.
One of the key membrane enzymes that has been shown to be involved in the 
regulation of monocyte cytokine secretion is the Na+/K+-ATPase. Inhibition of the 
Na7K+-ATPase with ouabain in vitro has been shown to induce the production of 
pro-inflammatory cytokines by PBMCs via alterations in intracellular cation levels. 
In RA Na+/K+-ATPase activity has been shown to be reduced in erythrocyte 
membranes and early work from our laboratory has extended this to cells of the 
immune system, where decreased Na7K+-ATPase in mononuclear cell membranes 
has been reported. Decreases in Na+/K+-ATPase activity in RA could be due to 
sulphydryl damage caused by the highly oxidative environment of the inflamed joint 
and this could well extend to effects on circulating cells.
Despite this strong evidence to support a role for the Na+/K+-ATPase in defining 
cytokine profiles in RA little work has been carried out to study the effects of 
Na+/K+-ATPase modulation under in vivo conditions. Hence one of the main aims of 
this thesis was to link the in vitro reports of ouabains pro-inflammatory effects with 
the reports of decreased Na+/K+-ATPase activity in RA by studying in vivo models of 
murine arthritis.
Upon the completion of the murine studies several questions arose as to the 
suitability of these models for assessing in vivo effects of ouabain. These studies did 
not provide definitive data for the pro-inflammatory effects of ouabain and thus
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further studies were entered into, using human mononuclear cells, to improve the 
knowledge of the effects of ouabain on cytokine induction. Of particular interest was 
the study of the variation in sensitivity of rheumatoid and healthy PBMCs to ouabain 
induced cytokine production. By improving data on ouabain induced cytokine 
production and comparing effects of ouabain on rheumatoid PBMCs it was hoped to 
improve the current knowledge on how intracellular cation levels may contribute to 
the severity of the inflammatory condition in RA.
The study of ouabain induced production of pro-inflammatory cytokines was hoped 
to give valuable insight into the possible pro-arthritic role of decreased Na+/K+- 
ATPase activity in mononuclear cell membranes. A more pertinent line of 
investigation, however, was thought to be the study of the balance between pro- and 
anti-inflammatory cytokine production and in particular the balance between IL-ip 
and IL-lra production. Consequently, one of the final aims of this study was to 
develop models for the investigation of IL-lp and IL-lra production from cells of the 
monocyte/macrophage lineage. In the case of RA the activity of cells of the 
monocyte/macrophage lineage is regulated by various factors such as the oxidative 
environment, soluble mediators within the joint or peripheral circulation and contact 
with inflammatory tissues or other cells involved in the inflammatory response. Of 
particular interest was the role that T cells might play in regulating monocyte 
production of IL-ip and IL-lra in the rheumatoid joint. Recent reports have 
demonstrated that helper T cells of the type I and type II phenotypes differentially 
stimulate the production of IL-lp and IL-lra from monocytes that they interact with 
via the secretion of immune-modulatory cytokines such as IL-4, IL-10, IFNy, MIF 
and IL-17, and also via direct cell-cell contact. Due to the reported enrichment of Thl 
cells in the rheumatoid joint we were particularly interested in the reports that Thl 
cells stimulate IL-lp production from monocytes via membrane specific interactions, 
whilst Th2 cells favour IL-lra production. By developing models for the study of T 
cell driven monocyte cytokine production it was hoped that greater information could 
be gained as to how T cells regulate the balance between IL-lp and IL-lra 
production by monocytes. Also it was hoped that T cells from various patient groups 
could be compared to healthy T cells for their ability to induce production of IL-lp 
and IL-lra from the monocytic cell line THP-1. Secondly, it was hoped that 
monocytes from the different patient groups could also be compared to healthy
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monocytes for their ability to respond to T cell signals derived from the J16 T cell 
line. By developing co-culture models we also hoped to be able to exploit them for 
the study of anti-inflammatory/rheumatic drugs. Whilst many studies have monitored 
the effects of potential therapies at modulating monocyte cytokine production in 
response to agents such as LPS we hoped to be able to demonstrate in vitro efficacy 
of compounds in co-culture experiments with conditions that are perhaps more 
relevant to the stimulation of monocytes in RA. Due to the award of a Basic Science 
Initiative grant from Pharmacia-Upjohn the specific goal of these later studies was to 
investigate the ability of Sulphasalazine to modulate T cell activation and the ability 
of T cells to stimulate monocyte production of II-1 p and IL-lra.
Having developed the co-culture model it was possible to study the consequences of 
T cell and monocyte interactions in more detail. Of particular interest was the 
specific membrane interactions that are involved in T cell stimulation of monocyte 
cytokine production. At present the specific cell surface molecules that are critical for 
the transduction of signals from T cells to monocytes have not been defined. A great 
deal of evidence supports the involvement of adhesion molecules and activation 
markers such as CD69 but T helper cell sub-type specific antigens that regulate 
monocyte activation have not been identified. By developing a co-culture model for 
the study of T cell driven monocyte cytokine production the opportunity arose to 
further investigate the principal molecules involved in the membrane interactions. It 
was felt, however, that rather than using antibody blocking experiments a more 
relevant method for assessing the role of a surface protein in cell-cell interactions 
was to clone the molecule into a neutral cell type. In an attempt to address the role of 
T cell expressed CD69 in regulating monocyte production of IL-1 (3 and IL-lra 
experiments were carried out to clone and express human CD69 in COS-7 cells.




All routine chemicals and reagents mentioned herein were purchased from Sigma 
Chemical Company Ltd., unless otherwise stated. The composition of buffers and 
growth media are detailed in Appendix 1. Tissue culture media concentrates and 
supplements were from Gibco BRL technologies, except the foetal calf serum that 
was from Sigma Chemical Company Ltd.
2.1.1: Antibodies
Several hybridomas, obtained from the American Type Culture Collection (ATCC) 
(Rockville, Maryland USA), are maintained by colleagues within the University and 
included CD2 (OKT11), CD3 (OKT3), CD25 (HB8784), CD69, CD14 (UCHMl) 
and HLA-DR4 (L243). The purified antibodies from these hybridomas were a kind 
gift from D. M. Sansom. The anti-CD 19 antibody BUI2 was a kind gift to D. M. 
Sansom from I. MacLennan (University of Birmingham, UK). The anti-CD80 (BB1) 
and the anti-CD28 antibody (9.3) were kind gifts to D. M. Sansom from P. Linsley 
(Bristol-Myers Squibb, Seattle, USA). Anti-mouse IgG (F(ab)'2 specific) and anti­
mouse polyvalent (anti-IgM, IgG and IgA) FITC was purchased from Sigma 
Chemical Company Ltd. Antibodies for ELISA of IL-1 p, IL-lra, IL-6 and TNFa 
were purchased from R&D Systems Ltd.
2.1.2: Molecular Biology Reagents
AquaPhenol was supplied by Appligene (Co. Durham, UK). Bacto-Agar, Bacto-yeast 
extract and Bacto-tryptone were obtained from Oxoid (Bristol, UK). Routine agarose 
from Sigma was used for resolving PCR products. DNA markers and restriction 
endonucleases, with appropriate digestion buffers, were supplied by New England 
Bioloabs (NEB).
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2.1.3: Cell lines
The murine monocyte/macrophage cell line P388-D1 was a kind gift from Knoll 
Pharmaceuticals. The human monocytic cell line THP-1 was obtained from ECACC 
and the human T cell line Jurkat (J16) from the ATCC.
2.1.4: Transfected cells
CHO cells transfected with the CD80 receptor, as previously described (407), were a 
kind gift from D. M. Sansom. COS-7 cells (ATCC) that were transfected with CD69 
cDNA were prepared as part of the studies in this thesis (see Chapter 7). Cells were 
assessed for surface protein expression using FACS analysis.
2.1.5: General equipment
Tissue culture plastics were purchased from Fahrenheit Laboratory Supplies Ltd, and 
cell culture was performed using sterile techniques in a laminar flow hood (Class II). 
All cell-based assays were incubated in a 5% C02 humidified incubator kept at 37°C. 
All PBMC and monocyte manipulations were carried out in polypropylene tubes to 
avoid loss through adherence. Where monocytes needed to be recovered after 
incubations, e.g. for FACS analysis, sterile polypropylene tubes were used (Falcon 
6ml capped FACS tubes). Cells were counted using a Neubauer haemocytometer.
An Ultraspec II spectrophotometer (LKB Biochrom) was used to perform the 
ATPase assay as well as RNA and DNA quantification. Protein determinations 
(BioRad assay) and ELISA plate readings were carried out on a Dynatech MR5000 
spectrophotometer. Proliferation assays were determined by a B Liquid Scintillation 
Top Counter (Packard).
FACS analysis was performed on a Becton Dickinson FACStar Plus, using a 
lOOmW, 488nm argon laser with light being channelled by an FL-1 filter 
(520nm±20) and FL-2 filter (580nm±20).
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2.2: GENERAL METHODS
2.2.1: Basic tissue culture
All cell lines were maintained in 75 ml culture flasks and incubated in a 5% C02 
humidified incubator kept at 37°C. Specific media and supplement information is 
detailed in Appendix 1. Cultures were initiated from frozen stores held in Bath and at 
Knoll Pharmaceuticals or from growing cultures obtained from ECACC. Frozen vials 
of cells were rapidly defrosted in a water bath (37°C), the cell suspension then being 
washed twice in warm medium before culture. THP-1 and P388-D1 cells were 
maintained between 0.2xl06/ml and lx l06/ml and J16s between 0.2xl06/ml and 
2xl06/ml.
Chinese Hamster Ovary (CHO) cells and COS-7 cells were maintained in Dulbeccos 
Modified Eagle Medium (DMEM) supplemented as shown in Appendix 1. Both 
CHO and COS cells were passaged every 2-3 days after they had reached a state of 
confluence. To remove the adherent CHO/COS cells the medium was removed by 
aspiration and then the cells were washed once with phosphate buffered saline (PBS) 
before the addition of trypsin-EDTA (GibcoBRL technologies) (1ml for a 75cm2 
flask). The cells were then incubated for five minutes at 37°C to allow the enzymatic 
digestion of the cell-plastic adhesion. Gentle tapping of the flask completely 
dislodged the cells after which fresh medium was added to inactivate the trypsin. At 
this point the cells were either taken for use or split approximately 1 in 10 in medium 
for continued culture. On occasion cells were taken at the sub-confluent stage for 
storage under liquid nitrogen.
2.2.2: Cell fixation
Prior to use, cells for membrane bound stimulations were fixed with 0.025% 
glutaraldehyde. This procedure leaves the cell intact allowing the surface molecules 
to be utilised, but negates the possibility of soluble mediator production or continued 
proliferation. To achieve fixation the cells were washed twice with PBS, counted and 
then resuspended for 2-3 minutes at room temperature with 0.025% glutaraldehyde 
(lml for every 5 million cells). Fixation was terminated by the addition of medium
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and the cells were washed twice in medium to prevent carry over of glutaraldehyde 
into cultures.
2.2.3: Freezing of cells
Cells for freezing were resuspended at lOxlO6 per ml in 40% FCS culture-medium. 
An equal volume of 20% DMSO (in medium) was then added to the cell suspension 
in a cryovial and then frozen at -80°C for at least 10 hours prior to storage in liquid 
nitrogen. THP-1 cells were frozen using 10% glycerol as a preservative instead of 
DMSO due to the differentiating effects of DMSO on monocytic cell types.
2.2.4: Peripheral blood mononuclear cell (PBMC) preparation
Blood samples were obtained from healthy human volunteers or patients attending 
clinics at the Royal National Hospital for Rheumatic Diseases, collected in 
heparinised 50ml falcon tubes (lOOU/ml) and diluted 1:1 with PBS before being 
layered onto a lymphoprep gradient (Nycomed, 1.077g/ml density). The tubes were 
centrifuged at 350g for thirty minutes at room temperature and then the 
plasma/lymphoprep interface cell layer was collected. In some cases the plasma was 
retained for cytokine analysis. PBMCs were washed three times with RPMI 1640 
medium and then counted.
2.2.5: Monocyte Preparation
Various methods were tested for the preparation of purified monocytes during these 
studies, including adherence selection, Percoll and Nycomed density gradient 
separation and magnetic-bead based immuno-magnetic selection. The quickest 
system that yielded the purest population of resting cells was that which utilised the 
Miltenyi Monocyte Negative selection kit (Miltenyi Biotec). The kit was used as per 
instructions, with a Variomacs magnet and LS+ columns and adapter. Briefly, 
PBMCs were washed in buffer (PBS supplemented with 10% autologous serum, 
0.5% BSA and 2mM EDTA) then resuspended in fresh buffer to a total volume of 
60pl per 107 cells. 20 pi of FcR Blocking Reagent and 20pl of Hapten-Antibody 
cocktail were added per 107 cells and incubated for 5 minutes at 6-12°C. The cells
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were then washed twice in buffer and resuspended as before. Blocking reagent was 
added again as were 20pl of anti-hapten microbeads per 107 cells. After 15 minutes 
incubation at 6-12°C the cells were washed, resuspended in 500pl of buffer and 
loaded onto a buffer treated column. Negatively selected monocytes were washed 
through the column with buffer and retained. Purity was assessed by CD 14 staining 
and routinely found to be greater than 90%.
2.2.6: T cell purification
50xl06 PBMCs, as prepared above, were placed in a petri dish at a concentration of 
5xl06/ml, and incubated for 1 hour at 37°C in complete RPMI-1640 medium. Non­
adherent cells were then recovered, washed twice with medium and pelleted in an 
8ml screw top tube. The cell pellet was then resuspended in 500pl of anti-DR4 
antibody (L243), 500pl anti-CD14 antibody (UCHM1) and lOOpl anti-CD19 (BU12) 
(all at 2pg/ml) and incubated for one hour at 4°C on a rotator. The cells were then 
washed and incubated for another hour at 4°C with lOOpl sheep anti-mouse IgG 
dynal beads (diluted with 400pl RPMI-1640). Cells that had been bound by antibody 
could thus be removed via the use of a magnet. The recovered negatively selected 
cells were analysed by flow cytometry and found to be greater than 95% CD3 
positive.
2.2.7: Preparation and maintenance of peripheral blood T cell blasts
For the preparation of T cell blasts, PBMCs purified as mentioned above were 
stimulated with staphylococcal enterotoxin A (SEA) (lOng/ml) which binds HLA- 
DR molecules on the surface of antigen presenting cells, such as monocytes, 
macrophages and B cells, within the PBMC population. The same cells also provided 
the co-stimulatory molecules that synergised with SEA to activate T cells. The 
antigen responsive blasts were cultured in RPMI 1640 medium at a density of 2- 
4xl06/ml for 8-10 days with medium added every 2-3 days. PBMCs or purified T 
cells were also blasted with PHA or combinations of phorbol ester (PMA or PDBu) 
and Ionomycin.
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2.2.8: Proliferation assays: Stimulation of resting T cells
Proliferation assays were performed in triplicate, in 96-well round bottom plates at a 
volume of 200pl per well. In each well, lOOpl of T cells (5x104), 50pl of medium or 
fixed CHO or CHO-CD80 cells (2x104) and 50pl of medium containing other 
stimuli such as PHA, phorbol ester, ionomycin, A23187 or soluble CD3 (OKT3) 
antibody. CD3 cross-linking in culture was achieved with an equal concentration of 
anti-mouse IgG. When the effect of drug manipulations was tested the T cells were 
pre-treated for at least thirty minutes before stimulation and drug levels were 
maintained throughout culture.
The plates were incubated at 37°C for 72hr at which point 50pl of tritiated 3H- 
thymidine (lmCi) was added per well. After an additional 18 hours incubation the 
plates were harvested on to replica 96 well fibre filter plates (Packard) using a 
Packard 96 well harvester. Radioactivity was measured via a P liquid scintillation 
counter (Top Count, Packard). The counted CPM represent the 3H-Thymidine 
incorporated into the DNA of the cells, during cell division. It is therefore an indirect 
measure of proliferation.
2.2.9: Human IgG Preparation
Human IgG was used during this study as a monocyte stimulus. The IgG was 
prepared in-house using the following method. lOOmls of blood was taken from a 
healthy volunteer (in two 50ml tubes) and left until clotting had taken place. The 
blood was then centrifuged at lOOOg and the serum collected from the top layer. The 
serum was then dialysed over-night against a 0.01M phosphate buffer (pH7.3). The 
dialysed serum was then mixed with DEAE sepharose beads that had been 
equilibrated with the same phosphate buffer and left to incubate for 2hrs at 4°C. The 
IgG solution was then filtered off the beads and adjusted with 10X [PBS] to achieve 
physiological isotonicity. After sterile filtering the IgG solution was assayed for 
protein concentration using the Bio-Rad DC protein assay (see below).
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2.9.10: Bio-Rad DC protein assay
Protein (IgG) concentration determinations were made using a Bio-Rad 
colourimetric assay. This assay is based upon the binding of Coomassie brilliant blue 
(G-250) to basic and aromatic amino acids of the protein. Briefly 5pi of each sample 
is mixed with 25pi of reagent A (supplemented with 20pl of solution S for every 
lml) and 200pl of reagent B. A standard curve was constructed using BSA (0- 
3mg/ml). After a 15 minute incubation at room temperature optical density is 
measured at 750nm.
2.3: ATPase ASSAY
In this assay ADP is utilised as follows to effect the oxidation of NADH:
ATP ----------------------  ► ADP + Pi
ATPase
Phosphoenolpyruvate + ADP ------------------------------------------► Pyruvate + ADP
Pyruvate Kinase
Pyruvate + NADH -------------------------------- ► Lactate + NAD
Lactate Dehydrogenase
The cells to be used were first washed in PBS, THP-1 cells being resuspended at a 
density of lx l06/ml and peripheral blood mononuclear cells at 5xl06/ml in PBS. The 
cell suspension was then sonicated with 3-4 five second pulses of 8-10 Hz to lyse the 
cell membranes and then kept on ice at 4°C. At this point, ouabain was added to test 
samples and the lysate incubated on ice for 30 minutes. The assay cocktail (see 
Appendix 1) was also prepared at this time by adding 0.25 mM (3-NADH and 1.2 
units/ml of both lactate dehydrogenase and pyruvate kinase and incubating at 37°C 
for 30 minutes. The assay was initiated by adding 800pl of cocktail to 200pl of cell 
lysate and the absorbance of 340nm UV light was measured to determine a start 
point. Further absorbance readings were taken over time and the effect of ouabain on 
the oxidation of NADH monitored.
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So that the activity of cell lysates can be correlated with specific ATPase activity and 
that the Na+/K+-ATPase component could be defined, a calibration curve was 
constructed using exogenously added ADP (0, 10, 20, 40, 80, 160mM) in the absence 
of cell lysate.
2.3.1: Preparation of Murine Cells for ATPase assay
Early attempts to harvest murine peripheral blood mononuclear cells were aborted 
due to poor separation on a 1.087 g/ml ficol gradient. Instead, the P388-D1 cell line 
was studied as were peritoneal macrophages. The following protocol was used for the 
preparation of peritoneal macrophages.
Mice were killed by C02 asphyxiation and cervical dislocation. The skin over the 
abdomen was then peeled back gently to reveal the peritoneal wall. The peritoneal 
cavity was then distended by the injection of 2ml of air and filled with 5ml of warm 
heparinised RPMI-1640. After gentle massage of the abdomen the media was 
extracted using a large bore needle. The murine cells were prepared for the ATPase 
assay as previously described above.
2.4: MURINE MODELS OF ARTHRITIS
For all murine studies female BALB/c mice (20-25g, aged 10-12 weeks) from 
Charles River were used. Before the animal models of arthritis could be set up a 
toxicology study for ouabain had to be carried out. Ouabain was made up in 0.9% 
saline and five groups of two mice were dosed via intra-peritoneal injection of 0.1 
ml. Ouabain was studied at 0, 4.25, 8.5, 17,34 and 170pg per kilogram, the animals 
being dosed daily for eleven days. Ouabain had no toxic effects on the mice at these 
doses so a dose of 34 pg per kilogram was decided upon for initial studies. Later 
experiments used 170 pg per kilogram in an attempt to increase effects of the drug.
2.4.1: Antigen Induced Arthritis
Animals were sensitised by sub-cutaneous (s.c.) injections into the flank of lOOpl of 
an emulsion comprising equal volumes of a 2mg/ml solution of m-BSA (Sigma) in
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sterile 0.15M NaCl and FCA (Difco), to which was added M. tuberculosis such that 
the final concentration of Mycobacterium was 1.5mg/ml. At the same time as the 
flank injections the animals also received an intra-peritoneal (i.p.) injection of 2x109 
heat-killedBordatellapertussis organisms (50pl). Omission of B .pertussis results in 
the development of a mild form of arthritis (408). In these studies there was a 
possibility that any effects of ouabain on the progression of the arthritis may be 
undetectable due to the gross severity of the inflammation. As a result a parallel 
group of animals were set up for antigen induced arthritis in the absence of 
Bordatella pertussis with the hope that a more mild arthritis might be a more 
sensitive model. The sensitisation injections were repeated seven days later and a 
further twelve days later i.p. injections of ouabain were commenced, control groups 
receiving physiological saline. Two days after the start of daily i.p. ouabain lOpl of 
m-BSA solution (lOmg/ml in sterile 0.15 M NaCl) was injected into the joint of the 
left knee using a Hamilton syringe fitted with a 26 gauge/3/8 in. needle. To ensure 
that the antigen was injected into the joint space, the knee was flexed and mild 
pressure with the shaft of the needle over the anterior surface located the patella 
ligament. After swabbing with alcohol, the needle was inserted through the patellar 
ligament into the joint space. Intra-articular injections did not necessitate shaving of 
the knee or administration of a local anaesthetic.
2.4.1.1: Preparation of Tissue Samples
Animals were killed by C02 asphyxiation and both hind legs removed. The femur 
and tibia were cut midway along their length and the knee joints trimmed free of skin 
and musculature. The joints were then placed in perforated plastic holders and fixed 
in 10% formol saline for at least 48 hours followed by decalcification in 5% formic 
acid for 48 hours with constant agitation (the formic acid being replaced after 24 
hours). The joints were then washed under running tap water for 2 hours followed by 
dehydration in graded alcohols before being embedded in paraffin wax. The fixed 
joints were sectioned in the sagittal plane at 5pm thickness, with several sections 
being taken to represent the entire joint. The slide mounted sections were stained for 
visualisation of cells, proteoglycans and collagen using hematoxylin/eosin, toluidine 
blue (or Alcian blue), and van Giesen’s stain, respectively.
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2.4.2: Zymosan induced arthritis
Mono-articular arthritis was induced in the left hind knee joint by the intra-articular 
injection of Zymosan A. The Zymosan was made up by grinding in a pestle and 
mortar at 18mg/ml in saline, a lOpl injection thus delivering 180pg to the joint. Two 
days prior to initiation of arthritis the ouabain groups started treatment with daily 
0.1ml intra-peritoneal injections of ouabain (initial studies received 34pg/kg, later 
changing to 170pg/kg). Control mice received saline.
The rapid development of inflammation required that animals were removed from the 
experiment from as soon as 1 day after initiation. Time course studies for the 
development of proteoglycan (PG) synthesis defects showed that days 1-7 were the 
most critical times as after this point the inflammation was starting to resolve. As a 
result in the majority of studies patellae were harvested on days 1, 2, 3, 4 and 7.
2.4.3: Murine Patellae Proteoglycan Synthesis Assay 
2.4.3.1: Tissue preparation
The mice were sacrificed by asphyxiation in a rising concentration of carbon dioxide 
followed by cervical dislocation. The skin was then peeled back from both knees to 
expose the joints. Cuts were made across the inferior ligaments with a scalpel and 
lifting with fine forceps allowed dissection parallel to the ligament. When the tissue 
could be lifted up sufficiently to reveal the patellae a final cut was made across the 
superior ligaments freeing the patellae, attached ligaments and surrounding tissue. At 
this point care had to be taken to leave as much ligament as possible to allow easy 
dissection of patellae in future steps. The patellae were placed into individual wells 
of a 96 well plate containing 0.2 ml of DMEM per well, to hold them until they could 
be trimmed further to remove inflammatory tissues.
Under low power microscopy (x20), excess tissue was removed from either side of 
the patellae leaving undamaged bone and cartilage with the attached ligaments. The 
patellae were then incubated for three hours, in a humidified incubator at 37°C in 
95% air/5%C02, in 0.1 ml DMEM containing 1.85 MBq 35S [N a^O J (Amersham, 
UK) to measure “ex vivo" levels of proteoglycan synthesis.
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2.4.3.2: IGF-1 Induced Proteoglycan Synthesis
Recombinant human Insulin-like Growth Factor (IGF-1) (Calbiochem) was prepared 
by first dissolving 250pg stock in 400pl lOmM HC1 (containing lmg/ml BSA) and 
then making up to 1ml in phosphate buffered saline (containing lmg/ml BSA). The 
effects of IGF-1 stimulation of PG synthesis in control and arthritic patellae were 
studied at concentrations of 0, 75, 150, 300 and 600ng/ml, the arthritic patellae being 
taken on day 1 after zymosan induced arthritis. The patellae were incubated in 0.2ml 
DMEM containing the IGF-1 for 24hrs in a humidified incubator at 37°C in 95% 
air/5%C02, with 1.85 MBq 35S [S04] per ml being added for the last 3hrs.
2.4.3.3: Measurement of 35S [SOJ Incorporation
After incubation the labelled patellae were transferred to a 96 well plate containing 
0.2% PBS + lmg/ml Na^C^ for 5 minutes to remove unbound 35S [SOJ label. 
Labelled glycosaminoglycans were then extracted from the patellae by a 
modification of the method described by de Vries et al. (409). Tissues were fixed in 
0.2 ml 4% phosphate-buffered formalin containing 0.2% cetylpyridinium chloride 
(CPC) for one hour at room temperature followed by decalcification in 0.2 ml 5% 
formic acid for 24 hours at room temperature. The patellae were removed intact from 
the surrounding tissue and digested at 60°C for 24 hours in 0.1ml sodium acetate pH 
6.0 containing 2mg/ml papain (Sigma), 0.2M sodium chloride, 50mM 
ethylenediamine tetraacetic acid (EDTA) and 10 mM L-cysteine hydrochloride. The 
plate was sealed in a humidified atmosphere to prevent evaporation.
The glycosaminoglycans were precipitated by incubating 0.15 ml of the digest with 
an equal volume of 0.2% CPC in an Eppendorf tube for 2 hours. Centrifugation at 
lOOOOg for 5 minutes in a micro-centrifuge pelleted the precipitate in the Eppendorf 
tubes. The pellets were washed once in 0.2 ml of 0.1% CPC, recentrifuged and then 
resuspended in 0.2 ml water. The degree of 35S [SOJ incorporation was then 
measured by transferring 0.1 ml of the precipitate to a 96 well “lumaplate”, adding 
0.2 ml microscint fluid and counting on a Packard Topcount.
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2.5: T CELL DRIVEN MONOCYTE CYTOKINES
2.5.1: THP-1 differentiation
In order that THP-1 cells could be used as a model for monocyte/macrophages they 
first had to be differentiated with l,25(OH)2 vitamin D3 (hereafter referred to as D3). 
In their resting state THP-1 cells express very low levels of CD 14 and respond 
poorly to LPS stimulation. THP-1 were suspended at a density of 5xl06/ml and 
incubated for 48hrs with lOnM D3. Differentiation was measured as an increase in 
CD 14 expression with populations routinely becoming approximately 70% CD 14 
positive (see figure 6.1A).
2.5.2: T cell/J16 Activation
Phorbol esters, ionomycin and CD3/CD28 ligation were tested for their ability to 
activate T cells. T cell activation was measured via tritiated thymidine incorporation, 
in proliferation assays (detailed above) and as changes in activation marker 
expression using FACS analysis (see below). The effect of activated T cells and J16 
cells on monocyte cytokine production was compared to that of resting cells in co­
culture assays. For these experiments T cells and J16 cells were suspended at 
lx l06/ml in RPMI-1640 and stimulated for 18hrs at 37°C. Before co-culture the T 
cells were assessed for activation by measuring surface CD69 expression.
2.5.3: Co-culture
The effect of T cell interactions on the production of monocyte cytokines was 
assessed using normal T cells, J16 cells and THP-1 cells as well as some 
experiments with purified PBMCs and monocytes. All experiments were carried out 
in 96 well round bottom polystyrene plates (Falcon). Differentiated THP-1 cells (see 
method 2.5.1) were suspended at lx l06/ml in RPMI-1640 and lOOpl added to each 
well. PBMCs or monocytes were suspended at 2xl06/ml and lOOpl added to each 
well. The monocytic cells, in some cases, had been pre-treated with drugs and 
incubated at 37°C prior to addition of T cells. lOOpl of activated or resting T cells or 
J16 cells, suspended at 5xl06/ml, were then added to the culture. At the same time 
any other stimuli, such as LPS, were added to give a total volume of 220pl per well.
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To assess the contribution of membrane signals from the T cells, in the absence of 
soluble factors, the T cells (or J16 cells) were fixed according to the protocol for 
CHO cells outlined above (see method 2.2.2). Each experiment was duplicated in 
two wells with controls receiving lOOpl of RPMI-1640 instead of T cells. 
Experiments were incubated for varying time-courses at the end of which 
supernatants were harvested by gentle aspiration of each well after the plate had been 
centrifuged for 5 minutes at 350g. Supernatants were stored in a clean 96 well plate 
and assayed immediately for cytokine content. Remaining supernatants were stored 
in a sealed plate at -18°C.
2.6: ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA)
NUNC maxisorb plates were coated overnight with lOOpl per well of primary 
antibody in bicarbonate buffer pH9.6. Prior to testing, antibody concentrations for 
optimal ELISA performance were determined by running titrations of coating 
antibody with different concentrations of detecting antibody. TNFa, IL-ip and IL-6 
coating antibodies were used at 4pg/ml and IL-lra coating antibody was used at 
lOpg/ml. To eliminate non-specific plastic adherence the plate was then blocked for 
90 minutes with 300pl per well of PBS containing 1% BSA and 5% sucrose. After 
this the plate was washed three times before the addition of samples. For each ELISA 
a six point standard curve was constructed using recombinant human protein. All 
standards and samples were assayed in duplicate, with the samples being diluted in 
RPMI-1640. The plates were then sealed and incubated for two hours at room 
temperature of overnight at 4°C. The plates were then washed three times before the 
addition of lOOpl of biotinylated secondary antibody, which was incubated at room 
temperature for two hours. TNFa and IL-ip detection antibodies were used at 
lOOng/ml, IL-6 detection antibody was used at 25ng/ml and IL-lra detection 
antibody was used at 50ng/ml. After washing, the plates were incubated with lOOpl 
streptavidin conjugated horseradish peroxidase (lpg/ml) for 20 minutes. The plates 
were then washed four times before the addition of lOOpl OPD substrate (Sigmafast 
P-9187). After suitable colour had developed the reaction was stopped with 50jLtl of 
0.5M H2S04 and absorbance values read at 490nm.
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2.7: FACS ANALYSIS
Surface staining was performed by incubating 2xl05 cells for 30 minutes at 4°C with 
50pl of primary antibody (lpg/ml). Cells were then washed with PBS and any 
primary antibody bound to the cells was detected using FITC-conjugated anti-mouse 
polyvalent Ig (Sigma) at 1:300 dilution (7pg/ml). To improve the level of non­
specific staining of monocyte/macrophages a F(ab)'2 specific FITC-conjugated anti­
mouse Ig was used (Sigma F-2653). As a control the staining of cells treated with 
only the secondary antibody was also determined.
2.7.1: Annexin-FITC Assay
The annexin-FITC binding assay (Apoptest™, Boehringer Mannheim) relies upon 
the affinity of annexin-V for binding phosphatidylserine (PS), which is rapidly 
externalised during apoptosis (410). Briefly, after experimental treatment, 3xl05 cells 
were washed once in ice cold PBS and resuspended in lOOpl HEPES buffer 
containing annexin-FITC (2pi neat per test) and the nuclear stain, propidium iodide 
(PI) (final concentration 2pg/ml). After a ten minute incubation at room temperature 
the cells were diluted 1:5 with HEPES buffer and analysed by FACS. Annexin-FITC 
binding was visualised as FL-1 channel fluorescence and PI staining as FL-2 channel 
fluorescence. Plotting FL-1 against FL-2 allowed the distinction of necrotic (FL-1 
+ve, FL-2 +ve) and apoptotic (FL-1 +ve, FL-2 -ve) cells.
In certain experiments, to measure general cell death, PI incorporation was used as 
determine membrane integrity.
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2.8: MOLECULAR BIOLOGY
2.8.1: CD69 mRNA Extraction
J16 cells readily express CD69 on their cell surfaces within one to two hours of 
activation with phorbol ester and calcium ionophore. For mRNA extraction, lOxlO6 
J16 cells were stimulated at a density of 2xl06 cells/ml with 5ng/ml PMA and lpM 
ionomycin for 2 hours in a 24 well plate. To isolate mRNA from Jurkat cells for 
subsequent PCR reactions a Pharmacia QuickPrep® Micro mRNA purification kit 
was used. This kit allows the isolation of polyadenylated RNA from small numbers 
of eukaryotic cells, bypassing the need for intermediate total RNA purification. For 
all RNA work only specific, reserved reagents, tips and pipettes were used to limit 
the possibility of RNAse contamination. All solutions were made up with 
Diethylpyrocarbonate (DEPC) treated water.
Briefly, the cell contents are extracted into an extraction buffer that contains a high 
concentration of guanidinium thiocyanate (GTC), ensuring rapid inhibition of 
endogenous RNAses. The extraction cocktail is then diluted with elution buffer 
which reduces the concentration of GTC sufficiently to allow the formation of 
hydrogen bonds between the poly(A) tracts on the mRNA and the oligo(dT) attached 
to the cellulose slurry. Incubation of the elution cocktail with the cellulose slurry, 
followed by salt buffer washing captures the mRNA which can then be eluted from 
the spin-column with 65°C elution buffer.
2.8.2: mRNA Quantification
RNA quantification was carried out using the Ultraspec II spectrophotometer (LKB 
Biochrom) according to the instruments instructions. Briefly 5pi of the RNA sample 
was diluted to a final volume of 125pl and the optical density ratio between 260nm 
and 280nm was calculated. Typically the latter was between 1.8 and 2, indicating low 
levels of impurities. Concentration of RNA was calculated according to the equation:
A260 x 40 x dilution = [RNA]/(mg/ml)
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2.8.3: Reverse Transcribed Polymerase Chain Reaction (RT-PCR)
Siliconised plastics were used for these reactions in order to prevent the newly 
formed cDNA from sticking. The following reaction was set up containing 
approximately 400ng total RNA:
Superscript RT enzyme (200U/ml) (Amersham) 2pl
RT buffer (5X) (Amersham) 6pl
DTT (0.1M) (Sigma) 3 pi
dNTPs mix (lOmM) (Pharmacia) 1.5pl
Oligo-dT (45 pM) (Pharmacia) lpl
RNAse inhibitor (Pharmacia) 1.5pl
DEPC water to 30pl
The reaction mixture was incubated at 37°C for 1 hour and stopped with a 5 minutes 
incubation at 95°C. Samples were kept on ice when PCR reactions were to be 
performed immediately or alternatively stored at -20°C.
2.8.4: PCR primer design.
Primers were designed using Mac vector and produced by Gibco BRL custom primer 
service. See section 7.3.2 for primer details.
The sequences of the primers utilised in this study (5’ to 3’) were
CD69 Forward: GGA ATC TTG AGA ATA AAG ATG AGC
CD69 Reverse: GTT TCC TTA TTA TTT GTA AGG
2.8.5: PCR conditions
PCR reactions were set up with 2pl of the freshly prepared cDNA together with 6pl 
of 25mM MgCl2, 10pl of 2mM dNTPs, lpl of each of the primers (stock of ImM)
and lOpl of Taq buffer (Promega). Water was added to a volume of lOOpl and 
reactions were covered with mineral oil and performed with a Robocycler gradient
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96 (Stratagene). The PCR cycle was initiated with a preincubation for 5 minutes at 
95°C, to denature the coiled DNA, followed by the addition of 0.5pl of Taq enzyme 
(Promega). After that the following cycle was performed 30 times
-1 minute at 95°C (denaturing)
-1 minute at 54°C (annealing: - Temperature depends upon Tm of primers)
-1 minute at 72°C (extension)
A final extension incubation at 72°C was performed before chilling the reaction 
mixtures to 4°C.
2.8.6: Restriction Digests
Restriction digests were carried out to prepare plasmid DNA for ligation reactions 
and to map cloned DNA fragments. Restriction enzyme usage depended upon the 
particular requirements of individual experiments and details are included where 
necessary with the relevant results. Digestions were carried out in 20pl volumes 
unless larger amounts of DNA were required for gel excision for further 
manipulation. A typical restriction digestion reaction was compiled as follows:
Plasmid DNA (0.5pg/ml) 5pl
Enzyme specific buffer (1 OX) 2pl
Restriction Enzyme (3.5 pg/ml) 1 pi
Water to 20pl
Restriction enzyme content was limited to a maximum of 10% of the reaction 
volume to prevent effects of contamination with the carrier glycerol.
Reactions were carried out on a heating block at the required temperature for the 
enzyme being used. Samples were electrophoresed on 1% (w/v) agarose gels for 
analysis on a UV transilluminator. Digested DNA was cleaned via phenol- 
chloroform extraction followed by precipitation with sodium acetate in ethanol. 
Briefly, the digested sample was expanded to lOOpl with water. To this was added 
lOOpl of phenol and lOOpl of chloroform. The sample was then vortexed vigorously 
before being centrifuged briefly at 10,000g in a micro-centrifuge. The upper aqueous
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layer was gently removed and kept and a repeat extraction performed on the 
remaining sample. The retained aqueous phase was then mixed with a one tenth 
volume of sodium acetate (3M) and two volumes of absolute ethanol. The mixture 
was then chilled at -18°C for five minutes to allow the formation of the DNA 
precipitate. The precipitate was pelleted by centrifugation and the alcohol removed. 
After the pellet had been air-dried it was resuspended in 20pl of water.
2.8.7: Ligation Reactions
DNA ligation was necessary for the generation of recombinant plasmid DNA, in the 
cloning of CD69. The following reaction was used:
Plasmid DNA (50ng/pl) 1 pi
cDNA (50ng/pl) lpl
Ligase buffer (1 OX) (New England Biolabs, NEB) 1 pi
Ligase Enzyme (T4 DNA ligase 400,000U/ml) (NEB) 1 pi
Water 6pl
Ligation reactions were carried out in Eppendorf tubes at 16°C for four to sixteen 
hours.
To achieve optimal ligation a vector: insert ratio of 1: 3 or 1: 5 molar ends of DNA 
was used. With information of the size of vector and size of insert available the 
amount of insert DNA needed for a given amount of plasmid DNA in the ligation 
reaction (50-100ng) was calculated as follows:
ng of vector x kb size of insert „  _ _ , _ ,. Insert
ng0fmSert=  kb size of vector  X Molar Ratro of ^
Ligation reactions were terminated by heating to 70°C (to inactivate ligase enzyme) 
before DNA was either used to transform bacteria or stored at -20°C. Controls such 
as plasmid self ligation in the absence of insert were used to assess possible 
transformation efficiency of recombinant clones. Plasmid DNA was analysed on an 
agarose gel to determine linearisation.
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2.8.8: Agarose gel Electrophoresis of PCR Product
Agarose gels were made in TAE buffer as a 1-2% solution (w/v), boiled in a 
microwave oven until the agarose was completely melted and then cooled to 
approximately 50°C. Ethidium bromide was added to a final concentration of 
500pg/ml before the gel was poured into an electrophoresis tray. All DNA 
electrophoresis was carried out in TAE buffer (containing ethidium bromide) using a 
standard horizontal electrophoresis tank attached to a power source of 70 -  100 volts.
Gels were analysed over a UV transilluminator and photographed.
TAE buffer was made as a 50X stock as follows:
Trizma Base (Sigma) 242g
Glacial Acetic acid (Sigma) 57.1ml
EDTA (0.5M pH 8) 100ml
Milli Q water to 1 litre
2.8.9: Transformation of Bacteria (Heat shock)
In order to identify recombinant clones of insert and vector DNA, TOPI OF’ 
(Invitrogen) bacteria were transformed via heat shock. For each transformation one 
50pl vial of bacteria were used, to which was added 2pl of p-mercaptoethanol and 
2pl of each ligation reaction. The cells were then mixed very gently and incubated on 
ice for thirty minutes. The bacteria were then heat-shocked at 42°C for exactly thirty 
seconds and then immediately placed back on ice for two minutes. At this point 
250pl of SOC medium (at room temperature) was added to each tube and then the 
vials were shaken for one hour at 37°C. The transformed bacteria were then plated 
out on to LB agar plates (see below) containing 50pg/ml ampicillin. When all liquid 
was absorbed the plates were inverted and incubated at 37°C overnight.
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2.8.9.1: Reagents required for bacterial manipulations
SOC medium (Invitrogen): 6ml vial containing 2% tryptone, 0.5% yeast extract,
0.05% NaCl, 2.5mM KC1, lOmM MgCl2 and 20mM glucose.
Luria-Bertani (LB) broth: lOg Bacto-tryptone (Oxoid), 5g Bacto-yeast extract 
(Oxoid) and lOg Sodium chloride made up to 1 litre with milli Q water and 
autoclaved.
Agar plates: 1% (w/v) Agar (Sigma) dissolve in LB broth then autoclaved before 
being cooled to 50°C for the addition of 50pg/ml ampicillin. Agar was then poured 
into petri dishes.
2.8.10: Selection of Transformed Colonies
Antibiotic treated plates selected colonies that had been transformed with plasmid- 
encoded antibiotic-resistance genes. To verify whether the individual colonies 
contained plasmid that contained the insert, PCR selection with CD69 primers was 
used. The DNA used for the PCR reactions was either prepared using a Wizard 
Miniprep system (Promega) or via the simple addition of a small dab of the bacterial 
colony into the PCR tube. In the later case cell lysis at the temperatures involved 
rendered the plasmid DNA available to the PCR reaction. Using 96-tube PCR plates 
it was possible to quickly screen many colonies for the presence of insert without the 
need of DNA preparation.
In some cases larger amounts of DNA were prepared for screening and analysis using 
the Miniprep system. Bacterial colonies were expanded overnight in 10ml of LB 
medium, supplemented with ampicillin (50pg/ml), contained in a 30ml tube and 
incubated at 37°C in a shaker. Aliquots of this culture were then used for DNA 
preparation as described in the kit. Briefly, 1.5ml of the overnight culture were 
pelleted by centrifugation at 6,500rpm in a bench-top micro-centrifuge for five 
minutes. The supernatant was aspirated and the pellet resuspended in lOOpl of 
resuspension buffer and vortexed. The cells were then lysed by the addition of 200pl 
of lysis buffer and mixed by inversion. 150pl of neutralisation buffer was then added 
to precipitate the non-DNA material. The precipitate was pelleted by centrifugation 
at 13,000rpm for five minutes and the supernatant removed to a fresh Eppendorf
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tube. The plasmid DNA was then recovered from this solution via phenol-chloroform 
extraction and ethanol precipitation as described previously.
Minipreps provided enough DNA to allow restriction mapping and thus the 
orientation of inserted DNA. Samples of miniprep DNA were also used for 
sequencing using T7 and SP6 primers to read the poly-linker region and inserted 
DNA in both directions. Larger quantities of DNA from selected colonies was 
prepared using Midiprep of Maxiprep kits also from Promega. The principals of both 
these kits were identical to the Miniprep but with larger quantities of materials.
2.8.11: Transfection of COS-7 cells
COS-7 cells are fibroblasts derived from African Monkey green kidney cells that 
have been transformed with an origin-defective mutant of SV40. As a result of SV40 
transformation they are ideal recipients to support the growth of the pcDNA3 
plasmid. Several different electroporation protocols were used in an attempt to 
transfect the cloned CD69 DNA into the COS-7 cells. Each was assessed for 
transient protein expression after twenty-four hours via surface staining on flow 
cytometry. The most successful protocol was as follows. Adherent COS cells were 
trypsinised and then washed in fresh DMEM as previously described. The cells were 
then resuspended at 2xl06/ml in DMEM and 1ml was transferred to a 4mm path 
length BioRad electroporation cuvette. Plasmid containing the DNA for transfection 
was added at 50pg/ml and the contents mixed well. A BioRad electroporator 
(BioRad Gene Pulser Tm) was used at a capacitance of 500pF and voltage of 350V 
to provide an electrical discharge to the cells with a time constant of between 5-6ms. 
Cells were allowed to recover in 1ml of DMEM at room temperature for five 
minutes before being plated out on petri dishes in 10ml of DMEM.
2.8.12: Immunomagnetic Selection of Transfected Cells
COS-7 cells that showed transient expression of CD69 were recovered via 
immunomagnetic bead selection with Dynal beads. Briefly, cells that had been 
identified as being positive for surface CD69 expression, via FACS analysis, were 
washed and resuspended in 500pl of mouse-anti-human CD69 (2pg/ml) and
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incubated at 4°C for one hour on a gentle rotator. Cells were then washed twice to 
remove unbound antibody and resuspended in 500pl of fresh DMEM. 10pl of Dynal 
Dynabeads (4xl08 beads/ml) coated with sheep anti-mouse IgG antibody were then 
added and incubated on the rotator for one hour at 4°C. CD69 positive cells where 
then positively selected due to the adherence of magnetic beads. The tube of bead 
labelled cells was placed in a magnetic field for one to two minutes and CD69 
positive cells were dragged to the side of the tube. Any CD69 negative cells 
remained in free suspension and were removed via aspiration. The labelled cells were 
washed five times and the magnetic selection repeated each time. The selected cells 
were then washed from the tube onto a petri dish for continued culture.
2.8.13: FACS Sorting
After several rounds of culture and immunomagnetic selection a population of stable 
CD69 positive transfected cells developed. This population was purified using 
Fluorescence Activated Cell Sorting. For FACS sorting the cells were prepared as for 
staining except that the volume of antibody was increased with accordance to the 
number of cells involved and that sterile technique was used. Flow cytometry is 
prepared to assess the degree of staining in the population and the cells that are to be 
recovered are gated in respect to their FL-1 fluorescence. The gated population is 
then deflected into a collection tube due to droplet charge. 100,000 cells were 
collected per tube and then cultured for several days before being analysed again for 
surface CD69 expression.
2.9: STATISTICAL ANALYSIS
Where applicable all data is presented as the mean ± standard deviation (STDEV). In 
cases where the group of data covers a large range standard errors (SEM) are used 
instead of STDEV. Statistical significance was tested using Man Whitney or analysis 
of variance according to the distribution of the data.
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CHAPTER 3
Effect of Na+/K+ATPase Modulation 
Murine Models of Inflammation
3.1: INTRODUCTION
The Na+/K+-ATPase is an important membrane enzyme that plays a significant role 
in control of cellular volume and the cationic homeostasis of sodium and potassium. 
Inhibition of the Na+/K+-ATPase with ouabain results in dramatic effects on cationic 
homeostasis where the electrogenic flux of two potassium ions inwards and three 
sodium ions outwards is prevented. Consequently, a transient rise in intracellular 
sodium levels is observed. When a cell has its intracellular sodium concentration 
artificially raised, it may react using existing cation exchange mechanisms to 
maintain the sodium ionic homeostasis. Blaustein et al. (1976) (411) have described 
that downstream to rises in intracellular sodium, a concomitant rise in intracellular 
calcium can be detected, via an increase in the activity of the Na+/Ca2+ exchanger.
Decreased Na+/K+-ATPase activity has been described in rheumatoid erythrocyte 
membranes have been described by Testa et al (1987) (412). Similarly, recent work 
from this laboratory has demonstrated decreased Na7K+-ATPase activity in 
rheumatoid mononuclear cell membranes, via the use of a histochemical assay of 
PBMCs (243). If this defect in Na7K+-ATPase activity is mimicked in healthy 
PBMCs via the use of the specific Na7K+-ATPase inhibitor ouabain profound effects 
on cytokine production are observed. Newton (1990) (219) reported ouabain 
induction of PBMC IL-lp production and work carried out by Foey, in this 
laboratory, has complemented this by showing that ouabain stimulates IL-lp and 
TNFa production and suppresses IL-6 production from PBMCs, whilst inducing IL- 
6 production by synovial fibroblasts (232,413). This cytokine profile is similar to that 
described in RA and it is the hypothesis of this study that defective Na+/K+-ATPase 
activity in RA mononuclear cell membranes, perhaps due to oxidation of sulphydryl 
moieties, contributes to the pathogenesis of disease. Consequently, in an attempt to 
complement in vitro cytokine data, experiments were conducted in murine models of 
inflammation to assess the immuno-modulatory potential of ouabain in vivo.
In order to address the role of the Na+/K+ATPase in the development of murine 
arthritic disease it was first necessary to define a method for the measurement of 
ATPase activity. The ability of ouabain to inhibit murine Na7K+ATPase activity had 
to be proven in order to validate the use of this compound in the animal models.
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Several assays for the measurement of Na+/K+-ATPase activity have been previously 
described. The ATPase assay used previously in this laboratory was based upon that 
described by Chayen et al. (414). It relied upon the densitometric measurement of the 
formation of lead sulphide in tissue sections or slide mounted cell preparations. In a 
hope to develop an assay with improved sensitivity the ATPase assay described by J. 
M. Hamlyn (415) was employed. In this assay the regeneration of enzymatically 
hydrolysed ATP is coupled to the oxidation of NADH (see method 2.3). As NADH 
absorbs UV light at 340nm measuring the absorbance of an assay cocktail, containing 
NADH, at 340 nm can monitor the activity of total ATPase. The UV absorbance 
decreases in proportion to the oxidation of NADH therefore by calibrating the assay 
with exogenously added ADP, in the absence of cell lysate, it is possible to indicate 
the degree of ATPase activity (see Figure 3.1A). As the Na7K+ATPase is ouabain 
sensitive the degree that this ATPase contributes to the oxidation of NADH can be 
measured by incubating the cells ± ouabain prior to initiating the assay. By 
subtracting the ouabain resistant activity from the total ATPase activity the 
Na+/K+ATPase activity can be defined.
3.1.1: Na+/K+ATPase Activity in Monocytes
The ATPase assay was initially developed using the human monocytic cell line THP-
1. These cells provided a convenient source of plasma membrane, as they were large, 
grew rapidly and due to their non-adherence were easy to prepare. Figure 3.1B 
shows the effect of 200pM ouabain on total ATPase activity, indicated by the drop in 
UV absorbance of the assay cocktail, over a two hour period. From the two curves 
plotted in figure 3.1B it can be seen that the optimal time-point to measure the effect 
of ouabain under these conditions is approximately 60 minutes for THP-1 cells. After 
this time the ouabain resistant ATPases degrade the available ATP at a similar rate to 
the total ATPases in the control group. As a result of this, it appears that the optimal 
time to measure the Na+/K+ATPase activity is before the availability of ATP becomes 
the rate-limiting step of the reaction. Consequently this became an important 
consideration and preliminary studies on all different cell types included a detailed 
time-course of total ATPase activity. After defining the rate of the reaction for each 
cell preparation, a suitable time-point was chosen at which to determine 
Na+/K+ATPase activity. In THP-1 cells, suspended at 106/ml, a 60-minute assay
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incubation was used for optimal Na+/K+ATPase activity determination. Figure 3.2A 
shows a ouabain concentration response curve for its effect on ATPase activity in 
THP-1 cells using these conditions. Optimal inhibition was seen at between lOOpM 
and 200pM with 28% of total ATPase activity being ouabain sensitive. Similar 
procedures were carried out to define the ouabain sensitivity of the Na+/K+ATPase in 
different cell types and the degree to which the Na+/K+ATPase contributed to total 
ATPase activity. Figure 3.2B summarises these data and highlights the differences 
between murine and human monocytes. From this graph it can be seen that THP-1 
cells have the highest level of Na+/K+ATPase activity with human PBMCs displaying 
a ouabain sensitive fraction of approximately 14% of total ATPase activity. When 
murine cells were compared to human cell types in this assay it was found that their 
Na+/K+ATPase was indeed less sensitive to ouabain, with ouabain concentrations of 
400pM being required to cause maximal inhibition. In addition, it was seen that 
Na+/K+ATPase contributed a lesser percentage to total ATPase activity in both 
murine peritoneal macrophages and the murine monocytic cell line P388-D1. From 
figure3.2B, it can be seen that in P388-D1 cells 6% of total ATPase activity is 
attributable to Na+/K+ATPase activity and in peritoneal macrophages Na+/K+ATPase 
activity accounts for a similar 8% of total ATPase activity. Interestingly, peritoneal 
macrophages taken from animals that had received 34pg/kg ouabain daily for 14 
days (Treated PMphage) showed no difference in total or ouabain sensitive ATPase 
activity, when compared to control mice.
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Figure 3.1: Determination of Na+/K+-ATPase Activity Using ATPase Assay.
Panel A: ADP calibration curve for the ATPase assay cocktail. Results represent 
the mean o f three cocktail sample readings ±STDEV.
Panel B: Effect o f 200pM Ouabain on ATPase activity in THP-1 cells 
(n=3±STDEV).






























Control PlVfchage Treated PlV h^age 
[Ouabain] 400pM 400pM
Figure 3.2: Inhibition of Na+/K+-ATPase in Different Cell Types.
Panel A: Concentration response curve for ouabain activity in THP-1 cells. 
Results indicate the percentage o f total ATPase activity that is due to 
Na7K+ATPase activity (n=3±STDEV).
Panel B: The percentage o f total ATPase activity in various cells that is sensitive 
to inhibition by ouabain. Murine peritoneal macrophages were taken after 14 days 
of ouabain treatment (34ptg/kg i.p.) or saline control (n=3±STDEV).
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3.2: ANTIGEN INDUCED ARTHRITIS
3.2.1: Introduction
Due to sponsorship links with Knoll Pharmaceuticals the opportunity arose to 
investigate the effects of ouabain in animal models of arthritis. Although at this point 
detailed examinations of the effect of ouabain on human mononuclear cell cytokine 
production had not been completed, based on earlier work from this laboratory it was 
felt that animal studies could well be very profitable. Time limitations ruled out 
certain rabbit models and initial studies investigated the effects of ouabain on antigen 
induced arthritis in mice.
There was however, some doubt concerning murine ouabain resistance, a 
phenomenon which is not discussed greatly in previous literature as the main animal 
mentioned in conjunction with ouabain resistance is the rat. There was little time for 
detailed study of the murine Na+/K+ATPase and in the light of work on ouabain 
induced IL-ip release from human PBMCs (219,232) it was hoped that even a 
modest effect from ouabain may lead to an appreciable exacerbation of arthritis.
In hypertension studies it has been shown that ouabain, given acutely, does not 
produce a blood pressure change in the rat (416) but does so in sensitive species such 
as guinea pigs. Long term studies, however, with chronic administration of 
14pg/kg/day ouabain in rats resulted in a significant increase in mean blood pressure 
after 6-8 weeks (417). This evidence gave hope that long-term effects of ouabain in 
mice would be evident in the arthritis model.
In human cells, the ATPase assay has shown the Na+/K+-ATPase to account for 
approximately 25-30% of the total ATPase activity. In mice however, using P388-D1 
cells and peritoneal macrophage cells, the Na/K-ATPase was shown to account for 
only 5-10% of the total ATPase activity. The insensitivity of the Na/K-ATPase 
required ouabain concentrations of over 400|iM for a measurable effect.
Although the ouabain sensitive portion of total ATPase activity was small in murine 
cells these experiments displayed potential for ouabain effects in the models of 
arthritis. However, the concentration of ouabain that had a measurable effect in vitro 
would not be tolerated by the animals so the consequence of long-term low dose 
treatment was critical to the in vivo results. As initial experiments were started as 
soon as possible a short murine toxicology study was carried out and 34pg/kg
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ouabain dose determined to be safe for the animals. The insensitivity of the murine 
Na+/K+ATPase to ouabain, demonstrated in vitro with the ATPase assay, did however 
prompt a second toxicology study and the initiation of a further set of antigen 
induced arthritis models using 170pg/kg ouabain.
3.2.2: Disease Assessments
Uptake of 99m-technetium can be used to quantify the severity of joint inflammation 
(418) and correlates well with inhibition of cartilage proteoglycan synthesis and 
chondrocyte death up to day 28. Also, serum levels of the acute phase protein serum 
amyloid P-component (SAP) correlate with the inflammatory changes in the joint 
during the acute phase of the arthritic response (days 0-7 after intra-articular 
challenge); however, during the chronic phase (day 7 onwards), serum SAP levels are 
unrelated to the extent of joint damage (419). Serum anti-BSA antibodies are readily 
detectable, but their measurement may be of limited value in that the steroid 
prednisolone, while markedly suppressing both synovitis and cartilage/bone erosions, 
did not reduce serum anti-BSA antibody levels (420).
As yet, histological observations provide the best means of disease assessment in this 
model. The slides are prepared as described in method 2.4.1.1, with samples being 
taken for sectioning on days 7, 14, 21 and 28.
3.2.2.1: Synovial Changes and Bone Erosion
Changes in the synovium are scored on a scale of 0-5 to take into account synovial 
lining cell hyperplasia, infiltration of the subsynovium by inflammatory cells, and 
pannus formation.
Bone erosions are scored on a scale of 0-5 to express the extent of cartilage and bone 
destruction, particularly focusing on the articulating cartilage of the femur and tibia. 
In some joints, more than 50% of these surfaces may eventually become eroded.
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Sections from each test are scored by at least two independent observers with the 
result being the mean value of both scorers. The score given for each parameter is the 
mean value taken from both sections from each animal. Although a similar scoring 
system can be derived to assess the cellular content of the synovial fluid (mainly 
PMNs), it is found that the intra-group scores for this parameter show wide 
variations, which may, in part, reflect loss of synovial fluid during tissue processing.
3.2.3: Synovial Joints: a guide to the joint histology displayed in the 
photographs
The articulating bony surfaces have at their ends a thin plate of dense cortical bone, 
known as the articular end-plate. Beneath this lies the cancellous bone often 
containing red (hematopoietic) marrow, and tightly adherent to the bony end plate is 
the hyaline articular cartilage (bearing and gliding surface).
Within the joint capsule and defining the inter-articular space is a specialised layer of 
connective tissue cells, the synoviocytes, which secrete the synovial fluid. Deep to 
this layer are varying amounts of highly vascular adipose, fibrous or areolar tissue 
supporting the synoviocytes and allowing the sac to be appropriately loose in certain 
ranges of motion, without allowing the synovial folds to become entrapped between 
the joint surfaces during movement. The synovial tissue has a rich blood supply to 
maintain the synoviocytes and also to provide the fluid they require. It also has 
numerous nerve endings that along with those in the capsule and spindles in the 
muscles, ligaments, and tendons, are responsible for the keen proprioceptive sense 
and deep pain perception that protect the joints.
Certain of the bodies joints have within their cavities complete or, more often, 
incomplete fibrocartilaginous discoid partitions known as menisci. The menisci are 
highly developed and well defined in the knee and can be seen as triangular pink/red 
forms either side of articulating contact point. Synovium does not cover the 
avascular, aneural fibrocartilaginous menisci, which are firmly fixed to the joint 
margin by attachment to bone and to ligaments or capsule, preventing abnormal 
movement or intra-articular displacement during joint function. The function of 
menisci varies from site to site but generally involves stability.
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Control Healthy Joint: Femur (F), tibia (T), 
meniscus (M) and growth plate (G).
Inflamed Joint: Showing bone erosion and 
synovitis. Femur (F) and tibia (T).
1w&viSrrffo
High power section showing synovitis. Synovial cavity (S) and 
articulating cartilage (C).
High power section showing synovitis and early bone erosion. 
Meniscus (M) and articulating cartilage (C).
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3.3: RESULTS
In total, four antigen induced arthritis (AIA) experiments were carried out. The two 
groups of two experiments compared the effects of 34pg/kg and 170pg/kg ouabain 
on antigen induced arthritis in animals immunised with or without B. Pertussis. In 
each experiment seven animals were taken at each time point (days 7, 14, 21 and 28) 
and the slides prepared of the histological samples were scored on a 1-5 scale for 
synovitis and bone erosion. In all cases a severe synovitis was observed, as early as 
day 7, which gradually became less severe over the 28 day study. Conversely, very 
little bone erosion was observed on day 7 but over the 28 day period cartilage 
degradation and erosion of the underlying bone became more apparent (see figure
3.3 A).
Figure 3.3 also shows a comparison between the groups immunised with (A) and 
without (B) B. Pertussis. Immunisation with B. Pertussis had no significant effect on 
the development of bone erosion but resulted initially in slightly greater levels of 
synovitis. The two different models did appear to give subtly different conditions in 
which to test the effects of ouabain but both were quite severe forms of arthritis, with 
high levels of cartilage destruction. Table 3.1 summarises the data of all four 
experiments, including that shown in figure 3.3, and shows that at no point did 
ouabain display any significant effect on the severity of disease. However, there was 
a trend for ouabain to cause a slightly higher degree of bone erosion in the 
experiments without immunisation with B. Pertussis. Also, on day seven after 
disease induction there was a slightly higher level of synovitis in these experiments. 
This effect was not statistically significant but did occur with both concentrations of 
ouabain studied and offered some evidence of a possible effect of ouabain in these 
models. It remained to be seen whether the effect of ouabain may just have been 
overwhelmed by the severity of the arthritis in this model.
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Figure 3.3: Effect of Ouabain on Murine Antigen Induced Arthritis (AIA).
Panel A: AIA in animals immunised with B. pertussis. Joints were taken for 
histological analysis on various days after disease induction. Ouabain treatment 
(170pg/kg i.p.) commenced two days prior to disease induction. Scores represent 
mean o f two independent observers (n=7± STDEV).
Panel B: AIA in animals immunised without B. pertussis. The ouabain treatment 
and disease assessment were carried out as in figure A except animals were not 
immunised with B pertussis prior to disease induction (n=7± STDEV).
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34|ng/kg Ouabain: Immunised with pertussis.
Synovitis Bone Erosion
Day control STDEV ouabain STDEV control STDEV ouabain STDEV
7 2.43 0.67 2.5 0.41 0.21 0.27 0.21 0.27
14 1.92 0.38 2 0.65 0.83 0.26 0.79 0.27
21 1.79 0.27 2 0.29 1.5 0.5 1.71 0.49
28 1.93 0.45 1.71 0.27 1.79 0.7 1.5 0.29
34)ig/kg Ouabain: Immunised without pertussis.
Synovitis Bone Erosion
Day control STDEV ouabain STDEV control STDEV ouabain STDEV
7 2.14 0.94 2.86 0.38 0.29 0.39 0.64 0.24
14 2 0.38 1.57 0.61 1 0.38 0.71 0.39
21 1.29 0.39 1.36 0.48 0.71 0.39 0.86 0.63
28 1.36 0.38 1.14 0.68 1.07 0.61 0.36 0.38
170pg/kg Ouabain: Immunised with pertussis.
Synovitis Bone Erosion
Day control STDEV ouabain STDEV control STDEV ouabain STDEV
7 3.29 0.52 3.57 0.53 0.14 0.24 0.36 0.38
14 4.00 0.52 3.21 0.39 1.25 0.52 0.93 0.45
21 2.36 0.38 2.14 0.38 1.64 0.24 1.50 0.41
28 2.33 0.26 1.64 0.56 1.92 0.38 1.29 0.86
170pg/kg Ouabain: Immunised without pertussis.
Synovitis Bone Erosion
Day control STDEV ouabain STDEV control STDEV ouabain STDEV
7 2.57 0.35 2.71 0.57 0.43 0.19 0.36 0.24
14 2.43 0.35 2.71 0.64 1.14 0.48 1.50 0.58
21 1.86 0.24 1.86 0.24 1.00 0.29 1.43 0.45
28 2.00 0.41 1.86 0.38 1.86 0.48 1.93 0.67
Table 3.1: Summary of all Antigen induced Arthritis data. Each of the four tables 
represents a separate experiment of 28 animals with the treatment conditions detailed 
in the legend. Data represents the mean assessment scores for seven animals at each 
time point.
Chapter 3: Effect of Na+/K+-ATPase modulation on murine models of arthritis - 8 2 -
3.4: ZYMOSAN INDUCED ARTHRITIS
3.4.1: Introduction
Zymosan induced arthritis was first described by Keystone et al. 1977 (64). Like 
antigen induced arthritis it is reported to be an IL-1 dependent inflammatory disease 
localised to the joint by intra-articular administration of the inducing agent, in this 
case Zymosan A (Saccharomyces cerevisiae). In contrast to antigen induced arthritis, 
however, zymosan induced arthritis does not rely upon an adaptive immune response 
but rather the innate inflammatory reaction. Consequently, a less chronic 
inflammatory condition occurs in the joint, giving a model that may be more 
sensitive to pro-inflammatory treatments and thus allow the detection of the effects 
of ouabain.
In these experiments a histological study was carried out, with slides being prepared 
as in the antigen induced arthritis, to investigate the gross effects of the inflammatory 
response. The less severe nature of this model also allowed a more sensitive assay of 
biochemical changes within the joint to be used, namely a proteoglycan (PG) 
synthesis assay in which the incorporation of 35S [S04] into the sulphated moieties of 
the proteoglycan monomers is monitored. Studies of the metabolism of articular 
cartilage demonstrate a surprising rate of synthesis and degradation of the component 
matrix materials. The rapid turnover of at least a small portion of the proteoglycan 
suggests the presence of an internal remodelling system, and evidence has 
accumulated that this system is based on the release of lysosomal enzymes from the 
chondrocytes, which have as their principal substrate the proteoglycan. Activity of 
this remodelling system is modulated by various cytokines and growth factors.
The physicochemical properties of PG/hyaluronic acid aggregates within the 
extracellular matrix confer upon articular cartilage its elastic properties. Under 
normal conditions, endogenous cartilage cells (chondrocytes) regulate the synthesis 
and matrix levels of PG. Recent studies have shown that the two main factors 
regulating PG production are insulin-like growth factor-1 (IGF-1) (421) and 
transforming growth factor p (TGFP) (422). These factors mediate their effects via 
specific receptors on the chondrocyte cell membrane. The observation that 
chondrocytes are able to synthesise both IGF-1 (423) and TGFp (521) suggest 
potentially important autocrine functions for these factors.
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It has long been recognised that depletion of the extracellular matrix components of 
articular cartilage, specifically proteoglycan (PG) and collagen, are pivotal events 
relating to restriction or loss of joint function in patients with rheumatoid or 
osteoarthritis, and in animal models of these diseases. If depressed Na+/K+ATPase 
activity in the mononuclear cells of the mice in this study contributes to the severity 
of arthritis then PG synthesis measurement would offer a clearly quantifiable method 
of detection that is relevant to human disease.
In inflammatory conditions, particularly RA, chondrocyte function may be 
modulated by cytokines derived from cells of the inflammatory lesion. IL-1 in 
particular appears to be of paramount importance as a cartilage catabolic factor. In 
vitro, IL-1 has been shown to both inhibit PG synthesis and stimulate PG degradation 
in cartilage of either animal (424) or human (425) origin. In vivo, IL-1 injected into 
either rabbit or rat knee joints, induced cartilage proteoglycan depletion in the 
challenged joints concurrent with an increase in synovial fluid PG levels (426). 
Furthermore, in mice intra-articular injection of murine recombinant IL-1 a  and IL-1 p 
suppressed chondrocyte PG synthesis whereas TNF only marginally affected PG 
synthesis at the highest dose used (427). Treatment of zymosan induced arthritis with 
anti-IL-l(a+p), but not with anti-TNF, resulted in normal PG synthesis, confirming 
the key role played by IL-1 in the inhibition of PG synthesis (428).
Evidence from studies in vitro has suggested that both IGF-1 (429) and TGFp (523) 
are able to counteract the effects of IL-1 both on PG synthesis and degradation.
In this study zymosan induced arthritis provides a model whose inflammatory effects 
have been shown to be highly dependent upon IL-1. By measuring PG synthesis in 
the patella as an indicator of the degree of inflammation, the consequences of 
changes in IL-1 levels within the joint should be determinable. The effects of ouabain 
upon the degree of induced inflammation, which were perhaps lost in the severity of 
antigen induced arthritis, may become detectable. The sensitivity of the PG synthesis 
assay to IL-1 modulation should show any ouabain-induced abnormalities in murine 
mononuclear cell production of IL-1.
This study also investigated the effect of ouabain upon IGF-1 stimulated PG 
synthesis. In-house studies at Knoll had shown that both basal and IGF-1 stimulated 
PG synthesis were significantly impaired in arthritic patellar cartilage compared with 
their non-arthritic controls. This diminished response to IGF-1 was also induced in
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normal patellae by exposure to IL-1. In both instances, IGF-1 mediated PG synthesis 
was inhibited before any change in basal PG synthesis was seen. This evidence 
indicates that IGF-1 stimulated PG synthesis is more sensitive to IL-1 levels than is 
basal PG synthesis therefore providing an even more sensitive system for the 
detection of ouabain induced IL-1 production.
3.5: RESULTS
3.5.1: Effect of Zymosan Induced Arthritis on Joint Pathology and 
PG Synthesis
The zymosan induced arthritis model was characterised using histological sectioning 
to compare it to the antigen induced arthritis model. As can be seen in figure 3.4A 
the degree of synovitis and bone erosion was much lower in zymosan induced 
arthritis than it was in antigen induced arthritis (Figure 3.3). Although on day 4 the 
synovitis appears to be worse in the ouabain group, the error involved renders this 
insignificant. Histologically ouabain (34pg/kg) had no effect on either synovitis or 
bone erosion in this model, but this was not surprising due to the short duration of the 
model inducing little joint pathology.
Initial experiments showed quite low incorporation of 35S [S04] into the PG of both 
arthritic and control patellae so in an effort to increase the availability of 35S [S04] in 
the incubating media the unlabelled S04 content was reduced by 50%. Labelled 
sulphate incorporation improved and showed a significant contrast between arthritic 
and control PG synthesis. The model consistently demonstrated that arthritic patellae 
had approximately a three-fold decrease in PG synthesis when compared to 
contralateral control patellae (figure 3.4B). Another interesting trend was the 
increased PG synthesis observed in arthritic patellae during the later stages of the 
model. Although the magnitude of this increase in PG synthesis was not always 
statistically significant, this trend appeared in every experiment and offered another 
window of opportunity for observing effects due to ouabain. It could be predicted 
that a worse inflammatory disease state would lead to a greater degree of rebound 
tissue repair.
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Figure 3.4: Zymosan Induced Arthritis (ZIA): Histological Analysis 
Compared to Biochemical Analysis.
Panel A: Histological analysis o f ZIA in animals treated ± Ouabain (34pg/kg). 
Joints were taken for analysis on various days after disease induction. Ouabain 
treatment commenced two days prior to disease induction. Scores represent mean 
of two independent observers (n=6± STDEV).
Panel B: Effect of ZIA on PG synthesis in murine patellae (n=6± STDEV).
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3.5.2: Effect of Ouabain on PG Synthesis
Mice were pre-treated with ouabain at 34pg/kg/day and 170pg/kg/day for two days 
prior to the initiation of arthritis, as described in method 2.4.2. Initial experiments 
quantified PG synthesis on days 1, 2, 3, 4 and 7 after disease induction in order to 
observe the severity and duration of the arthritis. At each time-point patellae were 
taken from 6 mice, with arthritic joints being compared to contra-lateral controls. The 
incorporation of 35S [S04] during three hours of incubation being measured. As can 
be seen in figure 3.5A, ouabain (34pg/kg) significantly inhibited the recovery of PG 
synthesis with day three patellae still having severely depressed 35S [S04] 
incorporation compared to the controls (p=0.0039). Also worthy of note is the 
slightly elevated, if not statistically significant, over-shoot in 35S [S04] incorporation 
on day seven.
Unfortunately, this was the only experiment that showed a significant effect of 
ouabain in this model. Several attempts were made to repeat this finding, two of them 
showed a trend for ouabain treated animals to have delayed PG synthesis recovery 
but the other experiments showed no effect for ouabain at all. Figure 3.5B shows the 
collated results for all these later experiments representing data from 18-30 animals 
per time point.
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Figure 3.5: Ouabain Modulation of PG Synthesis in Arthritic and Normal 
Murine Patellae.
Panel A: Effect o f ouabain (34jj.g/kg) on recovery o f PG synthesis in murine 
patellae over remission period of ZIA (** = p<0.005) (n=6 ± STDEV).
Panel B: Effect o f ouabain (170pg/kg) on recovery o f PG synthesis in murine 
patellae over remission period o f ZIA (n=18-30 ± STDEV).
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3.5.3: Effect of IGF-1 Stimulation on PG Synthesis
IGF-l stimulated PG synthesis has been previously shown, in studies at Knoll, to be 
more sensitive to IL-1 inhibition than basal synthesis. Consequently, it may be 
expected that any small change in IL-1 levels in the joint due to ouabain treatment 
may be more easily detected. Before ouabain could be used in a model of IGF-1 
induced PG synthesis various aspects of the model had to be defined. Firstly, an IGF- 
1 concentration response curve was constructed to compare the response of arthritic 
and control patellae. Patellae were incubated for 24hrs with IGF-1 and the level of 
35S[SOJ incorporation was measured over the last three hours. Control patellae 
showed an almost two-fold increase in PG synthesis compared to arthritic patellae 
(Day 1 after disease induction), with a maximal stimulus occurring at 150ng/ml IGF- 
1 (see figure 3.6A). However, at no concentration was IGF-1 able to reverse the 
inhibition of PG synthesis observed in the arthritic patellae.
Also, to confirm previous reports from Knoll pharmaceuticals, a short study was 
performed with normal patellae in which an IGF-1 concentration response curve was 
challenged with a single dose of IL-1 p. As can be seen from figure 3.6B IGF-1 
induced 35S[S04] incorporation was similar to that seen in the normal patellae in the 
previous study (figure 3.6A). Incubation of the patellae with 0.75ng/ml IL-ip 
resulted in a reduction of PG synthesis to levels which were approximately three-fold 
lower than those seen in the control patellae. Basal PG synthesis was also inhibited 
by IL-lp but not as significantly as IGF-1 induced PG synthesis. Interestingly, this 
concentration of IL-lp inhibited IGF-1 induced PG synthesis in a similar but more 
potent manner than zymosan induced arthritis. Similarly to the arthritic patellae in 
the previous study, IL-ip treated patellae displayed a reduction in PG synthesis 
which was not surmountable with IGF-1. Even at the highest dose used, IGF-1 could 
only bring PG synthesis back to levels similar to those seen in untreated healthy 
patellae.
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Figure 3.6: Effect of IGF-1 Stimulation on PG Synthesis in Murine Patellae. 
Panel A: PG synthesis in arthritic and control patellae induced by IGF-1. Arthritic 
patellae were taken form animals on day 1 after disease induction with Zymosan 
and responses were compared to contra-lateral controls. IGF-1 was incubated with 
the patellae for 24 hours and [35S]S04 was added for the last three hours o f culture 
(n=6 ± STDEV, **=P<0.005)
Panel B: Effect o f IL-1 (3 on IGF-1 induced PG synthesis in normal patellae (n=6 
± STDEV, *=P<0.05, **=P<0.005).
Chapter 3: Effect of Na+/K+-ATPase modulation on murine models of arthritis - 9 0 -
3.5.4: Effect of Ouabain on IGF-1 Induced PG Synthesis
From the previous studies it was decided to use an IGF-1 concentration of 300ng/ml 
to stimulate PG synthesis in patellae taken from the zymosan induced arthritis model 
on days one, three and seven. Using these time-points it was hoped that the effect of 
ouabain on the response to IGF-1 could be studied whilst the inflammatory condition 
was at its most severe, during its recovery phase and then during the “ remodelling” 
phase when PG synthesis was elevated.
Ouabain treatments and sample preparation were repeated as before. The patellae 
were incubated with IGF-1 for 24hrs, with 35S[S04] incorporation being measured 
over the last three hours.
Firstly, the effect of IGF-1 stimulation was studied over the time-course of this 
model without considering the effect of ouabain. Figure 3.7A displays data 
comparing PG synthesis in control normal and arthritic patellae to IGF-1 stimulated 
normal and arthritic patellae. Day one clearly shows that the difference between the 
IGF-1 stimulated normal and diseased responses is far greater than that between 
control normal and diseased patellae. These data highlight the fact that IGF-1 
stimulated PG synthesis is very sensitive to inhibition and complements the data, 
presented in the previous section, showing IL-lp inhibition of IGF-1 stimulated PG 
synthesis. Day three shows that in the control group arthritic patellae PG synthesis 
has recovered to equivalent levels seen in the normal patellae but that the IGF-1 
response is still slightly reduced in the arthritic group. On day seven the same trends 
are seen in both the controls and the IGF-1 stimulated groups, with the arthritic 
patellae displaying higher levels of PG synthesis than the controls.
This model offered several aspects that could be affected by ouabain. However at no 
point was there any significant difference in the responses of control and ouabain 
treated mice. As can be seen from figure 3.7B ouabain had no effect on control or 
arthritic responses to IGF-1 on any of the three days.
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Figure 3.7: Responses of Arthritic Patellae to IGF-1 Induce PG Synthesis 
During Disease Remission Compared to Contralateral Controls.
Panel A: Variation in the responsiveness o f patellae to IGF-1 induced PG 
synthesis during the progression o f zymosan induced arthritis (n=6 ± STDEV). 
Panel B: Effect o f ouabain (34pg/kg) on IGF-1 induced PG synthesis in normal 
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3.5.5: Zymosan Induced Arthritis in ICE_/‘ Mice
The results presented so far using the zymosan induced arthritis model have all been 
based upon the belief that the inflammatory condition induced in these animals is 
highly IL-ip dependent. Treatment of zymosan induced arthritis with anti-IL- 
l(ot+P), but not with anti-TNF neutralising antibodies, has been shown to result in 
normal PG synthesis, confirming the key role played by IL-1 in the inhibition of PG 
synthesis (428). Despite this evidence, because of the availability of ICE'7' genetically 
modified mice a complementary study was set-up to assess the role of ICE in ZIA. 
There were, however, only six mice available (with control wild types) so the results 
are just for day one of the arthritis. Therefore, only the severity of disease induced is 
shown and not the recovery phase. As can be seen from figure 3.8, PG synthesis in 
the arthritic patellae of the ICE knockout mice was depressed to the same extent as 
that in the arthritic patellae of wild-type mice. These data indicate that even in the 
absence of mature IL-ip, zymosan raises a reaction within the murine joint that 
severely depresses the ability of chondrocytes to synthesise proteoglycans. Of course, 
based on such low numbers these data is only preliminary but even so, the 
inflammatory response in the ICE 7' mice could not be mistaken. These data question 
the importance of IL-1 p in the pathogenesis of ZIA at 24 hr after disease induction 
and suggest the possibility that other cytokines, such as TNFa, may become 
dominant in the inflammatory response of ICE'7' mice.
Previous studies have shown that in mice intra-articular injection of murine 
recombinant IL-1 a  and IL-1 p suppresses chondrocyte PG synthesis whereas TNFa 
only marginally affected PG synthesis at the highest dose used (427). Also, anti 
TNFa neutralising antibodies have little effect on the pathogenesis of ZIA (57). This 
suggests that in both the healthy joint and the ZIA-arthritic joint TNFa may not play 
a critical role in the regulation of chondrocyte PG turnover when IL-ip is also 
present. Whether TNFa is more important in the pathogenesis of ZIA in ICE-/- mice 
remains to be seen.
Out of curiosity, three of the ICE'7' animals were treated with 170pg/kg ouabain, as 
described before, but again there was no effect seen on the PG synthesis in any of the 
animals.
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Figure 3.8: Effect of Zymosan Induced Arthritis on PG Synthesis in ICE'7' 
Mice.
PG synthesis was measured in ICE'7' knockout mice one day after zymosan 
induced arthritis. Responses were compared in Wild Type controls and the effect 
o f ouabain on disease severity was also assessed (n=3 ± STDEV).
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3.6: SUMMARY
This chapter has addressed some of the pathological features of murine models of 
arthritis and attempted to link evidence of abnormal Na+/K+ATPase activity with 
aberrant mononuclear cell activity in the inflamed joint. In summary, the results 
presented here have shown:
1. The development of an effective ATPase assay which allows the quantification of 
the ouabain sensitive Na7K+ATPase component.
2. Any effects attributed to ouabain in the inflammatory response can not be 
illustrated using the murine model of antigen induced arthritis.
3. Models of arthritis which are more mild, such as murine zymosan induced 
arthritis, may be more suitable for the detection of small changes in the severity 
of inflammation but still show that ouabain doesn’t show a consistent significant 
modulatory effect.
4. Murine ouabain resistance is sufficient to overcome any modulatory effects 
ouabain may have on inflammation.
Using the human monocytic cell line THP-1 an assay has been developed, based on 
that used by Hamlyn, to measure ATPase activity in cell lysates. This assay has 
shown that healthy cultured THP-1 cells have Na+/K+ATPase activity that accounts 
for 25-30% of total ATPase activity. The Na7K+ATPase activity in these cells was 
totally inhibited with 200pM ouabain.
Evidence of ouabain resistant forms of the Na+/K+ATPase enzyme have been 
reported in rodents and ouabain resistance can be conferred to primate cells via 
transfection with a 6.4 kB fragment of murine genomic DNA (known as murine 
ouabain resistance gene) (430). In this study, however, evidence of large changes in 
IL-ip production in human PBMCs, induced by very low (nM) concentrations of 
ouabain, and reports on ouabain sensitivity in rats after long-term treatment fuelled 
interest in the possible effects of ouabain on in vivo models of inflammation.
The murine model of antigen induced arthritis has been used at Knoll 
Pharmaceuticals to study putative anti-rheumatic drugs. During the period of work 
carried out at Knoll for this report time constraints and animal availability proposed 
this model as being the most convenient in which to try and demonstrate pro-arthritic
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properties of ouabain. Any doubts of murine ouabain resistance were disregarded in 
the hope that even a very small inhibition of the Na7K+ATPase by ouabain would 
result in a measurable defect in mononuclear cell activity and detectable changes in 
the model of arthritis.
The ATPase assay demonstrated that murine cells were resistant to ouabain with 
peritoneal macrophages and the monocytic cell line P388-D1 indicating that only 5- 
10% of the total ATPase activity was due to Na+/K+ATPase activity. The 
concentrations of ouabain that were used to inhibit the Na+/K+ATPase were greater 
than 400pM with ranges up to ImM being required for maximal inhibition. These 
results indicated that murine Na+/K+ATPase was about ten-fold less sensitive to 
ouabain than human Na+/K+ATPase. There was however potential for this degree of 
inhibition to be effective in the arthritis model but there was no way that 
concentrations of this kind could be attained in vivo. Recent in vivo studies in rats 
have shown that long-term treatment with ouabain (four weeks with 14pg/kg/day 
followed by four weeks at 28jig/kg/day) induced hypertension (417). The antigen 
induced arthritis model is a long term study (28 days) and levels of ouabain in excess 
of 14pg/kg could be given to the mice. By increasing the dose of ouabain to 
170pg/kg and by varying the disease induction by omitting pertussis toxin in some of 
the animals it was hoped to maximise the possibility of demonstrating pro-arthritic 
effects of ouabain.
Unfortunately ouabain had no effect on antigen induced arthritis in mice. All four 
studies carried out showed consistent inflammatory responses with active synovitis 
and bone erosion, but ouabain had no significant effect on either of these parameters.
It is possible that even without immunisation with pertussis toxin this model 
develops such a severe arthritis that any modulatory effects due to ouabain would be 
lost in a flood of pro-inflammatory cytokines. To try and counteract this problem the 
milder, non-immune model of zymosan induced arthritis was used.
In zymosan induced arthritis the hosts defence involves the innate immune response 
and not the adaptive immune response. Consequently a temporary, resolving 
condition is induced with measurable synovitis but little obvious bone erosion over 
the short period of each study. The innate response still relies heavily upon the
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production of IL-1 p from infiltrating mononuclear cells so any aberrant mononuclear 
cell activity due to ouabain treatment should be demonstrable.
Histologically ouabain had no effect on zymosan induced arthritis in mice. The 
measurement of synovitis and bone erosion over the seven-day period revealed a very 
mild inflammatory condition with quite large intra-group variations in disease 
assessments. In order to provide a more sensitive measure of whether ouabain 
treatment can modulate the inflammatory reaction proteoglycan synthesis in patellar 
cartilage was monitored. Even if ouabain did not cause a more severe inflammation 
this assay would provide a sensitive way of watching the recovery of the joint after 
disease induction and provide data on the ability of ouabain to prolong joint 
pathology. Again, IL-lp is of major importance in this hypothesis as very low doses 
incubated with patellae have been shown to almost totally inhibit PG synthesis (428). 
Depleted PG synthesis in arthritic patellae has also been shown to be reversible with 
anti-IL-lp antibodies and IL-lra treatment (428).
In this study ouabain showed its first positive signs of being pro-inflammatory. At 
34pg/kg ouabain treated animals showed significantly depressed PG synthesis on day 
three of the disease when compared to controls and a possibly higher reflex increase 
in PG synthesis on day seven. Unfortunately, this result was not reproducible and 
subsequent experiments showed trends towards pro-inflammatory activity for 
ouabain if anything at all. From these studies it was noticeable that the positive result 
and the trends towards pro-inflammatory activity had been shown in models that 
displayed conditions which showed improvement on day two for all groups. The 
negative results were in models that displayed a condition that worsened on day two. 
This evidence again indicated that the effects of ouabain may be being lost in the 
severity of the model and further attempts to improve assay sensitivity were made.
IGF-1 stimulation of PG synthesis was used to enlarge the window in which to 
observe the effects of ouabain. IGF-1 stimulated PG synthesis has been shown to be 
more sensitive to IL-ip levels than basal synthesis therefore small changes in EL-1 
levels are more easily detectable. Again ouabain was seen to have no effect although 
only one of the two experiments gave definable results.
Out of interest a small study at this point was carried out in ICE knockout mice. In 
theory their inability to process IL-lp should mean that the degree of inflammation
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induced by any of the above models is significantly less than that in control animals. 
This theory is based on the demonstrated IL-lp dependence of the models. 
Surprisingly, though, there was no difference between ICE knockout mice and wild 
type mice in the effects of zymosan induced arthritis measured by PG synthesis. In 
this study only three animals were used per group and measurements were only taken 
on day one of the model so no conclusions can be drawn on the progression of the 
disease model in the knockout mice. The initial severity of the PG synthesis 
inhibition however questions the importance of IL-lp in this model suggesting that 
there is a degree of redundancy within the pro-inflammatory cytokine family, with 
TNFa and IL-1 a  perhaps playing key roles. The study of IL-1 p knockout mice in the 
zymosan induced arthritis model would clarify the role of IL-lp.
Further investigation of these models would be interesting but in the mean time they 
have served their purpose and shown that ouabain has no significant acute pro- 
inflammatory effects in mice. It is possible that ouabain is modulating IL-ip release 
but that this is not of importance in this model due to the preponderance of effects 
from other cytokines. It is more likely, however, that murine ouabain resistance has 
proven sufficient to prevent effects from even the highest doses of ouabain used. Any 
long-term effects possible were overwhelmed by the severity of disease in the 
antigen induced arthritis model and more subtle effects that could have been 
observed in the zymosan model were lost due to the short duration of the model. A 
more suitable murine model might involve a long-term ouabain pre-dosing schedule 
followed by the use of low dose intra-articular zymosan to induce disease.
These results certainly do not rule out the possibility of ouabain having pro- 
inflammatory effects but indicate that a different animal model is required. The aj 
isozyme of Na+/K+ATPase is not present in animals such as monkey, dog and rabbit 
so perhaps these species could provide a more suitable model of inflammation. As 
investigations at Knoll could no longer be continued this question mark will have to 
remain.
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CHAPTER 4
Effect of Na+/K+ATPase Modulation on 
Human Mononuclear cell Cytokine
Production
- 9 9 -
4.1: INTRODUCTION
The regulation of the balance of cytokine production in health and disease is an area 
of intensive research. Despite considerable effort many questions remain as to how 
physiological processes such as inflammation are normally controlled and how they 
often become unrestrained in diseases such as rheumatoid arthritis (RA).
Within the immune system inhibition of the Na7K+-ATPase with the cardiac 
glycoside ouabain has been shown to suppress T and B lymphocyte activation in 
vitro (218) and to potently induce IL-lp production by human monocytes (219). 
Recent studies by Matsumori et al (231,431) have also shown that various drugs used 
to treat heart failure, including the cardiac glycosides, modulate cytokine release 
from various cell types. Inhibition of membrane Na+/K+-ATPase results in 
accumulation of intracellular sodium and depletion of intracellular potassium. In 
human monocytes Walev et al (1995) have demonstrated that intracellular potassium 
has regulatory effects on IL-lp processing. Using agents such as staphylococcal a- 
toxin and gramicidin, both of which selectively permeabilise plasma membranes for 
monovalent cations, the ionophores nigericin and valinomycin, and the Na+/K+- 
ATPase inhibitor ouabain they demonstrated that K+ depletion triggered processing 
of proIL-ip (235).
Whether cardiac glycosides affect monocyte cytokine production via depletion of 
intracellular potassium of elevation of intracellular sodium remains to be determined. 
The important feature that is critical to these studies is that the mechanism by which 
the cardiac glycosides modulate intracellular cation levels is through the inhibition of 
the key membrane enzyme Na7K+-ATPase.
In rheumatoid arthritis, erythrocyte membranes have been shown to possess 
markedly suppressed Na7K+-ATPase activity (412). Preliminary work carried out 
recently in this laboratory has complemented these data by showing decreased 
Na+/K+-ATPase activity in rheumatoid mononuclear cell membranes (243). In normal 
PBMCs inhibition of the Na7K+-ATPase with ouabain has been shown to mimic the 
pro-inflammatory cytokine profile seen in RA, with increased production of IL-ip 
and TNFa and decreased production of IL-6 from monocytes (232). The evidence, of 
ouabain induced pro-inflammatory cytokine induction and suppression of immuno- 
regulatory mechanisms, coupled with evidence of decreased Na+/K+-ATPase activity
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in rheumatoid mononuclear cells provided the impetus for the work presented here. It 
was felt that further research into the mononuclear cell responses to ouabain would 
lead to greater insight into the possible biochemical abnormalities that contribute to 
the pathogenesis of RA. By comparing normal, early rheumatoid and chronic 
rheumatoid peripheral blood mononuclear cell (PBMC) responses to ouabain it was 
hoped that the contribution of the Na+/K+-ATPase to the regulation of cytokine 
production in RA would become more apparent. Further to this, it was hoped that 
more detailed information could be gained on the contribution of intracellular cation 
levels to the balance within monocytes between pro-inflammatory cytokines such as 
IL-ip and TNFa and anti-inflammatory cytokines such as IL-lra.
Chronic rheumatoid patients selected for this study were defined as having sero­
positive rheumatoid disease for a period in excess of four years and were preferably 
not receiving second-line treatments. Patients who had been treated with 
corticosteroids within the last year were excluded for fear of modulatory effects on 
cytokine production. The early rheumatoid patients were selected based upon the 
symptoms of early synovitis and were preferably only receiving non-steroidal anti­
inflammatory treatments. Healthy volunteers were used to provide “ normal” PBMCs 
for control responses.
4.2: RESULTS
4.2.1: Effect of Na+/K+-ATPase Inhibition on Cytokine Production 
by PBMCs
Ouabain was used to inhibit the Na+/K+-ATPase in human PBMCs and the effect of 
this modulation on cytokine protein production monitored. Initial experiments were 
carried out in normal PBMCs to study the dose dependency of ouabain induced IL- 
1 p, TNFa, IL-6 and OSM production. PBMCs were purified from peripheral blood 
as described in method 2.2.4 and cultured at a density of 106/ml in polypropylene 
tubes (to avoid adherence activation) for 24hrs in the presence of ouabain (0.1 nM to 
lpM). As can be seen from figure 4.1 A, ouabain induced a concentration dependent 
increase in IL-ip production, with protein production reaching a maximum of 
1250pg/ml (mean ±700pg/ml) with a ouabain concentration of lpM. Similarly,
Chapter 4: Role of the Na7K+- ATPase in PBMC cytokine production - 101 -
TNFa was also induced in a concentration dependent manner by ouabain. However, 
a maximal response of 187pg/ml was seen with 0.1 pM ouabain after which TNFa 
production was seen to be reduced. In contrast, IL-6 and OSM did not appear to be 
induced by ouabain at all. Production of both these cytokines was very low in all 
samples, with levels not exceeding 50pg/ml. OSM production appeared to remain at 
basal levels of approximately 20pg/ml until at a ouabain concentration of 1 pM when 
OSM protein was no longer detected in the supernatants. IL-6 was detected at levels 
of approximately 5pg/ml in unstimulated PBMCs and ouabain had no effect on this 
until a slight induction of 20pg/ml was seen at lOnM.
4.2.2: Effect of Ouabain on IL-ip Production by Normal, Early 
Rheumatoid and Chronic Rheumatoid PBMCs
PBMCs were purified from normal volunteers and patients attending clinics at the 
Royal National Hospital for Rheumatic Diseases in Bath. Again, cells were incubated 
in polypropylene tubes, to avoid adherence activation, at a density of 106/ml. Before 
incubation a sample of PBMCs from each patient was assessed for monocyte 
numbers via CD 14 staining using the flow cytometer (FACS). After the supernatants 
had been harvested for ELISA the cells were tested for viability using trypan blue 
exclusion under light microscopy or propidium iodide staining analysed by flow 
cytometry. As can be seen in figure 4.2, all three groups responded to ouabain with 
initial protein induction being seen at lOnM ouabain. However, the concentration 
response curves to stimulation by ouabain were quite different in the three groups. 
The normal and early rheumatoid groups gave similar “bell-shaped” concentration 
response curves with levels of IL-lp production initially being induced and then 
dropping off. The normal group gave a concentration dependent response with a 
maximum of 321pg/ml IL-lp being produced with lpM ouabain. Increased 
concentrations of ouabain then lead to reduced levels of IL-lp production. The early 
rheumatoid group gave a concentration dependent response with a maximum of 
371pg/ml IL-ip being produced with 0.1 pM ouabain. Ouabain concentrations above 
0.1 pM then gave a decreased level of IL-lp production. In contrast, the chronic 
rheumatoid group displayed a concentration dependent induction of IL-lp across the 
whole range of ouabain concentrations studied. The chronic rheumatoid group was
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less sensitive to ouabain with comparable levels of IL-lp being produced with ten­
fold higher concentrations of ouabain when compared to the normals. These data 
suggest that IL-ip production was most sensitive to ouabain induction in the early 
rheumatoid group followed by the normal group and then the chronic rheumatoid 
group. Maximal levels of IL-1 p produced by the three groups were not significantly 
different but they occurred with different concentrations of ouabain. The early 
rheumatoid group produced significantly more IL-ip in response to 0.1 pM than the 
normal group (P<0.05).
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Figure 4.1: Effect of Ouabain on Cytokine Release from Normal PBMCs. 
Panel A: Shows effect o f Ouabain on basal release o f IL-lp and TNFa.
Panel B: Shows effect o f Ouabain on basal release o f IL-6 and OSM.
Cells were purified from healthy volunteers and cultured with ouabain in 
polypropylene tubes. Cytokine release was determined after 24 hours 
(n=4±STDEV).
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Figure 4.2: Ouabain induced IL-ip from human PBMCs.
Data represents a comparison of normal, early rheumatoid and chronic 
rheumatoid PBMCs in their response to ouabain. Each point represents an average 
of all patients in that group ±STDEV, with each protein determination being 
carried out in duplicate (*=P<0.05).
Patient % of PBMCs CD14 +ve STDEV
Control (n=16) 14.99 7.59
Chronic RA (n=5) 17.36 5.65
Early RA(n=ll) 13.65 8.94
Table 4.1: Monocyte population o f peripheral blood mononuclear cells defined by 
CD 14 staining using flow cytometry.
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4.2.3: Effect of LPS on IL-1 (3 Production From PBMCs
The responses to ouabain seen so far in PBMCs complement the evidence that 
decreased Na+/K+-ATPase activity could contribute to the pro-inflammatory cytokine 
profile in rheumatoid arthritis. Inhibition of the Na+/K+-ATPase with ouabain gave a 
dose dependent increase in IL-1 (3 production and chronic rheumatoid patients 
appeared to be less responsive to ouabain, perhaps indicating reduced Na7K+- 
ATPase expression or activity in their PBMCs. One observation with these data, 
however, was that the levels of IL-1 p produced in these experiments was very low 
when compared with reports from Foey (1997) (232). They were in accord, however, 
with reports from Newton (1990) (219) who used ouabain (0.1 pM) alone to stimulate 
a maximal release of 700pg/ml IL-lp. This decreased response to ouabain could be 
the result of numerous factors including different culture medium and foetal calf 
serum (FCS), different culture conditions (i.e. variations in plastics) or different cell 
purification techniques. However, it was noted that not only were the response to 
ouabain reduced in this study but the basal release of IL-lp in the control groups was 
also very low. Consequently it can be assumed that it is not hypo-responsiveness to 
ouabain in the studies presented so far but rather general conditions of decreased 
mononuclear cell activation. In fact, when comparing the results previously presented 
by Foey in our laboratory to similar studies in the literature, the levels of IL-ip 
production that he recorded are similar to those reported by Walev (1995) (235) who 
measured the effect of ouabain on LPS stimulated monocytes. It is possible that 
changes in culture medium in our laboratory and perhaps lower mitogenicity of the 
recent FCS used caused the decreased monocyte responsiveness that is recorded here. 
To test this theory experiments were set up to define ouabain modulation of PBMC 
responses to the classical IL-lp inducer, bacterial lipopolysaccharide (LPS).
PBMCs were prepared as described previously and the effect of LPS on IL-ip 
production measured after a 24hr incubation. Figure 4.3 shows a concentration 
response curve for LPS from Salmonella Typhimurium in normal and rheumatoid 
PBMCs. Again, control basal levels of IL-lp production were very low, indicating 
clean, resting culture conditions. With LPS, however, there was a marked induction 
of IL-lp production with as little as lOng/ml LPS. The response to LPS reached a 
plateau at lpg/ml, with a maximum mean value of 3874pg/ml IL-ip being produced
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by normal PBMCs. The response of rheumatoid PBMCs was similar to normal 
PBMCs but with slightly higher levels of IL-1 p being produced. The difference 
between the two groups was not significant.
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Figure 4.3: Effect of LPS on IL-lp production from human PBMCs.
Data shows response o f rheumatoid (n=7) and normal (n=9) PBMCs (± STDEV) 
cultured for 24 hrs in the presence o f various concentrations o f LPS (Sal. Typh).
□  CTRL RA
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4.2.4: Effect of Ouabain on LPS Induced PBMC Cytokines
LPS was used to prime PBMCs in order to allow the study of the effects of ouabain 
on activated mononuclear cells. A concentration of lOng/ml LPS was used as the 
previous study showed this to give a sub-maximal induction of IL-lp (figure 4.3). 
Culture conditions were repeated as before with effects of ouabain being monitored 
after a 24hr incubation. LPS and ouabain were added to the samples simultaneously 
at time zero, with controls receiving only LPS.
Figure 4.4A shows the IL-ip response to ouabain, after LPS activation, and clearly 
displays the greatly elevated production of IL-lp in comparison to ouabain alone 
(figure 4.1). Control levels of IL-1 p production were similar to those seen in figure
4.3 with lOng/ml LPS inducing 1156pg/ml IL-lp. A small increase in IL-ip 
production was seen with 0.1 nM and InM ouabain inducing 1697pg/ml and 
2441pg/ml respectively. With lOnM ouabain, however, a significant increase in IL- 
ip  production was seen (P<0.05) with levels reaching 7778pg/ml. On increasing the 
ouabain concentration to 0.1 pM another elevation to 19206pg/ml IL-lp production 
was observed but further increases in the ouabain concentration lead to a drop in IL- 
lp  production. The production of IL-lp induced by LPS was clearly sensitive to 
modulation by low levels of ouabain but it was not until ouabain concentrations 
reached between lOnM and 0.1 pM that dramatic synergy was observed.
The same supernatants from the IL-ip experiment above were also tested for TNFa, 
IL-6 and OSM protein levels. Figure 4.4B shows the TNFa response recorded for 
the effects of ouabain on LPS stimulation. The control response to lOng/ml LPS was 
greatly elevated above control basal levels, with a mean level of 2652pg/ml TNFa 
being produced compared to a basal of approximately 5pg/ml in controls. Similarly 
to IL-lp, TNFa production was also sensitive to low levels of ouabain with O.lnM 
and InM ouabain inducing 2866pg/ml and 3228pg/ml TNFa respectively. With 
TNFa production, however, the synergy between ouabain and LPS was not 
statistically significant and was not as dramatic as that seen with IL-ip production. 
Maximal induction of TNFa was observed with lOnM ouabain + LPS inducing 
4646pg/ml. Higher concentrations of ouabain reduced TNFa production to levels 
below those seen with LPS stimulation alone but this inhibition was not statistically 
significant.
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Figure 4.4: Effect of Ouabain on LPS (lOng/ml) Stimulated Cytokine Release 
from human PBMCs.
Panel A: Shows effect o f Ouabain on LPS induced release o f IL-lp.
Panel B: Shows effect of Ouabain on LPS induced release o f TNFa.
Cells were purified from healthy volunteers and cultured with LPS ± ouabain in 
polypropylene tubes. Cytokine release was determined after 24 hours 
(n=4±STDEV, *= P<0.05).
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Interestingly, the effect of ouabain on LPS induced IL-6 production followed a 
similar trend to that observed with TNFa. As can be seen from figure 4.5A, LPS 
alone induced 4394pg/ml IL-6 compared to a control value of approximately 5pg/ml. 
This LPS response was sensitive to low concentrations of ouabain but in contrast to 
TNFa a maximal induction was seen with InM ouabain. At InM ouabain a mean IL- 
6 protein level of 7066pg/ml was observed and although this was 75% greater than 
that released from control cells due to low experimental numbers this did not prove 
to be statistically significant. Further elevations in ouabain concentration resulted in 
levels of IL-6 dropping below control LPS stimulated levels. At lpM, ouabain 
reduced the level of IL-6 produced to about 25% of that seen in controls (P<0.05).
Of all the cytokines studied in this model OSM was the only one that did not appear 
to be induced by ouabain. As can be seen from figure 4.5B, OSM was induced by 
LPS, with lOng/ml LPS stimulating the production of 134pg/ml OSM. This level of 
OSM production is quite low but significantly greater than that seen in basal control 
conditions (figure 4.1). When ouabain is added to the LPS stimulation, however, 
there was a concentration dependent inhibition of OSM production, with levels 
dropping to 29pg/ml with 0.1 pM ouabain. At concentrations of 0.1 pM ouabain 
significantly inhibited LPS induced OSM production (P<0.05).
4.2.5: Effect of Ouabain on LPS Induced IL-ip From Normal, Early 
Rheumatoid and Chronic Rheumatoid PBMCs
In this experiment marked synergy was seen in all groups between LPS and ouabain 
induced IL-lp as it was in the previous study. In contrast to the effect of ouabain on 
basal release of IL-lp, however, there was no significant difference between any of 
the three groups. There was a slight variation in the amounts of IL-lp produced by 
the PBMCs from the different patient groups but this did not extend to significant 
differences in response to ouabain. As can be seen in figure 4.6, maximal IL-ip 
induction was seen in all groups with 0.1 pM ouabain, with normal cells producing 
19206pg/ml.
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Figure 4.5: Effect of Ouabain on LPS (lOng/ml) Stimulated Cytokine Release 
from human PBMCs.
Panel A: Shows effect o f Ouabain on LPS induced release o f IL-6.
Panel B: Shows effect o f Ouabain on LPS induced release o f OSM.
Cells were purified from healthy volunteers and cultured with LPS ± ouabain in 
polypropylene tubes. Cytokine release was determined after 24 hours 
(n=4±STDEV, *= P<0.05).
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Figure 4.6: Effect of Na+/K+-ATPase Inhibition on LPS Induced IL-ip 
Production from Normal and Rheumatoid PBMCs.
PBMCs were purified from the blood o f early RA/synovitis patients, chronic RA 
patients and healthy volunteers. Cells were simultaneously stimulated with LPS 
(lOng/ml) and various concentrations o f ouabain. Cytokine levels were 
determined in culture supernatants after 24 hours.
Normal n=16, Early RA n=l 1, Chronic RA n=5 (± STDEV).
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4.2.6: Effect of Ouabain on the Time-course of Cytokine Production
Induced by LPS in Normal PBMCs
4.2.6.1: IL-lp
From the previous studies that investigated the concentration dependent effects of 
ouabain on basal and LPS induced cytokines from PBMCs, it is apparent that 
ouabain at different concentrations has quite different effects on the various 
cytokines analysed. Although generally stimulatory at lower concentrations, it was 
found that at higher concentrations ouabain synergised with LPS to give a dramatic 
induction of IL-ip and a modest induction of TNFa but tended to inhibit the 
production of IL-6 and OSM. In the following experiments PBMCs were prepared 
and incubated as described before but supernatants were harvested every hour for 
eight hours after stimulation and then at 24 hours after stimulation. All samples were 
stimulated with lOng/ml LPS but only lOnM and lOOnM concentrations of ouabain 
were used. After harvesting the supernatants, the cells were lysed to release the 
intracellular cytokine contents and these too were analysed by ELISA. Cells were 
lysed in 200pl of lysis buffer so that the concentration of cytokines was comparable 
to those in the 200pl of culture supernatant. As PBMCs were suspended at lx l06/ml, 
cytokine determinations in pg/ml represented the cytokine production in pg/106 cells.
Figure 4.7 shows the IL-ip response of normal PBMCs. Panel A shows the released 
cytokine protein measured in the supernatants and panel B shows the cytokine 
content of the cell lysates. At time zero there is no IL-lp released in to the 
supernatant or being stored intracellularly, confirming that these cells are in a resting 
state. With lOng/ml LPS stimulation mature 17kD IL-lp protein is detectable within 
one hour. The level of IL-lp detectable in the cell lysates rises rapidly over the next 
six hours until a maximal level of lOOng/ml is present by seven hours after 
stimulation. Ouabain at both concentrations studied had no effect on intracellular IL- 
lp content until at the five-hour time point when a noticeable drop was seen with 
lOOnM ouabain. This effect remains over the rest of the 24hour time-course, with 
lOnM ouabain having little effect on intracellular IL-ip levels and lOOnM ouabain 
causing a significant drop. By the 24 hour time-point intracellular IL-lp levels in the 
control (LPS) group and the lOnM ouabain (+LPS) group are comparable at 55ng/ml 
but in the lOOnM ouabain group levels are undetectable (P<0.05). The IL-ip content
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of the supernatants complements the intracellular cytokine data. In this figure there is 
little IL-lp detectable in any of the supernatants until at the three-hour time-point 
when a mean value of 456pg/ml is detectable in just the lOOnM ouabain samples. At 
the four-hour time point IL-lp becomes detectable in the LPS controls and the 
LPS+lOnM ouabain group with levels around 450pg/ml. In the lOOnM ouabain 
group, however, the IL-ip level rises to 5ng/ml at four hours and then climbs rapidly 
until a maximum of 50ng/ml IL-ip is detectable at eight hours. In the control LPS 
group and the LPS+lOnM ouabain group released IL-lp levels do not exceed 5ng/ml 
and plateau between six and twenty-four hours.
4.2.6.2: IL-lra
To complement the pro-inflammatory IL-ip data in these experiments the level of 
IL-lra in the cell lysates and supernatants was also analysed. From these data, shown 
in figure 4.8, it can be seen that IL-lra is regulated in a very different way to IL-lp 
in response to LPS. Whereas IL-ip production is rapidly induced by LPS and found 
to be elevated intracellularly within one to two hours and secreted within three to 
four hours IL-lra remains at very low levels for many hours. In these experiments, 
intracellular IL-lra remained at the 200-3OOpg/ml level for the first eight hours of 
culture and it was not until the twenty-four hour time-point that a significant 
induction was seen. At twenty-four hours after stimulation intracellular IL-lra levels 
reached 12613pg/ml in the control LPS stimulated group. This LPS induction of IL- 
lra was inhibited slightly by lOnM ouabain, with levels measured at 8251pg/ml and 
totally blocked with lOOnM ouabain (P<0.05). In the complementary supernatant 
data IL-lra production was again low for the first eight hours of culture. Levels of 
IL-lra were initially undetectable and gradually climbed to 850pg/ml in the control 
LPS group. Again, it was not until the twenty-four hour time point that significant 
levels of IL-lra were secreted, with control levels reaching 4179pg/ml. Ouabain had 
no effect on LPS induced IL-lra over the first seven hours of culture. After eight 
hours of culture the lOOnM ouabain group showed a reduced level of 250pg/ml IL- 
lra, compared to control LPS induced levels of 853pg/ml. At the twenty-four hour 
time-point lOnM ouabain had a slight inhibitory effect on LPS induced IL-lra 
production but lOOnM ouabain almost blocked the response completely, with levels
Chapter 4: Role of the Na7K+-ATPase in PBMC cytokine production -114-
remaining at 450pg/ml. The ability of ouabain to inhibit LPS induced IL-lra 
secretion was marked but unfortunately with this low experimental number was not 
statistically significant.
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Figure 4.7: Effect of Ouabain on Time-course of LPS Induced IL-ip 
Production in Healthy PBMCs.
Panel A: Shows time-course for LPS (lOng/ml) induced IL-lp release from 
PBMCs cultured with or without Ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV, *= P<0.05).
Panel B: Shows time-course for LPS (lOng/ml) induced IL-lp content o f PBMC 
lysates cultured with or without Ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV, *= P<0.05).
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Figure 4.8: Effect of Ouabain on Time-course of LPS Induced IL-lra 
Production in Healthy PBMCs.
Panel A: Shows time-course for LPS (lOng/ml) induced IL-lra release from 
PBMCs cultured with or without Ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV).
Panel B: Shows time-course for LPS (lOng/ml) induced IL-lra content of PBMC 
lysates cultured with or without Ouabain at concentrations o f lOnM and 100nM 
(n=3±STDEV, *= P<0.05).
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4.2.6.3: TNFa
The effect of ouabain on LPS induced TNFa release and intracellular TNFa levels is 
shown in figure 4.9. In agreement with the concentration response curve to ouabain, 
displayed in figure 4.3, the twenty four hour time point in this experiment showed 
that LPS induced TNFa release, that lOnM ouabain enhanced this stimulation and 
that lOOnM ouabain suppressed it. Over the twenty four-hour time-course of this 
study, however, very little intracellular TNFa was measured in the cell lysates and 
no obvious effect was seen with either of the ouabain groups. All three groups, 
control LPS, lOnM ouabain+LPS and lOOnM ouabain+LPS showed resting levels of 
approximately 5pg/ml TNFa at time zero. This level increased to a maximum of 
150pg/ml by the five-hour time-point and dropped steadily back to approximately 
25pg/ml by the eight-hour time-point. There were tendencies over the time-course 
for the lOnM ouabain group to display higher levels of TNFa but these were very 
erratic, statistically insignificant and concerned perhaps insignificantly low levels of 
protein. In contrast, however, secreted TNFa rapidly reached high concentrations 
with protein levels being clearly detectable, after just one hour of incubation, at 
230pg/ml. LPS induced a steady increase in secreted TNFa over the twenty four 
hour time-course, reaching a maximum level of 4024pg/ml. The inclusion of lOnM 
ouabain had no effect on LPS induced TNFa until the last time-point at which it 
increased the secreted protein level to 5361pg/ml. In contrast, however, from the 
five-hour time-point lOOnM ouabain suppressed the effects of LPS on secreted 
TNFa production (P<0.05) with levels reaching a maximum of 1850pg/ml and 
remaining constant over the duration of the experiment.
4.2.6.4: IL-6
From the ouabain concentration response curve shown in figure 4.5 it can be seen 
that both lOnM and lOOnM ouabain had suppressive effects on LPS induced IL-6. 
Consequently these doses may not have been the best with which to challenge 
PBMCs for this time-course study. For completion of this data set, however, the IL-6 
contents of both supernatants and cell lysates were analysed and displayed in figure 
4.10.
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LPS induced secretion of IL-6 within two to three hours of stimulation. The level of 
IL-6 released into the supernatants increased steadily until a maximum of 1800pg/ml 
was reached at the eight-hour time-point. At no point in the twenty-four hour time- 
course did lOnM ouabain have any effect on LPS induced IL-6 release. In contrast, 
lOOnM ouabain slightly inhibited LPS induced IL-6 production in the four to eight 
hour samples. However, by the twenty-four hour time-point IL-6 secretion was 
equivalent in all three groups, at levels of approximately 8000pg/ml.
Intracellular accumulation of IL-6 was rapid after stimulation with LPS. By the two- 
hour time-point IL-6 levels had increased from a basal production of 5pg/ml to 
600pg/ml. The accumulation of IL-6 increased rapidly until a maximum of 
2963pg/ml was reached at the four-hour time point. Up until the four-hour time-point 
neither of the ouabain concentrations had any effect on LPS induced intracellular IL- 
6. From the four hour to the eight-hour point IL-6 accumulation diminished rapidly 
in all groups studied, especially the lOOnM ouabain group. By the twenty-four hour 
time-point IL-6 levels were equivalent in all groups at about 300pg/ml.
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Figure 4.9: Effect of Ouabain on Time-course of LPS Induced TNFa in 
Healthy PBMCs.
Panel A: Shows time-course for LPS (lOng/ml) induced TNFa release from 
PBMCs cultured with or without ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV, *= P<0.05).
Panel B: Shows time-course for LPS (lOng/ml) induced TNFa content o f PBMC 
lysates cultured with or without ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV).
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Figure 4.10: Effect of Ouabain on Time-course of LPS Induced IL-6 
Production by Healthy PBMCs.
Panel A: Shows time-course for LPS (lOng/ml) induced IL-6 release from 
PBMCs cultured with or without ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV).
Panel B: Shows time-course for LPS (lOng/ml) induced IL-6 content o f PBMC 
lysates cultured with or without ouabain at concentrations o f lOnM and lOOnM 
(n=3±STDEV).
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4.3: SUMMARY
The work detailed in this chapter sought to compare the effects of ouabain on the 
production of monocyte derived cytokines from PBMCs of rheumatoid patients and 
healthy controls. The hypothesis of decreased Na+/K+-ATPase activity in rheumatoid 
mononuclear cell membranes was tested via the measurement of functional responses 
to ouabain in vitro. Ouabain is a specific Na7K+-ATPase inhibitor and thus when 
used to treat PBMCs in vitro can mimic the decreased Na+/K+-ATPase activity 
suggested in rheumatoid mononuclear cells in vivo. Consequently, the experiments 
carried out offered the answers to two questions. Firstly, what effect does Na7K+- 
ATPase inhibition have on the cytokine profile produced by normal PBMCs? 
Secondly, do the PBMCs from rheumatoid patients display altered sensitivity to the 
effects of ouabain in vitro?
The results displayed in this chapter show that ouabain has potent modulatory effects 
on mononuclear cell cytokine production. When used to stimulate resting PBMCs 
ouabain induced a concentration dependent increase in IL-ip and TNFa release but 
had little effect on IL-6 and OSM release. Cytokine levels induced by ouabain, 
however, were not as high as was expected when compared to some similar studies in 
the literature. Maximum IL-ip levels of 1250pg/ml were induced by lpM ouabain 
and maximum TNFa levels of 187pg/ml were induced by 0.1 pM ouabain. 
Production of all four cytokines studied was low but this did, however, offer a very 
clean system in which to compare the responses of different rheumatoid patients to 
healthy controls. As IL-6 and OSM release over a twenty-four hour culture were 
minimally induced by ouabain, rheumatoid and healthy PBMCs were compared for 
their IL-lp response to ouabain. Chronic rheumatoid patients selected for this study 
were defined as having sero-positive rheumatoid disease for a period in excess of 
four years and were preferably not receiving second-line treatments. Patients who 
had been treated with corticosteroids within the last year were excluded for fear of 
modulatory effects on cytokine production. The early rheumatoid patients were 
selected based upon the symptoms of early synovitis and were only receiving non­
steroidal anti-inflammatory treatments. When assessing ouabain induced IL-ip 
production from PBMCs the patient groups were compared for the amount of protein 
secreted in response to various concentrations of ouabain. As IL-lp is a monocyte 
derived cytokine all PBMCs were tested for monocyte numbers via anti-CD 14
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surface staining using flow cytometry. Monocyte numbers were comparable between 
the three groups but interestingly the IL-lp production in response to ouabain was 
quite different. The early rheumatoid group showed the greatest sensitivity to 
ouabain, producing significantly more IL-lp in response to 0.1 pM, followed by the 
normal group and then the chronic rheumatoid group. The maximum level of IL-ip 
release was seen with 0.1 pM ouabain stimulation in the early rheumatoid group, 
lpM ouabain stimulation in the normal group and lOpM ouabain stimulation in the 
chronic rheumatoid group. These data show that IL-lp secretion from PBMCs is 
modulated by Na+/K+-ATPase inhibition and that the different patient groups differ in 
their sensitivity to ouabain. This variation in sensitivity to ouabain could be a result 
of different levels of Na+/K+-ATPase expression in the different patient groups, 
different levels of Na7K+-ATPase activity or perhaps differing affinities for ouabain 
binding. Alternatively, the signal that is induced by inhibition of the Na7K+-ATPase 
in PBMCs could regulate cytokine gene transcription or protein processing to 
varying degrees in the different patient groups.
The observation that ouabain did not affect mononuclear cell production of IL-6 
contradicts the work of Foey (1997) (232), who demonstrated concentration 
dependent inhibition with ouabain stimulation of PBMCs. Similarly, it was 
unexpected that ouabain would have no effect on OSM production. In fact, when the 
control cytokine responses to ouabain displayed here were compared to similar 
studies reported in the literature it was felt that they were due to a particularly 
quiescent culture system. The levels of IL-lp produced here were in accord with data 
presented by Newton (1990) (219) but were much lower than those described by 
Walev (1995) (235) who looked at the effect of ouabain on LPS primed mononuclear 
cells. Consequently, experiments were carried out to study the effect of ouabain on 
LPS stimulated PBMCs from the different patient groups.
LPS alone was seen to potently induce IL-ip release from PBMCs in a concentration 
dependent manner. Similarly, LPS induced TNFa, IL-6 and OSM release. Using 
lOng/ml LPS to induce a sub-maximal priming stimulus in healthy PBMCs the effect 
of ouabain was now observed on the production of IL-lp, TNFa, IL-6 and OSM. 
Ouabain synergised greatly with LPS to induce the release of IL-ip. Similarly, but to 
a lesser extent, ouabain also synergised with LPS to induce TNFa and IL-6 release. 
In contrast, however, ouabain caused a concentration dependent inhibition of OSM
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release. The maximum response to ouabain occurred at 0.1 pM for IL-lp, lOnM for 
TNFa and InM for IL-6 release. Concentrations of ouabain above these maximal 
effective levels induced a concentration dependent inhibition of the release of the 
cytokine in question. From these data it would appear that the effects of ouabain on 
LPS primed PBMCs involve variable concentration dependent responses. In addition 
to the signal through CD 14 induced by LPS there is a complex imbalance in 
intracellular cation levels induced by ouabain. It would appear that at low 
concentrations ouabain favours the induction of IL-6 and TNFa and to a similar 
extent IL-ip but then at concentrations above lOnM to 0.1 pM ouabain induces a 
marked release of IL-lp and down-regulates TNFa and IL-6 release. Whether the 
decrease in ouabain induced IL-6 and TNFa is as a direct consequence of the IL-lp 
release cannot be shown here. It is perhaps most likely that at higher concentrations 
ouabain is inducing such a shift in cation levels that the cells are undergoing a 
stressed response. Calcium influxes due to elevated intracellular sodium levels may 
synergise with LPS induced cytokine production initially but at a certain point may 
over-load the cells and perhaps even deliver a cytotoxic signal.
Comparing rheumatoid and healthy PBMC responses to ouabain after priming with 
LPS displayed quite a different cytokine profile to that seen in resting PBMCs. 
Although LPS induced a comparable IL-lp response in rheumatoid and normal 
PBMCs the addition of ouabain stimulation had less of a variable effect in the 
different patient groups. Ouabain synergised greatly with LPS induced IL-lp 
production in all groups studied but there was no difference between the responses of 
early rheumatoid, chronic rheumatoid and normal PBMCs. In their resting state, the 
patient PBMCs displayed quite variable sensitivities to ouabain stimulation but when 
primed with LPS all were equally sensitive to synergy with low concentrations of 
ouabain.
The complexities of the concentration dependent ouabain induced cytokine profile 
from PBMCs suggested that there might be time-dependent relationships between the 
induciton of IL-ip release and effects on IL-6 and TNFa. To explore the possibilities 
of feedback regulation in the development of the cytokine profile observed with 
ouabain a time-course of the effects of ouabain on LPS primed PBMCs was carried 
out. The results displayed in figures 4.7 to 4.10 show that the synergistic release of 
IL-ip induced by LPS and 0.1 pM ouabain coincides with the decrease in IL-6
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production at about four hours after stimulation. The reduction in TNFa release 
induced by 0.1 pM ouabain occurs a little later, at between five and six hours after 
stimulation. Interestingly, the marked release of IL-lp induced by the combination of 
LPS and 0.1 pM ouabain was mirrored by a drop in the intracellular concentration of 
IL-lp. This could either indicate that the IL-ip is being secreted more rapidly than it 
is being made or that intracellular IL-ip processing is being halted at a certain point 
after stimulation. The latter is perhaps the most likely as the concentration of IL-lp 
released drops between eight and twenty-four hours.
It is also interesting to note that although the effects of ouabain on LPS induced 
TNFa release from PBMCs are not evident during the earlier hours of the time- 
course it would appear that LPS induced TNFa release precedes that of IL-lp.
The cytokine profile induced by ouabain in these studies is typically pro- 
inflammatory but the exaggerated IL-ip response in LPS primed PBMCs is by far 
the most dramatic response observed. To test whether the IL-ip family is particularly 
involved in the response to ouabain, secreted and intracellular levels of IL-lra were 
also measured over the same time-course in LPS primed PBMCs. Unfortunately, it 
appears that the early time-points in this time-course were irrelevant as released and 
intracellular IL-lra remained very low until between eight and twenty-four hours. At 
this point LPS induced a marked elevation in released and intracellular IL-lra. 
Interestingly, however, in complete contrast to IL-lp responses, ouabain almost 
totally abolished the production of IL-lra both intracellularly (P<0.05) and secreted 
(n=3; P=0.1).
From these data it would appear that altering the concentration of intracellular 
cations differentially regulates the production of pro- and anti-inflammatory 
cytokines. The ability of ouabain to inhibit basal IL-lra release was not measured but 
in LPS stimulated studies ouabain significantly favoured the production of IL-lp 
over that of IL-lra. If oxidative damage of the Na+/K+-ATPase in mononuclear cell 
membranes in RA occurs the resulting imbalance in intracellular cation levels may 
well add to the pro-inflammatory. These studies may highlight a possible cycle of 
events where activation of monocytes infiltrating the inflamed synovium may 
perpetuate an inflammatory reaction.
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5.1: INTRODUCTION
The Na+/K+-ATPase is an important membrane enzyme that plays a significant role 
in control of cellular volume and the cationic homeostasis of sodium and potassium. 
Inhibition of the Na+/K+-ATPase with ouabain results in dramatic effects on cationic 
homeostasis where the electrogenic flux of two potassium ions inwards and three 
sodium ions outwards is prevented. Consequently, a transient rise in intracellular 
sodium levels is observed. When a cell has its intracellular sodium concentration 
artificially raised, it may react using existing cation exchange mechanisms to 
maintain the sodium ionic homeostasis. It has been described by Blaustein et al 
(1976) (432) that downstream to rises in intracellular sodium, a concomitant rise in 
intracellular calcium can be detected, via an increase in the activity of the Na+/Ca2+ 
exchanger.
Ouabain has been shown to have potent effects on the production of cytokines, 
especially IL-ip, from PBMCs. Preliminary trypan blue exclusion assays carried out 
initially in this study showed ouabain to be relatively non-toxic at concentrations less 
than lOpM. Suspicions of cytotoxicity arose, however, when more detailed studies 
using propidium iodide staining and flow cytometry were employed. Data indicated a 
more sinister action of ouabain in the induction of monocyte cytokine expression.
Due to the role of the Na+/K+-ATPase in the regulation of cell volume, inhibition 
with ouabain could cause swelling and necrosis of sensitive cell types. Conversely, it 
is possible that specific death signals are initiated through alterations in intracellular 
sodium or potassium concentrations or even via reflex effects on calcium levels 
within the cell. Apoptosis has been shown to involve a cascade of intracellular 
proteases, collectively known as caspases (433-435). The IL-lp converting enzyme 
(ICE), alternatively known as caspase-1, was the first such protein identified on the 
basis of its sequence homology to the pro-apoptotic Caenorhabditis elegans gene 
product, ced-3 (126). At least ten members of the caspase family have been identified 
to date (435). Each is capable not only of degrading key cytostructural and reparative 
proteins but also of activating other caspase family members by cleaving the pro 
forms of the enzymes at aspartic acid residues. ICE, however, is not only involved in 
apoptosis, it is also critical in the production of mature IL-ip from the cleavage of 
pro-IL-1 at an aspartic acid residue. This relationship between IL-lp, ICE and
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apoptosis suggested possibilities that if the induction of IL-ip seen with ouabain in 
the previous chapter was linked with mononuclear cell death, apoptosis could well be 
involved. Consequently, this chapter set out to investigate possible toxic effects of 
ouabain on mononuclear cells. To complement the previous cytokine data it was 
necessary to fully understand the time-course, ouabain sensitivity and nature of any 
such cytotoxic reactions.
5.2: RESULTS
The effect of stimulation with ouabain on cell viability was tested in PBMCs purified 
from the blood of RA patients and healthy controls. Initial experiments tested the 
effects of ouabain over a twenty-four hour culture period in order to complement the 
cytokine production data shown at the beginning of chapter 4. The aim of these 
studies was to show that the effects of ouabain on cytokine production were not due 
to non-specific cytotoxicity.
5.2.1: Effects of Ouabain on PBMC Viability
PBMCs that had been stimulated with various concentrations of ouabain for twenty- 
four hours were pelleted by centrifugation and retained after the supernatant had been 
harvested for cytokine ELISA. The cells were then washed once in PBS, re­
suspended in FACS sheath fluid and analysed immediately by flow cytometry. The 
nuclear stain propidium iodide was added to each tube of cells immediately prior to 
analysis and dead cells, with permeable membranes, were detectable due to high FL- 
2 fluorescence. As can be seen in figure 5.1 A basal cell death in PBMCs cultured for 
twenty-four hours was consistently around 5%. Ouabain had no effect on cell 
viability until at a concentration of 0.1 pM when a doubling in the number of PI 
positive cells was seen. Increasing concentrations of ouabain gave increased cell 
death until a plateau was reached at lOpM ouabain. Cell death rarely exceeded 20- 
30% of the PBMC population and it was observed to correlate often with CD 14 
expression of the purified PBMC population.
To investigate the possibility that ouabain was having cytotoxic effects on the 
monocyte population of the PBMCs initial observations used FACS light scatter
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analysis. As the PBMCs were being cultured in polypropylene tubes to prevent 
adherence-activation induced cytokine production it was possible to retrieve all the 
cells for FACS analysis. By observing the light scattering properties of the PBMC 
population it was possible to identify and track any changes in the morphology of the 
monocytes. Using the FACS, when a cell passes through the laser beam some light is 
reflected and detected as side scatter (SSC) and some light passes by the cell and is 
detected as forward scatter (FSC). Consequently the cell population can be assessed 
for size by the amount of light that is detected as FSC and for membrane morphology 
by the degree of SSC that is detected. As monocytes are larger and more ruffled than 
lymphocytes, they are detectable as a population of cells in the upper-right quadrant 
of the PBMC population. To confirm that light scattering properties were a reliable 
way to identify the monocyte population experiments were carried out using anti- 
CD 14 stained PBMCs that were stained with a FITC conjugate. By plotting FL-1 
fluorescence against either FSC or SSC it was clear that it was the high FSC and high 
SSC cells that became FL-1 bright upon CD14 staining (data not shown). By 
observing the FSC and SSC of the PBMC population after twenty-four hour 
stimulation with ouabain it was now possible to identify which cells were being 
affected. As ouabain inhibition of the Na+/K+-ATPase affects cell volume it might be 
expected that such changes would be visible on the FSC-SSC FACS plot. As can be 
seen in figure 5.IB the monocyte population is clearly distinct from the lymphocyte 
population as a separate cloud of cells in the upper-right region (for clarity the 
monocyte population is circled in the first plot). Upon stimulation with ouabain the 
monocyte cloud initially becomes more diffuse but at concentrations of 0.1 pM or 
above is seen to disappear completely. Interestingly, the lymphocyte population 
appears to remain unaffected by ouabain. From these results it appears that the cell 
death induced by ouabain is restricted to the monocyte population of the PBMCs.
Although the FACS data offered compelling evidence for ouabain induced death of 
monocytes further studies were carried out to investigate the mechanism of this 
response. Efforts had to be made to correlate cell death with cytokine release in order 
to understand how ouabain may be modulating monocyte cytokine production.
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5.2.2: Ouabain Induced Death of Monocytes
To confirm that ouabain was specifically affecting the viability of the monocyte 
population of the PBMCs experiments were carried out to purify monocytes from 
peripheral blood and to study these directly. In theory, this was to be a simple 
procedure but in practice it proved to be quite difficult to purify a population of 
monocytes that were in a suitable resting state for experimentation.
Most classical monocyte purification procedures utilise plastic adherence as the main 
selection tool, with all other PBMCs being washed away. Unfortunately, however, 
this leaves the monocytes adhered to culture dishes and obviously unsuitable for 
FACS analysis. Attempts were made to lift the monocytes after plastic adherence so 
that they could then be cultured with ouabain in polypropylene tubes. It was found, 
however, that using cell dissociation buffer (Sigma) or even Trypsin EDTA caused a 
high degree of cell death in itself and proved unsuitable for these studies. The next 
approach for monocyte purification utilised centrifugal separation over a density 
gradient. Percoll concentrations of 50% to 54% were tested but unfortunately these 
also retained the larger lymphocytes which were of a similar buoyant density to the 
monocyte population. A second density gradient approach was tested using 
NycoPrep™ (Nycomed). NycoPrep has a density of 1.068g/ml, which therefore 
retains the more buoyant cells in a similar manner to Percoll. The difference with 
NycoPrep, however, is that it has an osmolality of 335mOsm that causes the 
lymphocytes to shrink, becoming more dense and passing through the gradient. 
Purified monocytes can then be collected from the plasma/gradient interface. These 
monocytes were found to be greater than 70% CD 14 positive and their viability 
remained reasonably constant and high in control cultures.
The effect of ouabain on the viability of enriched monocytes was assessed using PI 
staining on flow cytometry. Cells were cultured with various concentrations of 
ouabain and assessed for viability after eight, sixteen and twenty-four hours. As can 
be seen in figure 5.2A ouabain caused a concentration and time dependent increase 
in cell death. Death was only apparent in the 0.1 and lpM ouabain groups and only 
significantly noticeable after sixteen hours of culture (P<0.05). Although marked, the 
ability of 0.1 pM ouabain to induce death of monocytes was not statistically 
significant over the twenty-four hour study. Increased experimental numbers would 
probably prove 0.1 pM ouabain to at least be toxic after twenty-four hours.
Chapter 5: Ouabain Induced Death of Monocytes -130-
To complement the data on ouabain induced death of peripheral blood monocytes 
experiments were also carried out using the monocytic cell line THP-1. The THP-1 
line had already been characterised in terms of Na+/K+-ATPase activity and thus 
proved to be a suitable model for studying the effects of ouabain on cell death. 
Resting THP-1 were cultured for twenty-four hours with various concentrations of 
ouabain and assessed for viability using PI staining. The results for this experiment 
are displayed in figure 5.2B and show that THP-1 cells are similarly sensitive to 
ouabain induced death as peripheral blood monocytes. No effect on cell viability is 
seen with ouabain stimulation until at a concentration of 0.1 pM when significant cell 
death is observed (P<0.05). Cell death increases with increasing concentrations of 
ouabain until a plateau is reached with lOpM ouabain.
The effects of ouabain on PBMC cytokine production occur rapidly, with IL-ip 
release being measurable within four hours of stimulation (section 4.2.6.1). The data 
presented here, using PI staining to assess viability of purified monocytes, suggests 
that little toxicity occurs in ouabain treated cells within eight hours of culture. PI 
staining, however, gives no information on the state of cell activation so attempts 
were made to study the monocyte population in more detail over a time-course of 
ouabain stimulation. The time-course of ouabain effects on monocyte morphology 
were assessed using FSC and SSC analysis on flow cytometry. Healthy PBMCs were 
cultured with 1 pM ouabain and cells harvested for analysis at three, five, six, eight 
and eighteen hours. A typical FACS trace is shown in figure 5.4 with the monocyte 
cloud being clearly distinct from the lymphocyte cloud. With ouabain treatment it 
can be seen that as early as three hours after stimulation the monocyte cloud appears 
to increase slightly in FSC and SSC. The monocytes become slightly larger and more 
distinct from the lymphocyte population, perhaps as a result of increased volume or 
activation. Five hours after stimulation the monocytes appear to be a more diffuse 
population but it is not until between six and eight hours that the size of the 
monocyte population appears to be reduced. By eighteen hours after stimulation the 
entire monocyte cloud has disappeared.
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Figure 5.1: Ouabain induced death of PBMCs.
Panel A: Death o f PBMCs incubated with various concentrations o f ouabain for twenty- 
four hours. Cell death is measured as an increase in FL-2 fluorescence, due to uptake of 
tie nuclear stain propidium iodide, detected using flow cytometry. (RA, n = l l ,  Control, 
n=9 ±STDEV).
Panel B: Ouabain concentration response curve in PBMCs incubated for twenty-four 
hours. The plots display the light scattering characteristics o f the cell population and 
h ghlight the effect o f ouabain on the monocytic cells. The monocytic population can be 
icentified, due to its increased size and more ruffled surface, as the upper right cell cloud 
(circled in the first plot).
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Figure 5.2: Ouabain induced death of monocytes.
Panel A: Ouabain-induced death o f purified human blood monocytes after 
twenty-four hour incubation (n=3±STDEV, *= P<0.05). Death measured as PI 
staining by flow cytometry.
Panel B: Ouabain-induced death o f THP-1 cells after twenty-four hours 
incubation (n=3±STDEV, *= P<0.05). Death measured as PI staining by flow 
cytometry.
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Figure 5.3: Time-course of Ouabain-Induced Death of Monocytes.
PBMCs from normal individuals were treated with 1E-6M ouabain and tested for 
viability at various times after stimulation. The monocytic population was 
identified as the upper-right cloud on the FACS scatter plot.
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5.2.3: Ouabain Induced Apoptosis of Monocytes
The molecular mechanisms of apoptosis are not fully understood but are known to 
involve the IL-ip converting enzyme (ICE) family of proteases. In a variety of cell 
systems ICE family proteases have been shown to be activated during apoptosis 
(436-439). Also, in similar studies, over-expression of certain proteases caused cells 
to undergo apoptosis (434,440-446). Inhibitors of the ICE family proteases have been 
used to block the induction of apoptosis in other cell systems (436,437,447). In this 
study ouabain has been shown to dramatically induce production of IL-lp and cause 
significant toxicity in monocytic cells. As ICE is the enzyme responsible for the 
production of mature IL-ip and may also be involved in apoptosis, experiments were 
carried out to see if ouabain induction of IL-ip may involve apoptotic pathways.
Annexin V staining of phosphatidyl serine (PS) was used to distinguish between 
apoptotic and necrotic death of monocytes using flow cytometry. PS has been shown 
to be externalised during apoptosis (433,448,449) and is one of the identifying 
features that allows macrophages to recognise and eliminate apoptotic cells. As 
apoptotic cells externalise PS in the early stages of apoptosis without losing 
membrane integrity they will not take-up the nuclear stain propidium iodide. When 
stained with Annexin V-FITC (FL-1) and PI (FL-2) necrotic cells will become both 
FL-1 and FL-2 bright when analysed by flow cytometry. Under the same conditions 
apoptotic cells stain FL-1 bright and FL-2 dark.
Purified peripheral blood monocytes and the monocytic cell line THP-1 were used to 
study the mechanisms of ouabain induced cell death. As the degree of cell death 
shown via PI staining in figure 5.2 is only just measurable eight hours after 
stimulation this time-point was initially used as a starting point for the study of 
Annexin V binding. Purified peripheral blood monocytes were stimulated with 
0.1 pM ouabain and harvested at various time points for double staining with PI and 
Annexin V. Typical results are shown in figure 5.4 where the FACS plot is split into 
four quadrants. The lower-left quadrant represents the double-negative cells, i.e. 
those that are alive. The lower-right quadrant represents the Annexin positive, PI- 
negative cells, i.e. those that are apoptosing. The upper-left quadrant represents cell 
debris and the upper-right quadrant represents the double-positive cells, i.e. those that 
are necrotic or have lost membrane integrity after apoptosis. Over twenty-four hours
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of culture the majority of the monocyte population remains healthy, in the lower left 
quadrant. There is a little background AnnexinV staining and a little necrosis, 
probably due to the stress of purification and culture. In the ouabain treated group, 
however, there is a measurable induction of death that displays the clear 
characteristics of apoptosis. In the eight-hour ouabain treated group there is little 
difference in the FACS profile when compared to controls. By twelve hours, 
however, there is a clear increase in both the apoptotic population and the necrotic 
population. After twenty-four hours of stimulation there are still cells that appear to 
be undergoing apoptosis and the percentage of necrotic cells has increased slightly. 
The outcome of these apoptotic cells was not followed further than twenty-four 
hours.
In an attempt to simplify the study of ouabain induced death the THP-1 cell-line was 
utilised for further experiments on apoptosis. THP-1 cells are described as being pro- 
monocytic and undergo differentiation when treated with l,25(OH)2-vitamin D3 
(352). Differentiated THP-1 cells express CD14 and in many respects behave like 
normal peripheral blood monocytes. The effects of ouabain on THP-1 cell death, 
measured by PI staining, were similar to those seen in blood monocytes so it was 
hoped that apoptosis responses would be similar. As can be seen in figure 5.5, 
however, it appears that in THP-1 cells ouabain does not induce an apoptotic 
response. Both resting and differentiated THP-1 cells did not develop an annexin 
bright population upon stimulation with ouabain. Ouabain was tested from 0.1 pM to 
lOpM over a twenty four hour time-course but all toxic effects induced were detected 
as necrosis. The live cells cross straight from the double-negative quadrant to the 
double-positive quadrant. The results displayed in figure 5.5 are representative of 
three experiments and detail the early events in the induction of death. Interestingly, 
THP-1 cells die more rapidly in response to ouabain stimulation than peripheral 
blood monocytes and it also appears that differentiated THP-1 cells are more 
sensitive than resting THP-1 cells. At 6.5 hours after ouabain stimulation four-fold 
more necrotic cells were present in the differentiated THP-1 cells than in the control 
THP-1 cells.
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Figure 5.4: Ouabain Induced Apoptosis of Purified Peripheral Blood 
Monocytes
Purified monocytes were treated with 1E-7M ouabain and then stained with 
Annexin V to detect apoptosis (FL-1 +ve, lower right). Necrosis was 
differentiated from apoptosis using propidium iodide to double stain (FL-1 + FL-2 
+ve, upper right).
Quadrant Control 1E-7M (3uabain8 hour 24 hour 8 hour 12 hour 16 hour 24 hour
Upper
Left 0.70% 0.67% 0.56% 1.39% 0.86% 1.89%
Upper
Right 5.30% 3.20% 7.57% 14.70% 13.60% 18.89%
Lower
Left 83.37% 88.40% 81.83% 60.34% 63.91% 56.9%
Lower
Right 10.63% 7.73% 10.04% 23.57% 21.63% 22.33%
Table 5.1: Quadrant Statistics for data shown in Figure 5.4.
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Figure 5.5: Ouabain Induced Death of THP-1 Cells.
D3-differentiated and undifferentiated THP-1 cells were cultured with 0.4pM  
ouabain for various times. Cell viability was assessed using Annexin V and PI 
staining. Quadrant definitions: LL = live cells, LR = apoptotic cells, UL = cell 
debris and UR = necrotic cells.
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5.2.4: Effect of LPS on Ouabain Induced Monocyte Death
The effects of ouabain on PBMC cytokine production, especially IL-ip, were 
enhanced greatly by LPS stimulation. To test whether this may involve cytotoxicity 
PBMCs were stimulated with both ouabain and LPS and assessed by flow cytometry 
using scatter analysis. Typical responses, representative of three experiments, are 
shown in figure 5.6. Eight hours after stimulation, cells treated with lOng/ml LPS 
did not vary greatly to control cells. The monocyte population of the PBMCs was a 
little more diffuse than controls, perhaps indicating activation-induced changes in 
morphology. In this system, at eight hours, ouabain alone had no effect on the 
monocyte population. The addition of lOng/ml LPS, however, rendered the 
monocytes more sensitive to ouabain induced death. LPS + 10nM ouabain had no 
effect on cell viability but the combination of 0.1 pM ouabain and LPS caused 
marked disruption of the monocyte cloud.
To complement these data purified monocytes were stimulated with ouabain ± 
lOng/ml LPS and assessed for death using PI staining. The cells were cultured for 
twenty-four hours so controls were expected to be relatively insensitive to lOnM 
ouabain but to die readily when stimulated with 0.1 pM ouabain (compare with 
figure 5.2A). The mean data of two experiments are shown in figure 5.7 and clearly 
demonstrate that LPS treated monocytes are more sensitive to ouabain induced death.
To test whether LPS was affecting ouabain-induced apoptosis of peripheral blood 
monocytes or was merely contributing to activation induced necrosis, Annexin V 
staining was again employed. Purified monocytes were stimulated with ouabain and 
LPS over a twenty-four hour time-course similar to that displayed in figure 5.4. At 
no point, however, did the addition of LPS contribute to the degree of ouabain 
induced apoptosis. In fact, as shown in figure 5.8, LPS stimulation resulted in a 
decrease in ouabain induced apoptosis and an increase in the percentage of necrotic 
cells.
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Figure 5.6: Effect of LPS on Ouabain-Induced Monocyte Death.
PBMCs were incubated for twenty-four hours and the viability o f the monocyte 
cloud was visualised from FACS scatter plots. The effect o f lOng/ml LPS was 
assessed against control and ouabain treated cells.
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Figure 5.7: Effect of LPS on Ouabain-Induced Death of Enriched Monocytes.
Purified human blood m onocytes were incubated with various concentrations of 
ouabain for twenty-four hours ±  lOng/ml LPS. Cell viability w as determined 
using the nuclear-stain propidium iodide (PI). Data represents the mean o f  two 
experiments.
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Figure 5.8: Effect of LPS on Ouabain-Induced Monocyte Apoptosis.
Purified human blood monocytes were stimulated with 1E-7M ouabain ± 
lOng/ml LPS for twenty-four hours. Cell viability was assessed using the 
combination o f Annexin V and propidium iodide staining. Apoptotic cells bind 
just Annexin V (FL-1 +ve, lower right). Necrotic cells bind both PI and 
Annexin V (FL-1 + FL-2 +ve, upper right).
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5.3: SUMMARY
When measured using propidium iodide (PI) staining assessed by flow cytometry, 
ouabain concentrations above 0.1 pM were seen to cause a low percentage of death in 
resting PBMCs. There was no mean difference between rheumatoid and healthy 
samples but it was noticed that the degree of death would often correlate with the 
number of monocytes observed in the PBMC preparation using anti-CD 14 staining. 
Complementary data recorded using FACS scatter analysis of whole PBMC 
populations and PI measurements in purified monocyte preparations and the 
monocytic cell line THP-1 cells showed that ouabain concentrations above 0.1 pM 
induced cell death after eight hours of stimulation. Between three and six hours of 
stimulation monocyte enlargement could be observed but after this the monocyte 
population disappeared from the FACS plots.
Based upon the data displayed in chapter four it appears that before death is observed 
there is a large release of IL-ip. Due to evidence that ICE (Caspase 1) may well play 
a role in apoptosis, experiments were carried out to try and define whether ouabain 
may be inducing an apoptotic response in monocytes and that the secretion of IL-ip 
may be related to over-activation of ICE during apoptosis. Although the results 
displayed here are by no means conclusive, based upon AnnexinV staining, they do 
suggest that in purified blood monocytes ouabain induces apoptosis to occur between 
eight and twenty four hours after stimulation. However, THP-1 cells did not display 
any signs of apoptosis and were seen to die via necrosis upon stimulation with 
ouabain.
Ouabain was seen to synergise dramatically with LPS to induce IL-ip release so the 
effects of LPS on ouabain induced death of monocytes was also measured. LPS 
promoted ouabain-induced death after eight hours stimulation with 0.1 pM ouabain 
and lOng/ml LPS. However, death did not occur as early as the production of IL-ip 
so it is possible that cytokine production or release could be related to a specific 
death response. It seems unlikely that the cells are simply dying and releasing their 
contents as the monocyte preparations appear quite healthy according to analysis by 
flow cytometry for several hours after cytokine production is elevated. The synergy 
between LPS and ouabain in the induction of IL-ip does not transfer to an apoptotic
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effect as if anything LPS appeared to promote necrosis after twenty-four hours of 
stimulation with 0.1 pM ouabain.
From these data it is possible that the synergy between ouabain and LPS in inducing 
monocyte IL-lp production may well involve an apoptotic event. From the studies 
with PBMCs in chapter 4 it can be seen that LPS alone induces the secretion of IL-ip 
and intracellular accumulation of high levels of IL-lp but no measurements were 
made in relation to intracellular levels of pro-IL-ip. From the evidence presented in 
this chapter it is possible that ouabain induced apoptosis of peripheral blood 
monocytes could result from activation of ICE and that the increased production of 
IL-lp is as a consequence of increased processing of intracellular pro-IL-lp. 
Experiments using specific ICE inhibitors such as Zvad would help to define the role 
of ICE in ouabain induced secretion of IL-ip and induction of apoptosis.
In this model it is possible that the outcome of stimulation with ouabain depends 
upon the substrate availability for ICE. It has been shown that intracellular proIL-ip 
protects cells against apoptosis via competing with apoptotic substrates for cleavage 
by ICE (524). In the model described here it is possible that if ouabain induces the 
activation of ICE the enzyme may favourably process LPS induced proIL-lp until 
levels start to decline. After which ICE starts to cleave components of the apoptotic 
cascade. However, ouabain did not induce apoptosis of THP-1 cells but has similar 
effects on THP-1 production of IL-lp as those seen with LPS stimulated PBMCs 
(data not shown). Consequently the question arises as to whether ouabain may act at 
the level of cytokine secretion, that apoptosis occurs via feedback stimulation of 
monocytes and that THP-1 cells may be insensitive to such an apoptotic mechanism.
At high concentrations of ouabain it is possible that cell necrosis occurs simply due 
to the high osmotic stress that the cells are under. The time-course of death events 
demonstrated here, however, supports the data that cytokine secretion occurs first. 
The fact that ouabain selectively inhibits IL-lra release whilst markedly inducing IL- 
1 p release further supports the evidence that ouabain selectively modulates cytokine 
release and that death also occurs via specific processes rather than simple necrosis.
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CHAPTER 6





The goal of this chapter was to study the differential regulation of monocyte IL-lp 
and IL-lra production and to establish a model for the determination of T cell 
induced monocyte cytokine release. Such a model could well have fulfilled the data 
requirements of an entire thesis and as a result what is presented here only really 
scratches the surface of a fascinating area of monocyte regulation. Due to time 
constraints some of the data is unfortunately not as strong as it could be and 
represents what were really pilot studies in the development of the co-culture model. 
The need to develop this model was hastened by the award of a Basic Science 
Initiative grant from Pharmacia and Upjohn, the proposal for which was to assess the 
ability of Sulphasalazine (SPZ) to modulate T cell activation and T cell driven 
monocyte cytokine production.
By developing a greater understanding of signals that regulate the balance between 
IL-ip and IL-lra production from human monocytes it was hoped to develop a 
model suitable for the study of immuno-modulatory compounds. In this case a model 
suitable for the study of anti-rheumatic compounds such as SPZ would be equally as 
useful for the study of compounds such as ouabain. By identifying signals that 
favour the production of IL-lp or IL-lra one could establish a model in which the 
balance of these two cytokines can be studied and compared. It would be possible to 
compare the balance between IL-ip and IL-lra production from rheumatoid and 
normal monocytes in response to control stimuli. Also, using a model monocyte, it 
would be possible to observe the ability of T cells from rheumatoid patients and 
controls to induce monocyte responses. After developing such a model it was hoped 
to be able to study the effects of ouabain against control IL-lp and IL-lra stimuli. It 
would be interesting to see whether ouabain could modulate monocyte responses to 
stimuli which favour the production of IL-lra as well as synergising with LPS 
induced IL-ip production.
The co-culture system developed here was based upon that used in the laboratories of 
J-M Dayer (352), who showed that activated T cells could stimulate THP-1 cytokine 
production. Using the THP-1 cell line Dayers’ group has demonstrated T cell 
modulation of MMP expression (379), IL-lp production and IL-lra production
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(381). THP-1 cells have also been used to demonstrate differential induction of IL- 
ip and IL-lra by Thl and Th2 T cell clones (397).
One of the aims of this part of the thesis was to compare the ability of normal and 
rheumatoid T cells to induce cytokines from THP-1 cells and also to look at the 
response of the autologous monocytes to Jurkat T cells. This meant first having to 
define T cell activation, in response to various stimuli, in terms of proliferation and 
cell surface marker expression.
Before THP-1 cells could be used as a model for the study of T cell driven cytokine 
responses they first had to be characterised in terms of basal cytokine production. As 
the main focus of this chapter is the balance between IL-lp and IL-lra production 
positive control responses for each of these cytokines had to be established. From 
previous studies presented in this thesis, and extensive reports in the literature, LPS 
was chosen as the primary candidate for induction of IL-lp. Early studies using 
THP-1 cells had reported that they are unresponsive to LPS stimulation. More recent 
reports published by Dayer, however, have demonstrated that after differentiation 
with l,25-(OH)2-vitamin D3 THP-1 cells readily produce IL-lp in response to LPS 
activation. Dayer has also measured IL-lra responses from THP-1 cells in response 
to LPS but more classical stimuli that have been reported include immune-complexes 
and aggregated IgG. For the purpose of this study plastic bound IgG was investigated 
as a suitable positive control for monocyte IL-lra induction.
In all experiments using THP-1 cells for cytokine production the cells were cultured 
at an initial density of 5xl05/ml. It was found that, at greater densities, THP-1 cells 
rapidly over-crowded the well, especially in long time-course experiments. All the 
following experiments were carried out in 96 well round bottom polystyrene plates 
(Falcon) with a maximum volume of 250pl per well. As THP-1 cells in resting or 
differentiated form are non-adherent there was no concern for adherence induced 
activation. Supernatants were harvested at the end of culture by gentle aspiration 
after pelleting of the cells at 350g in a Beckman microplate GH3.7 rotor.
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6.2: RESULTS
6.2.1: IL-1|3 but not IL-lra Production by THP-1 cells is dependent 
on Vitamin D3 differentiation
THP-1 cells were cultured at a density of 5xlOs/ml in RPMI-1640 with l,25(OH)2- 
vitamin D3 (D3). D3 is reported to induce responsiveness to LPS and as CD 14 is a 
monocyte marker and receptor for LPS this study monitored CD 14 induction as a 
marker of THP-1 differentiation. As can be seen from figure 6.1, D3 induced a 
concentration dependent increase in CD 14 expression in THP-1 cells. CD 14 
expression was observed to be increased within twenty-four hours of activation and 
to have reached a plateau between forty-eight and seventy two hours. For the 
following experiments D3 differentiation was carried out using a concentration of 
lOnM D3 cultured with the THP-1 cells for forty eight hours.
When resting THP-1 cells were compared to differentiated THP-1 cells (D3 THP-1) 
for their responsiveness to LPS and IgG it was found that only LPS responses were 
D3 dependent. Figure 6.2 displays the IL-lp response to LPS and the IL-lra 
response to IgG. It can be seen that normal THP-1 cells produce no IL-lp under 
resting conditions and only 163pg/ml after stimulation with 5fig/ml LPS. In contrast, 
D3 THP-1 produce a large quantity of IL-lp, with 1937pg/ml being released on 
twenty-four hour stimulation with 5pg/ml LPS. In response to plastic bound IgG, 
however, both normal and D3 THP-1 produce IL-lra in equivalent amounts. FACS 
surface staining data complements these results as it is seen that CD 14 is up 
regulated with D3 differentiation but Fc receptor expression remains constant (figure 
6.1B).
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Figure 6.1A: l,25(OH)2-Vitamin D3 Induced CD14 Expression on THP-1 Cells
Cells were cultured for forty-eight hours in different concentrations o f D3 and 
CD 14 induction determined by FACS analysis.
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Figure 6.1B: FcR Expression in Normal THP-1 cells.
THP-1 cells from resting cultures were analysed for expression of CD 16 
(FcyRIII), CD32 (FcyRII) and CD64 (FcyRI). D3 differentiated THP-1 cells were 
found to have identical surface FcyR phenotypes.
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Figure 6.2: Effect of D3-Differentiation on THP-1 Cytokine Production.
Panel A: D3-THP-1 cells were differentiated for 48 hours before being stimulated 
with 5g/ml LPS for 24 hours. Responses were compared to undifferentiated THP- 
1 cells (n=3±sem).
Panel B: D3-THP-1 cells were differentiated for 48 hours before being cultured 
on plastic bound IgG for 48 hours. Responses were compared to undifferentiated 
THP-1 cells (n=2).
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6.2.2: Time-course of IL-1J3 and IL-lra production By D3 THP-1 
cells
The release of IL-lra from the LPS and ouabain stimulated PBMCs studied in 
chapter four was much slower than that of IL-ip. In order to be able to study the 
balance between IL-lp and IL-lra production from THP-1 cells suitable time-points 
for their comparison had to be determined. In the following experiments D3 THP-1 
were cultured with varying concentrations of LPS and the IL-lp and IL-lra protein 
secretion measured over a seventy-two hour time-course. Figure 6.3 represents IL-lp 
release in the top panel and IL-lra release in the bottom panel. As can be seen in both 
graphs, stimulation with LPS gave a concentration dependent increase in IL-lp and 
IL-lra production. However, IL-lra production was very low over the first twenty- 
four hours of culture and increased rapidly over the last forty-eight hours of the time- 
course. In contrast, IL-lp production did not increase significantly between twenty- 
four and seventy-two hours.
The data represented in figure 6.4 also reflects the time-course of IL-ip and IL-lra 
production from D3 THP-1 cells. This time, however, it applies to IgG driven 
cytokine production over a forty-eight hour time-course. The first obvious feature of 
these data is that plastic-bound IgG is a poor inducer of IL-ip, especially in 
comparison to its effects on IL-lra levels. Although IgG driven IL-lp production 
appears to be more time dependent than LPS driven IL-lp production, the differences 
between the levels measured at twenty-four and forty-eight hours relate to relatively 
small amounts of protein. In comparison, the IL-lra production increases markedly 
between twenty-four and forty-eight hours in response to IgG, with levels rising from 
5000pg/ml to 20000pg/ml in the 200pg/ml IgG group.
As a consequence of these studies, in D3 THP-1 cells, an incubation of at least forty- 
eight hours appears to be required for the maturation of an IL-lra-inducing signal 
into significant protein secretion. In contrast, IL-ip levels appear to reach a peak 
more rapidly and then climb slowly over the duration of the time-courses studied. 
Consequently to compare the effect of a stimulus on the balance between IL-lra and 
IL-lp production from D3 THP-1 cells an incubation of at least forty-eight hours was 
used.
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Figure 6.3: Effect of LPS on Cytokine Production by D3-Differentiated THP- 
1 cells.
Panel A: Shows IL-1 p release from 48 hour differentiated D3 THP-1 cells. Cells 
were cultured in the presence o f LPS (0.1-5ug/ml) and cytokine secretion was 
determined over a three-day time-course.
Panel B: Shows the parallel IL-lra content o f the same supernatants 
(n=3±STDEV).
0. lug/ml LPS lug/ml LPS 5ug/ml LPS
Chapter 6: T cell Monocyte co-culture - 152-
35000
□  24hr □48hr
30000 -
□  24hr ^48hr
25000






C trl lOOug/mllgG 200ug/ml IgG
Figure 6.4: IgG Driven IL-lp and IL-lra Release from D3 THP-1 Cells.
Panel A: Shows IL-ip release from 48 hour differentiated D3 THP-1 cells 
cultured on plastic-bound IgG. Supernatants were assessed for cytokine content 
after 24 and 48 hours o f culture (n=3 ±STDEV).
Panel B: Shows parallel IL-lra content o f same supernatants.
lOOug/ml IgG 200ug/ml IgG





6.2.3: Comparison of IL-lra and IL-ip Production from PBMCs 
and Purified Monocytes
As well as using THP-1 cells as model monocytes for the interpretation of T cell 
derived signals and their role in regulating monocyte cytokine profiles a major goal 
of this study was to define monocytic responses to different T cell subsets. In order to 
be able to study the responses of mononuclear cells from different patient groups, 
protocols had to be defined to determine basic responses to positive control stimuli. 
Comparisons were made between simple PBMC preparations and purified resting 
monocyte preparations that had been harvested using MACS monocyte negative 
selection beads. As both IL-lp and IL-lra are monocyte derived cytokines it was 
expected that purified monocytic cells would provide a cleaner experimental system 
to study. Consequently, the next experiments sought to look at basic LPS and IgG 
responses. PBMCs and monocytes were prepared as described in method 2.2.4/5, 
cultured at lx l06/ml in RPMI-1640 and incubated in 200pl volumes in round bottom 
96 well plates. Purified monocytes were routinely found to be greater than 90% 
CD 14 positive whereas PBMCs varied between 10% and 25% CD 14 positive.
Figure 6.5 shows a comparison between IL-ip (top panel) and IL-lra (bottom panel) 
secretion from PBMCs and monocytes in response to a forty-eight hour incubation 
with LPS. In both the monocyte and PBMC preparations, in spite of adherence to the 
plastic of the culture plates, it can be seen that basal IL-ip release was low with 
levels of 20pg/ml and 57pg/ml respectively. IL-lp secretion was much more 
responsive to LPS than that seen in THP-1 cells with significant induction being 
observed with just lng/ml. Interestingly, the IL-ip response of PBMCs to LPS was 
not considerably different to that of purified monocytes despite the fact that the 
CD 14 positive population was as much as nine fold smaller. In both cell populations 
maximal IL-ip induction was seen with lOng/ml LPS with levels of 1751pg/ml in 
PBMCs and 2630pg/ml in monocytes. In contrast to IL-lp secretion, in these 
experiments LPS inhibited IL-lra production. In control groups both cell populations 
produced high levels of IL-lra, but compared to IL-ip secretion there was a large 
difference between the amounts of IL-lra the two populations produced, with 
PBMCs secreting 6018pg/ml and monocytes secreting 13885pg/ml.
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Figure 6.5: Comparison of Cytokine Production from Purified Monocytes 
and PBMCs in Responses to LPS.
Panel A: IL-lp production induced by LPS over a 48hr culture in 96 well plates 
(n=3±SEM).
Panel B: Parallel IL-lra production induced by LPS over a 48hr culture in 96 well 
plates (n=3±SEM).
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As can be seen in figure 6.6, similar to the results observed in D3 THP-1 cells, IgG 
had a much more dramatic effect on IL-lra production than IL-1 p production in both 
PBMCs and monocytes. In the purified monocyte population there was a 
concentration dependent increase in IL-lp production but the levels of protein 
secreted were very low with a maximum of 95pg/ml being achieved with lOOpg/ml 
IgG stimulation. The PBMC population responded in a similar manner, but with 
slightly greater levels of IL-1 p secretion. The IL-lra responses to IgG stimulation 
were much more consistent than the IL-lp responses. In both the PBMCs and the 
monocytes IgG stimulation resulted in a concentration dependent increase in IL-lra 
release. In PBMCs control levels of IL-lra were measured at 6018pg/ml, rising to 
15046pg/ml with lOOpg/ml IgG stimulation. In monocytes, however, control levels 
of IL-lra were measured at 13885pg/ml, rising to 24505pg/ml with lOOpg/ml IgG 
stimulation.
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Figure 6.6: Comparison of Cytokine Production from Purified Monocytes 
and PBMCs in Responses to IgG.
Panel A: IL-lp production induced by plastic-bound IgG over a 48hr culture in 
96 well plates (n=3±SEM).
Panel B: Parallel IL-lra production induced by plastic-bound IgG over a 48hr 
culture in 96 well plates (n=3±SEM).
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6.2.4: T cell Activation
Having tested and compared the suitability of THP-1 cells, monocytes and PBMCs 
for their IL-lp and IL-lra responses to control stimuli the next step in the 
construction of a co-culture model was the definition of T cell activation. T cell 
activation is characterised by cell enlargement, proliferation and clonal expansion 
and the production of cytokines that mediate specific effector functions. For this to 
occur requires the presentation of an antigen and co-stimulation provided through the 
engagement of CD28 (432,450,451). CD28 is expressed on the surface of 
naive/resting T cells and interacts with molecules present on the APCs, that belong to 
the B7 receptor family (452,453). Extensive investigations have identified CD28 as 
an important T cell receptor in the process of activation. Studies using monoclonal 
antibodies for CD28 have clearly shown the co-stimulatory potential of this receptor. 
In this study, however, the natural ligand CD80 expressed in CHO cells was used. 
CHO cells were routinely assessed for CD80 expression using FACS analysis to 
assure co-stimulation (see figure 6.7). The ability of CD80 to synergise with TCR 
signals and induce T cell activation was examined. Signals of the TCR pathway were 
induced by aggregated CD3 antibodies, superantigen (SEA) and pharmacological 
agents like the phorbol ester PDBu and ionomycin. Phorbol esters activate Ras and 
PKC (454,455), which are downstream targets of TCR signalling and represent the 
calcium independent pathways of the TCR. Ras is a GTP binding protein and 
phorbol esters are thought to promote Ras activation by inhibiting GTPase activating 
proteins that restrict Ras activity (456,457). Ionomycin on the other hand increases 
calcium levels in the cell (454). T cell activation was quantified via the use of in vitro 
proliferation assays and analysis of surface expressed activation markers. 
Experiments were performed with freshly purified human resting T cells and the J16 
human T cell line.
As can be seen in figure 6.8, unstimulated resting T cells proliferate at a very low 
rate. CD80 stimulation alone has a mild proliferative effect, but increasing the basal 
response to CD28 amplifies T cell responses triggered by pharmacological agents 
such as the phorbol ester PDBu and the calcium ionophore ionomycin (458). As 
figure 6.8 shows PDBu alone at low concentrations was unable to induce 
proliferation of T cells. However, when combined with CD80 a strong proliferative 
response resulted, which was not observed with control CHO cells. At higher
Chapter 6: T cell Monocyte co-culture -158-
concentrations, of 5ng/ml, PDBu alone induced mild proliferation but synergised 
strongly with CD80 co-stimulation.
As well as synergising with CD80, PDBu could also synergise with ionomycin, as 
shown in figure 6.8B. Although slight synergy was observed between 0.lng/ml 
PDBu and CD80 in the previous experiment it appears that the combination of 
ionomycin with PDBu is even more potent at stimulating T cell proliferation. These 
results suggest that compared to CD80, the calcium induced pathways that 
ionomycin initiates can co-stimulate PDBu at lower concentrations. At higher 
concentrations of PDBu, however, the combination with ionomycin soon plateau’s in 
its ability to synergise proliferative responses. With 0.5ng/ml PDBu and lpM 
ionomycin the addition of CD80 co-stimulates the T cell response further. However, 
5ng/ml PDBu with lpM ionomycin has a comparable proliferative effect to 0.5ng/ml 
PDBu with lpM ionomycin but now the addition of CD80 co-stimulation actually 
depresses T cell proliferation. From these data it appears that increased stimulation 
with phorbol ester and ionomycin may induce a phenotypic change in the T cell 
population in which CD 80 has a negative regulatory function. Such negative 
regulation of T cell proliferation by CD80 may be a result of ligation to CTLA-4. 
CTLA-4 is a counter-regulatory relative of CD28 that delivers an opposing signal to 
the stimulated T cell (459).
As one of the aims of this study was to compare the effects of T cells from different 
patient groups for their ability to activate monocytes, these initial experiments 
defined activation responses of T cells from rheumatoid and normal samples. The 
proliferative responses of both rheumatoid and normal T cells were comparable when 
stimulated with phorbol ester ± ionomycin, with or without co-stimulation through 
CD28. When CD3 responses were studied, however, a markedly lower stimulation 
was observed in rheumatoid T cells. Figure 6.9A displays the considerably reduced 
response of sero-positive RA patients to CD3/CD80 (P<0.05-0.005) stimulation but 
comparable response to PMA/CD80 stimulation. This lack of CD3 responsiveness in 
these experiments was determined not to be due to decreased CD3 expression as 
surface FACS analysis confirmed equivalent expression between normal and SPRA 
patients (see figure 6.10).
The J16 cell line was also assessed for proliferative responses to phorbol ester, 
ionomycin, CD3 and CD80. Being a cell line, however, under resting conditions J16
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cells proliferate at a considerable rate. Pharmacological stimulation of J16 cells with 
PMA and ionomycin actually leads to a decrease in proliferation. In contrast to PMA, 
however, direct stimulation of J16 through antibody aggregation of CD3 does not 
appear to modulate proliferation, even in combination with CD80 (see figure 6.9B).
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Figure 6.8: Activation Induced Proliferation of Resting T cells.
Panel A: Normal purified T cells were cultured for 72 hours with various 
concentrations o f PDBu and co-stimulated with fixed CHO or CHO-CD80 cells. 
3H Thymidine incorporation was measured over the last 18 hours o f culture (n=6- 
8±SEM).
Panel B: lpM  ionomycin was combined with the stimuli used in panel A (n=6- 
8±SEM).
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Figure 6.9 A: Reduced CD3/B7 Induced Proliferation In SPRA T cells n=5-9
T cells purified from RA patients and normal controls were stimulated for 72 
hours with aggregated CD3 ± CD80. 3H thymidine incorporation was measured 
over the last 18 hours o f culture. PMA/CD80 stimulation was used as a positive 
control (*=P<0.05, **+P<0.005).
Panel B: Proliferative responses o f Jurkat cell line to various stimuli. J16 cells 
were stimulated as described for normal T cells.
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Figure 6.10: Surface antigen expression on normal and rheumatoid resting T 
cells.
Shows the percentage o f the total population that stained positive for each 
particular surface antigen. This was determined by defining an area that would be 
considered positive, and measuring the number o f cells that moved into this area 
upon staining (Norm n=9, RA n=7: *=P<0.05).
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6.2.5: T Cell Surface Activation Markers
Interactions between T cell surface molecules and monocytes are critical for signal 
transduction in the immune response. As T cell membrane derived signals were being 
assessed for their ability to induce monocyte activation, T cell activation was also 
monitored in terms of surface activation markers.
Upon T cell activation several surface proteins are modulated including CD25, 
CD28, CD69 and CD95. The earliest activation marker to be upregulated is CD69 
and as it has been implicated in the interaction between cell membranes in T cell- 
monocyte co-culture systems it was the molecule of most interest here. In this study 
CD69 expression was measured in order to quantify the degree of T cell, T cell blast 
and J16 activation induced by various stimuli.
Typical FACS plots for J16 and T cell activation marker expression are shown in 
figure 6.11. Although not all traces are shown in this figure it was observed that 
PDBu induced a concentration dependent increase in CD69 expression and that 
manipulating intracellular calcium levels with the ionophore ionomycin synergised to 
further enhance CD69 expression. Similarly, co-stimulation of the T cells with CHO- 
CD80 and PDBu also enhanced CD69 expression. In fact, the degree of surface 
CD69 expression induced correlated with the ability of the stimulus to induce T cell 
proliferation.
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Figure 6.11: T cell Activation Surface Marker Expression.
Panel A: J16 cells were stimulated for 24 hours and assessed for surface marker 
expression using FACS analysis. Results are typical traces representative o f three 
experiments.
Panel B: Purified T cells were stimulated for 24 hours and assessed for surface 
marker expression using FACS analysis. Results are typical traces representative 
of three experiments.
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6.2.6: J16 Induced production of IL-ip  and IL-lra From Monocytes
Initial experiments to define basic monocyte responses to T cell stimulation used J16 
cells as model T cells. Obviously, being a cell line, J16 cells vary greatly to resting T 
cells in terms of surface marker expression and proliferation. Upon activation with 
PDBu and ionomycin, however, J16 cells demonstrate a similar surface activation 
marker profile to normal T cells. Consequently, fixed activated and resting J16 cells 
were tested for their ability to deliver a membrane bound signal to monocytic cells. 
In the following experiments J16 cells were activated for eighteen hours with 5ng/ml 
PDBu and lpM ionomycin, fixed with 0.025% glutaraldehyde and resuspended at a 
density of 5xl06/ml in RPMI-1640. Fixed J16 cells were cultured with monocytes at 
a ratio of 5:1, similar to that seen in peripheral blood, and incubated for forty-eight 
hours.
Figure 6.12 compares the responses of D3 THP-1 cells, purified monocytes and 
PBMCs, with IL-lp production being displayed in the top panel and IL-lra 
production in the bottom panel. All three monocyte preparations responded to J16 
co-culture. IL-lp secretion was induced in PBMCs and purified monocytes to a 
similar extent by both resting and activated J16 cells. In D3 THP-1 cells, however, 
resting J16 cells had no effect on IL-ip secretion but activated J16 cells did, with 
protein levels increasing from a control concentration of llpg/ml to 105pg/ml. In all 
experiments, however, although J16 co-culture induced a significant increase in IL- 
lp release the actual levels were quite low compared to LPS stimulation. The IL-lra 
response from all three cell preparations was quite different to the IL-lp response. 
D3 THP-1 cells produced IL-lra in response to resting J16 cells but significantly 
more in response to activated J16 cells. The response from purified monocytes and 
PBMCs to J16 cells was not as dramatic as that of D3 THP-1 cells, perhaps due to 
adherence activation stimulating high control levels of IL-lra. Monocytes 
particularly had a very high basal production of IL-lra that was inhibited slightly by 
resting J16 cells and augmented slightly by activated J16 cells. In contrast, PBMCs 
gave a more consistent response with resting J16 cells having no effect on IL-lra 
production but moderate induction occurring with activated J16 cells.
Control resting and activated J16 cultures themselves gave no IL-ip or IL-lra 
production.
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Figure 6.12: Comparison of Cytokine Production from Purified Monocytes , 
THP-1 and PBMCs in Responses to Stimulation with fixed J16 cells.
Panel A: 48 hour IL-lp release. Blood PBMCs, purified monocytes and the 
monocytic cell line D3 THP-1 were cultured with fixed resting J16s or fixed 
activated J16s (*J16). Cell supernatants were harvested after 48 hours (Monocyte 
n=3, THP-1 n=4, PBMCs n=6 ±SEM).
Panel B: Parallel IL-lra release from same supernatants.
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6.2.7: T cell Driven Monocyte IL-lp  and IL-lra Production
To test whether normal T cells would have the same effect as J16 cells on monocyte 
IL-ip and IL-lra production an experiment was carried out in which half of a blood 
sample was purified to monocytes and the other half to T cells. The T cells were then 
activated with various stimuli before being fixed and then added back to the 
autologous monocytes. The cell co-culture was incubated for forty-eight hours and 
then the cytokine release into the supernatants determined. Figure 6.13 displays the 
combined data of two experiments with IL-ip and IL-lra release in the top and 
bottom panels respectively. Due to the fact that these data represents just two 
combined experiments it is difficult to read too much into it. However, what can be 
seen is that normal T cells have the ability to modulate the IL-ip and IL-lra 
production of their autologous monocytes. In these figures, the control levels of 
cytokines produced are consistent with previous purified monocyte experiments with 
low IL-ip production and relatively high IL-lra production. Co-culture of the 
monocytes with resting T cells has no effect on IL-ip production but does induce a 
large increase in IL-lra release. T cells that have been activated with a proliferative 
stimuli, such as PMA/CD80 or CD3/CD80 gain the ability to induce IL-ip 
production but do not affect IL-lra production particularly more than resting T cells. 
These data are of course preliminary so should not be over-interpreted. However 
interesting features persist, such as the fact that T cells that have been incubated with 
PMA, ionomycin and CD80, a stimulus linked with CTLA4 expression and down- 
regulation of proliferation, result in much less IL-lp induction than just PMA and 
ionomycin activated T cells.
Chapter 6: T cell Monocyte co-culture -168-
200 
180 ~i 
^ 1 6 0  -
^  140 -00
3 4 2 0  - 
^TOO
1  80 - 
3  60 - 





|  35000 00
3 3 0 0 0 0  
^ 2 5 0 0 0  - 
V 20000 - 












la, i l l
C« O
H  X •o U
S ^
3
0  00 
Q
1  3






p  p  
< 
s








0 °  oo
® Q
^  O

















tr1 O °S  d  ooS ffi Q
S  ^  UOh di
S I  ^
■§> ?  s
fljaJL
S g 









y  ^  B
to R Q3 y  u
H I  sI >
Figure 6.13: T cell Driven IL-ip and IL-lra Production from Autologous 
Monocytes.
Panel A: 48 hour IL-ip release. Blood samples were split, half purified to 
monocytes and half to T cells. The T cells were stimulated with various 
combinations of PMA, ionomycin, CD3 and CD80 for 18 hours then fixed and re­
added to the monocytes. Cell supernatants were harvested after 48 hours (n=2). 
Panel B: Parallel IL-lra release from same supernatants.
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6.2.8: Effect of LPS and IgG on J16 Driven IL -lp and IL-lra
Production from D3 THP-1 cells
In resting D3 THP-1 cells the basal release of both IL-lra and IL-ip is very low. 
Both of these cytokines have been shown to be highly inducible by IgG and LPS 
respectively and also modulated by T cell co-culture. Although J16 cells, particularly 
activated J16 cells, provide a strong inducing signal for the production of IL-lra their 
effect on IL-lp release stimulates relatively small amounts of protein. The effect of 
J16 cells on basal IL-ip release from D3 THP-1 cells is significant but, compared to 
an LPS response, relatively minor. As a result, the aim of this section is to compare 
the effect of J16 co-culture on the responses of D3 THP-1 cells that have already 
been primed with IL -ip- or IL-lra-inducing stimuli. In these experiments resting or 
eighteen-hour PDBu/ionomycin activated J16 cells were fixed and co-cultured with 
D3 THP-1 cells in the presence of various concentrations of LPS or in wells coated 
with IgG.
Figure 6.14 shows IL-lp and IL-lra production, in the top and bottom panels 
respectively, from D3 THP-1 cells that have been co-cultured as described above. 
The control response to LPS shows a concentration dependent increase in IL-lp and 
IL-lra release. In the top panel it can be seen that activated J16 cells alone produce a 
small but significant (P<0.05) increase in IL-lp production from D3 THP-1 cells but 
that the magnitude of this is almost lost in the synergy that occurs when LPS is added 
to the culture. The maximum response in control D3 THP-1 cells to 5 fig/ml LPS is 
604pg/ml. Activated J16 cells alone induce 105pg/ml IL-ip but the combination of 
activated J16 and 5pg/ml LPS results in an induction of 4122pg/ml IL-ip. The 
synergy between activated J16 and LPS is dependent upon the concentration of LPS 
but even at 0.1pg/ml LPS an induction of 2276pg/ml is seen compared with a control 
secretion of 189pg/ml. This synergistic stimulation of IL-lp production was not 
mirrored by IL-lra release in this study. Although IL-lra is potently induced by both 
LPS and J16 cells (especially activated J16 cells) when cultured alone, addition of 
LPS to J16 stimulated monocytes has no effect on IL-lra levels.
Interestingly, IgG addition to the D3 THP-1/J16 co-culture also affected the IL-lp 
and IL-lra levels produced, as is shown in figure 6.15. The effects of IgG, however, 
were quite different with mild synergy being seen with J16 induced IL-ip and an
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additive effect being seen with J16 induced IL-lra. Where LPS had no effect on 
activated J16 induced IL-lra, with levels remaining at about 6500pg/ml, 200pg/ml 
IgG raised the response to 14245pg/ml. It must be stressed, however, that although 
the synergy between IgG and J16 driven IL-lp is clear, again it concerns quite low 
levels of protein secretion especially compared to the combination of LPS and 
activated J16.
6.2.9: Effect of Fixation on J16 Induced Production of IL-ip and IL- 
lra from D3 THP-1 cells and normal PBMCs
In all the experiments detailed so far, using co-culture to stimulate monocyte 
production of IL-lp and IL-lra, the T cells have been fixed in order that only 
membrane interactions could occur. The following experiment sought to compare the 
effect of fixation on the ability of resting and activated J16 cells to induce D3 THP-1 
production of IL-lp and IL-lra and synergise with LPS stimulation. Figure 6.16 
shows IL-ip release and IL-lra release, after a forty-eight hour incubation, in the top 
and bottom panels respectively. Unfortunately the data presented in this figure 
confuses the message that was derived from figure 6.14. In contrast to the previous 
experiment, which only saw synergy between LPS and fixed J16 cells in inducing IL- 
lp production, this experiment also shows synergy in the stimulation of IL-lra 
release. This response is unexplainable and could be due to many factors including 
the state of differentiation of the THP-1 cells, the culture conditions of the J16 cells 
or the condition of the LPS used. Despite all attempts to keep conditions absolutely 
constant something had obviously changed in this system and affected the results 
accordingly. The important thing here, however, is that despite this inconsistency the 
data presented in figure 6.16 still displays an interesting difference between the 
responses induced by fixed compared to unfixed J16 cells. It appears that unfixed J16 
cells, especially activated J16 cells deliver a more potent IL-ip inducing signal and 
synergise more greatly with LPS when compared to fixed J16 cells. In contrast, 
fixation of the J16 cells leads to a far greater ability to induce IL-lra production 
(P<0.05). It appears from these data that membrane-derived interactions and soluble 
mediators from T cells may differentially regulate production of IL-lp and IL-lra 
from differentiated THP-1 cells. Interestingly, unfixed resting J16 cells significantly
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inhibited LPS induced IL-lra release (P<0.05) even though they had little effect upon 
LPS induced IL-lp.
Figure 6.17 shows the effect of fixation on J16 cell stimulation of PBMCs. 
Unfortunately as this figure only represents two experiments significant conclusions 
can’t be made. The data, however, shows complementary trends to the THP-1 cell 
responses and is therefore worthy of discussion. Panel A shows the IL-lp release 
from PBMCs cultured with fixed and unfixed resting and activated J16 cells. 
Similarly to the D3 THP-1 cell responses a marked synergy is seen between the 
unfixed resting of activated J16 cells and LPS in stimulating IL-ip release from 
PBMCs. Fixation of the J16 cells practically negates this synergy, with IL-ip 
production being comparable to LPS alone. Due to high basal release of IL-lra from 
the PBMCs it is difficult to interpret the effect of fixation on J16 stimulated PBMC 
IL-1 ra production.
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Figure 6.14: Effect of LPS on J16 Stimulated Cytokine Release from D3 
THP-1 Cells.
Panel A: 48 hour IL-lp release. D3 THP-1 were cultured with fixed resting J16s 
or fixed activated J16s (*J16) with different concentrations o f LPS. Cell 
supernatants were harvested after 48 hours (n=4-8±SEM: *=P<0.05).
Panel B: Parallel IL-lra release from same supernatants.
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Figure 6.15: Effect of IgG on J16 Stimulated Cytokine Release from D3 THP- 
1 Cells.
Panel A: 48 hour IL-lp release. D3 THP-1 were cultured with fixed resting J16s 
or fixed activated J16s (*J16) on plates coated with different concentrations of 
IgG. Cell supernatants were harvested after 48 hours (n=3-4 ±SEM: *=P<0.05). 
Panel B: Parallel IL-lra release from same supernatants.
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Figure 6.16: Effect of Fixation on J16 Stimulated Cytokine Release from D3 
THP-1 Cells.
Panel A: 48 hour IL-ip release. D3 THP-1 were cultured with fixed/unfixed 
resting J16s (F/UFRJ16) or fixed/unfixed activated J16s (F/UF*J16) with 
different concentrations o f LPS. Cell supernatants were harvested after 48 hours 
(n=4-7 ±SEM: *=P<0.05).
Panel B: Parallel IL-lra release from same supernatants.
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Figure 6.17: Effect of Fixation on J16 Stimulated Cytokine Release from 
PBMCs.
Panel A: 48 hour IL-ip release. Normal PBMCs were cultured with fixed/unfixed 
resting J16s (F./U.F.RJ16) or fixed/unfixed activated J16s (F./U.F.*J16) with 
different concentrations o f LPS. Cell supernatants were harvested after 48 hours 
(n=2).
Panel B: Parallel IL-lra release from same supernatants.
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6.2.10: Effect of T cell Blasts on Production of IL-1|3 and IL-lra
from D3 THP-1 cells
In light of the apparent synergism between LPS and T cell derived signals seen in the 
J16/D3 THP-1 co-culture system attempts were made to complement these data 
using normal T cells. A problem occurred, however, in that the T cell purification 
system used occasionally left a small monocyte contamination. Consequently the 
large concentrations of LPS required for IL-lp responses in D3 THP-1 cells induced 
a considerable level of IL-ip release from the contaminating monocytes. As a result, 
instead of studying the effects of resting T cells on cytokine production from D3 
THP-1 cells activated T cell blasts were used. Unfortunately, due to time constraints 
the data presented in following figures is based on just one experiment. Consequently 
no clear conclusions can be drawn from these experiments but interesting 
observations are worthy of discussion.
The first experiment used T cell blasts generated by PDBu/ionomycin stimulated 
PBMCs, PDBu/ionomycin stimulated T cells and SEA stimulated PBMCs, co- 
cultured with D3 THP-1 cells and compared surface FACS data to cytokine induction 
profiles on days three, five and seven. Co-cultures were incubated for forty-eight 
hours with various concentrations of LPS. From day three onwards all of the T cell 
blast populations used to stimulate the THP-1 cells were found to be CD 14 negative 
and when incubated with LPS did not produce either IL-ip or IL-lra themselves.
Over the three time-points of T cell activation studied it was found that there was 
quite a variation in the amount of IL-ip and IL-lra production induced in the D3 
THP-1 cells. Looking at the surface marker expression in the T blasts (bottom panels 
of each page, figures 6.18 to 6.20) CD25 is up-regulated in all groups on day three 
and steadily drops over the time-course of the experiment. Similarly, CD69 is 
elevated on day three in all groups and also declines on day five and day seven after 
activation. In contrast, CD28 and CD95 levels remain fairly constant for the duration 
of the time-course. It is difficult to say how the surface marker expression relates to 
the induction of monocyte cytokines in this study, especially as the data is based 
upon one experiment. When analysing the cytokine production, however, there are 
some trends that are interesting if not conclusive. On each of the three time-points all 
three T cell populations displayed an ability to induce both IL-ip and IL-lra
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production from D3 THP-1 cells. On day three, all three blast groups induced 
equivalent amounts of IL-lp and all displayed synergy with LPS in the induction of 
both IL-ip and IL-lra. The synergistic response to lpg/ml LPS and T cell blast co­
culture yielded an IL-lp production of 600 to 700pg/ml. In comparison, the IL-lra 
responses seemed much greater, with up to 7000pg/ml being produced in the PIP + 
LPS group. The IL-lra production measured in response to stimulation with day 
three blasts was higher than that using day five or seven. The degree of IL-lra 
production correlated to some extent with the surface expression of CD69 on the 
blasts. The control IL-lp response to LPS in this particular experiment was a little 
low, however, with only 216pg/ml being produced in response to 1 fig/ml LPS. Usual 
D3 THP-1 IL-ip responses to lpg/ml LPS range between 300 and 500pg/ml. In 
contrast, the IL-lra response to LPS was a little higher than usual with about 
lOOOpg/ml being produced compared to a more usual value of between 600 and 
800pg/ml. The balance between IL-1 p and IL-lra in the controls of this experiment 
highlight the difficulty in interpreting these data as in the day five experiment control 
responses are a little different. As can be seen in figure 6.19, the control response to 
LPS is a little higher in terms of IL-1 p production and a little lower in terms of IL- 
lra production. The differences are not great however but the trend in the blast co­
cultures is the same, with increased IL-ip and reduced IL-lra. The magnitude of the 
responses to T cells in figure 6.19, however, indicates that the variations in the 
control levels of cytokines produced are not sufficient to negate the blast induction 
data. The elevation in the control IL-lp response to LPS is not as large as the 
increased response to T cells, especially the PIP cells. The PI activated PBMC 
generated T cell blasts are particularly good at inducing IL-lp and IL-lra and 
interestingly also appear to be the most activated T cell population, with highest 
levels of CD69 expression. There is also quite a clear correlation between the CD69 
expression in the other T cell blasts and their ability to induce IL-lra production. The 
day seven blast co-culture data also displays a little variation in control LPS 
responses, with average IL-lp production but quite high IL-lra production. In this 
experiment, however, as can be seen in figure 6.20, there is a very large IL-ip 
response to SEA blasts, which is paralleled with a lesser IL-lra response. In general, 
the high control LPS induced IL-lra production was not affected by the addition of 
any of the T cell blasts and all blasts, except those generated with SEA, were poor
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inducers of IL-lp. The profile of IL-lra induction again correlated with CD69 
expression between the blast groups and in general the low induction of IL-lra 
reflected low levels of T cell activation in the day seven blasts.
The large induction of IL-1 p and parallel reduction in IL-lra production seen using T 
cells generated from SEA blasted PBMCs to stimulate D3 THP-1 cells prompted 
further investigation. Again, only one experiment is displayed here but the dramatic 
effects observed warrant mention. The goal of the experiment was to compare the 
data using fixed and unfixed J16 cells to stimulate D3 THP-1 cells with that using T 
cell blasts. The results with the J16 cells suggested the possibility that unfixed J16 
cells modulate monocyte responses in a different manner to fixed J16 cells. Upon 
activation, fixed J16 cells adopt the ability to induce both IL-ip and IL-lra 
production from D3 THP-1 cells. During the co-culture stimulation fixation was used 
to rule out the contribution of soluble mediators and limit responses to membrane 
interactions only. As can be seen from figure 6.16, membrane signals from J16 cells, 
in the absence of soluble mediators, favour the production of IL-lra. When activated 
unfixed J16 cells are co-cultured with D3 THP-1 cells in combination with LPS there 
is a large induction of IL-1 p production that is lost upon fixation. In this experiment, 
the ability of live T cell blasts to synergise with LPS and give a more significant 
induction of IL-lp production was tested.
PBMCs were prepared and activated with PHA, P/I or SEA. After six days the T 
cells that had been generated were taken and split into two groups. Half of the cells 
were fixed with 0.025% glutaraldehyde and the other half left unfixed. Both were 
resuspended in fresh RPMI-1640 at 5xl06/ml. Co-cultures were set-up as described 
previously using either fixed or unfixed blasts with various concentrations of LPS. 
All blasts were determined CD 14 negative and control cultures of all blasts, in the 
absence of THP-1 cells gave no IL-lp or IL-lra response to LPS. FACS analysis of 
the surface antigen expression of the different blast populations is shown in figure 
6.21.
Unfortunately, due to the magnitude of the IL-lp response to unfixed SEA blasts in 
combination with LPS the rest of the IL-ip results displayed in figure 6.22 are hard 
to discern. However, as the SEA response is the main observation of this experiment 
there is no need to extend the graphic. As far as IL-lp is concerned the D3 THP-1
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cells responded well to LPS alone and the addition of all of the blasts resulted in an 
induction of protein production. The unfixed blasts, however, although not 
dramatically better at inducing IL-lp production alone synergised most greatly with 
LPS stimulation. Of the three blasting protocols studied the unfixed SEA blasts gave 
a five-fold greater synergy, with LPS for the induction of IL-lp, than any other of the 
T cells. Although only representing data from one experiment there are clear 
indications that soluble factors derived from T cells synergise with LPS stimulation 
in inducing IL-ip production.
All of the unfixed T cell blasts were also able to induce IL-lra production but 
similarly to IL-lp production, the clearest IL-lra induction was seen when the THP-1 
cells were stimulated with unfixed T cells. These results are opposite to what is seen 
with J16 cells where fixation increases the monocyte IL-lra response. The three 
different blast populations were equivalent in their ability to induce IL-lra 
production but the SEA blast synergy with LPS was not as marked as that seen with 
PHA and P/I blasts. From these data it appears that SEA blasts, when unfixed and co- 
cultured with D3 THP-1 cells synergise with LPS stimulation to favour induction of 
IL-1 p.
CD69 expression correlates with the abitity of T cells to induce monocyte IL-lra 
production (R=0.727, p=0.024) but doesn’t correlate with IL-1 beta induction (R=- 
0.383, p=0.323).
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Figure 6.18: Day 3 blasts co-cultured with D3 THP-1 Cells for 48 Hours. 
Panel A: IL-1 p release from D3 THP-1 cells stimulated w ith fixed T cell blasts 
and various concentrations o f  LPS (n = l).
Panel B: Parallel IL-lra release from same supernatants.
Panel C: FACS analysis o f  surface antigen expression.
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Figure 6.19: Day 5 blasts co-cultured with D3 THP-1 Cells for 48 Hours. 
Panel A: IL-1 p release from D3 THP-1 cells stimulated with fixed T cell blasts 
and various concentrations o f LPS (n=l).
Panel B: Parallel IL-lra release from same supernatants.
Panel C: FACS analysis o f surface antigen expression.
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Figure 6.20: Day 7 blasts co-cultured with D3 THP-1 Cells for 48 Hours. 
Panel A: IL-1 (3 release from D3 THP-1 cells stimulated with fixed T cell blasts 
and various concentrations o f LPS (n=l).
Panel B: Parallel IL-lra release from same supernatants.
Panel C: FACS analysis o f surface antigen expression.
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Figure 6.21: Surface Antigen Expression on T cell Blasts.
PBMCs were purified from normal blood and stimulated with PHA (2|ig/ml), 
5ng/ml PDBu/lpM  ionomycin o f SEA (lOng/ml). After six days cells were taken 
for co-culture with D3 THP-1 cells and also assessed for surface antigen expression 
using FACS analysis. The T cell receptor CD3, activation marker CD69 and 
chemokine receptors CCR3 and CCR5 were measured in order to give an idea o f T 
cell purity, activation and possible helper family phenotype.
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Figure 6.22: Effect of Fixation on Day Six PBMC Blast Driven THP-1 Cells. 
Panel A: IL-1 p release from D3 THP-1 cells stimulated with fixed/unfixed T cell 
blasts and various concentrations o f LPS (n=l). Fixed (F) and unfixed (UF) blasts 
were derived from PHA (2pg/ml), SEA (lOng/ml) and PDBu (5ng/ml)/ionomycin 
(lpM ) stimulated PBMCs (n=l).
Panel B: Parallel IL-lra release from same supernatants.
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6.2.11: Effect of PI3-K  Inhibition on the Balance Between IL-ip
and IL-lra Production
IgG induced IL-lra production is reported to involve PI3-K activity. The PI3-K 
inhibitor LY294002 (Sigma) (460) was used to challenge PBMC and D3 THP-1 
responses to plastic adhered IgG, LPS and activated J16 cells.
Unfortunately, these data was not completed to statistical significance but does 
present clear trends that are worthy of note. The first experiment, displayed in figure 
6.23, shows the effect of LY294002 (LY) on PBMC responses to LPS. As can be 
seen from the top panel, LY has no effect on LPS induced IL-lp. In contrast, control 
and LPS induced IL-lra production is sensitive to LY in a concentration dependent 
manner.
Using activated J16 cells to drive PBMCs a weak induction of IL-1 p was seen as 
well as a strong induction of IL-lra (see figure 6.24). LY augmented IL-lp 
production but inhibited IL-lra production in a concentration dependent manner.
PBMC responses to IgG were also affected by LY, as can be seen in figure 6.25. The 
IL-ip response to IgG was very small and LY showed inconsistent effects but with 
no obvious inhibition. In contrast the strong induction of IL-lra, using IgG, was 
potently blocked by LY, with almost total inhibition seen with 10pM LY.
In D3 THP-1 cells LY was used to challenge IgG, J16, LPS and T cell blast induced 
IL-lra production. As can be seen from figures 6.26 and 6.27, similarly to PBMC 
responses, LY inhibited IL-lra production induced by LPS stimulation, Fc receptor 
aggregation or T cell co-culture.
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Figure 6.23: Effect of PI3-Kinase Inhibition on LPS Stimulated Cytokine 
Release from PBMCs.
Panel A: IL-1 p release from PBMCs stimulated with LPS. In test samples the 
PBMCs were pre-treated with the PI3-K inhibitor LY294002 (LY) for 30 minutes 
prior to stimulation. Supernatants were harvested after 48 hours o f culture (n=l). 
Panel B: Parallel IL-lra content o f same supernatants.
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Figure 6.24: Effect of PI3-Kinase Inhibition on Activated J16 Stimulated 
Cytokine Release from PBMCs.
Panel A: IL-ip release from PBMCs stimulated with fixed activated J16s 
(F*J16). In test samples the PBMCs were pre-treated with the PI3-K inhibitor 
LY294002 (LY) for 30 minutes prior to stimulation. Supernatants were harvested 
after 48 hours o f culture (n=l).
Panel B: Parallel IL-lra content o f same supernatants.
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Figure 6.25: Effect of PI3-Kinase Inhibition on IgG Stimulated Cytokine 
Release from PBMCs.
Panel A: IL-lp release from PBMCs stimulated with plastic bound IgG. In test 
samples the PBMCs were pre-treated with the PI3-K inhibitor LY294002 (LY) 
for 30 minutes prior to stimulation. Supernatants were harvested after 48 hours of 
culture (n=l).
Panel B: Parallel IL-lra content o f same supernatants.
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Figure 6.26: Effect of PI3-Kinase Inhibition on J16 and LPS Stimulated 
Cytokine Release from D3 THP-1 cells.
Panel A: IL-lp release from D3 THP-1 cells stimulated with LPS and unfixed 
activated J16s. D3 THP-1 cells were pre-treated with the PI3-K inhibitor 
LY294002 (LY) for 30 minutes prior to stimulation. Supernatants were harvested 
after 48 hours o f culture (n=l).
Panel B: Parallel IL-lra content o f same supernatants and also form D3 THP-1 
cells stimulated with unfixed activated J16s alone.
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Figure 6.27: Effect of PI3-Kinase Inhibition on D3 THP-1 IL-lra Production. 
Panel A: IL-lra release from D3 THP-1 cells stimulated with fixed activated J16s 
or plastic bound IgG.
Panel B: IL-lra release from D3 THP-1 cells stimulated with fixed/unfixed T cell 
blasts. Fixed (F) and unfixed (UF) blasts were derived from PHA (2pg/ml), SEA 
(lOng/ml) and PDBu (5ng/ml)/ionomycin (lpM ) stimulated PBMCs.
D3 THP-1 cells were pre-treated with the LY294002 (LY) for 30 minutes prior to 
stimulation. Supernatants were harvested after 48 hours o f culture (n=l).
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6.2.12: Effect of Ouabain on PBMC Responses to J16 Co-culture
Having established the conditions for co-culture it was hoped to assess the effect of 
ouabain on T cell induced IL-ip and IL-lra responses. Unfortunately, due to time 
constraints, the following experiment has only been carried out twice so far.
In LPS stimulated PBMCs ouabain has been shown to dramatically induce a 
synergistic IL-ip response, and inhibit IL-lra production. In the following 
experiments ouabain treated PBMCs were co-cultured with fixed and unfixed 
activated and resting J16 cells and the supernatants were analysed after forty-eight 
hours of culture. This time, however, slightly lower concentrations of ouabain were 
used (InM and lOnM) in order to avoid the complication of any toxic effects. With 
LPS stimulation, lOnM ouabain had been shown to augment the IL-ip response and 
inhibit the IL-lra response. The data for co-culture responses are displayed in figure 
6.28 and show the production of IL-ip in panel A and IL-lra in panel B. In these 
experiments J16 cells, especially unfixed J16 cells induced a large increase in IL-ip 
production. Interestingly this induction of IL-ip was not dependent upon activation 
of the J16 cells. Under control conditions ouabain had little effect on IL-ip 
production but in the unfixed J16 groups a potent synergistic effect on IL-lp 
production was observed. Particularly affected was the response to unfixed activated 
J16 cells. Unfortunately in the parallel IL-lra studies the J16 cells did not induce IL- 
lra production from the PBMCs and as a result it is difficult to assess any effects of 
ouabain. In all groups studied, however, it can be seen that ouabain had a mild 
concentration dependent inhibitory effect on IL-lra release.
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Figure 6.28: Effect of Ouabain on PBMC Responses to J16 Co-culture.
Panel A: IL-lp release from PBMCs stimulated with fixed (F) / unfixed (UF) 
activated (*) / resting (R) J16s.
Panel B: Parallel IL-lra content o f same supernatants.
PBMCs were pre-treated with the ouabain for 30 minutes prior to stimulation. 
Supernatants were harvested after 48 hours o f culture (n=2).
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6.3: SUMMARY
The aim of this chapter was to define conditions for improved study of the 
modulation of the balance between IL-ip and IL-lra production from monocytes. It 
was hoped that, in determining stimuli which selectively modulated IL-lp or IL-lra 
production, a model system could be developed in which to study the effect of 
modulatory compounds such as ouabain or anti-inflammatory drugs. The 
predominant system of interest was that of T cell co-culture, where activated or 
resting T cells can be used to stimulate the production of monocyte cytokines. This 
model has been described by Vey et al. (352) but it was hoped that we could expand 
it to explore the responses of rheumatoid PBMCs. By defining a model monocytic 
response it would be possible to measure the ability of T cells from different patient 
groups to stimulate IL-ip and IL-lra release. Similarly, by defining a model T cell it 
would be possible to measure the responsiveness of patient monocytes to a T cell 
derived stimulus.
Initial experiments detailed here sought to define model monocytic IL-lp and IL-lra 
responses. The THP-1 cell line was used to explore IL-ip and IL-lra responses to 
LPS and IgG. Upon differentiation with l,25(OH)2-vitamin D3 (D3) expression of 
CD 14 was induced in THP-1 cells but expression of CD32 and CD64 remained at 
resting levels. In agreement with this, it was observed that LPS induced IL-ip 
production in THP-1 cells was D3 dependent but IgG induced IL-lra production was 
not. Consequently, D3 differentiated THP-1 cells were considered to be a suitable 
model monocyte as they responded to control stimuli for both IL-ip and IL-lra 
production.
PBMC and purified blood monocytes were also compared for their responsiveness to 
LPS and IgG stimulation. It was expected that as IL-lp and IL-lra are monocyte- 
derived cytokines their production would be greatly increased in a purified monocyte 
preparation. In contrast, however, considering that the monocyte preparations 
routinely contained ten-fold more monocytes, little difference in cytokine production 
was observed. LPS stimulated IL-lp levels were very similar whereas IgG induced 
IL-lra production was about two-fold higher in the purified monocyte preparation. 
Interestingly, in both PBMCs and monocytes, IgG was a very poor inducer of IL-ip 
and LPS was a very poor inducer of IL-lra. IL-lra levels were very high in control
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conditions, perhaps due to adherence activation. In contrast, THP-1 cells, which do 
not adhere to plastic responded to LPS with both IL-lp and IL-lra production, 
although IL-lp production is dependent upon the differentiation state of the THP-1 
cells. However, in THP-1 cells IgG was also a poor inducer of IL-lp.
In light of the time-course of IL-lra production observed in chapter 4 an extended 
study was made in these experiments. IL-lra production was seen to increase 
dramatically over seventy-two hours but after twenty-four hours IL-ip levels only 
climbed slowly. As a result, from this point onwards all comparisons between IL-ip 
and IL-lra release were made after a forty-eight hour culture period.
Before a T cell-monocyte co-culture system could be established basic parameters of 
T cell activation had to be defined. T cells from healthy volunteers and rheumatoid 
patients, as well as J16 cells, were tested for proliferative and surface activation 
marker responses to various stimuli. Anti-CD3 mAh, PDBu and ionomycin were 
used in combination with CHO-CD80 co-stimulation. Anti-CD3 stimulation and to a 
similar extent PDBu synergised with CD80 and ionomycin to induce potent 
proliferative responses in T cells. PDBu and ionomycin induced proliferation was 
also observed to correlate with surface CD69 expression. In J16 cells, however, none 
of the stimuli studied were able to modulate the already high proliferation rate. PDBu 
and ionomycin did however induce a concentration dependent increase in surface 
CD69 expression comparative to that seen in normal T cells. As a result of these 
studies 5ng/ml PDBu and lpM ionomycin was used to induce J16 activation for 
monocyte co-culture and surface CD69 expression was monitored to measure the 
duration of the activated state. As T cell responses to the various stimuli were much 
subtler than those of J16 cells T cells activated with a broader range of stimuli were 
considered for co-culture.
Interestingly, when observing the proliferative responses of rheumatoid T cells it was 
found that there was a marked impairment in anti-CD3 responses. Responses to 
PDBu, which activates signalling cascades down-stream of the TCR, were 
comparable between rheumatoid and normal T cells as were the synergistic responses 
to PDBu and CD80. When assessing surface marker expression in resting T cells it 
was seen that CD3 expression was no different in rheumatoid T cells. Consequently, 
it can be concluded that CD3 in rheumatoid T cells does not transduce signals as 
effectively as that in normal T cells upon antibody induced aggregation.
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When fixed J16 cells were used in co-culture to deliver a membrane bound stimulus, 
it was found that IL-lp and IL-lra production was induced in THP-1 cells. The 
production of IL-lp and to a similar extent IL-lra was dependent upon J16 activation 
with PDBu and ionomycin. In PBMCs and purified monocytes resting and activated 
fixed J16 cells induced IL-lp production but had less of an effect on IL-lra 
production. Monocyte and PBMC basal production of IL-lra was so high that it is 
possible that any stimulatory effects would not be as dramatically noticed as they 
were in THP-1 cells. Nevertheless, activated J16 cells produced a mild induction of 
IL-lra in monocytes and a slightly more pronounced effect in PBMCs.
It is worthy of note that the magnitude of the IL-lra response to J16 stimulation 
(resting or activated) was much greater than that of IL-ip in terms of the 
concentration of protein secreted.
Preliminary studies using activated T cells, which were then co-cultured with their 
autologous monocytes, showed a similar profile of activation dependent induction of 
IL-ip and IL-lra. Due to the complexity of this experiment and the amount of blood 
needed to be taken from a patient to allow the separate preparation of enough T cells 
and monocytes for co-culture, only two experiments were carried out. These results 
did, however, confirm that it was possible to differentiate between the activation state 
of normal T cells based upon their ability to induce monocyte cytokine production. 
These data supported the possibility of measuring monocyte responses to rheumatoid 
T cells and comparing them to normal healthy T cells.
To increase the understanding of the THP-1 response to J16 cells various attempts 
were made to modulate the IL-lra and IL-ip responses. Although activated J16 cells 
induced the secretion of both IL-lp and IL-lra the magnitude of the IL-lra response 
dominated. Consequently, LPS was used to prime the THP-1 cells in order to see if 
there would be a shift in the balance between IL-lp and IL-lra production. In parallel 
experiments IgG was used to prime an IL-lra response. It was found that LPS 
synergised greatly with activated J16 cells to induce IL-lp production but had little 
effect on IL-lra production. In contrast, IgG synergised with resting and activated 
J16 cells to induce both IL-lp and IL-lra. The levels of IL-ip induced by IgG and 
J16 stimulation were however ten-fold lower than those observed with LPS and J16 
cells. This dramatic synergy between J16 and LPS stimulation on THP-1 production
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of IL-lp was explored further to assess the role of the J16 cells. The signal coming 
from a fixed J16 was supposed to be entirely due to membrane bound interactions but 
to observe whether soluble mediators from the J16 cells could have any effect on 
THP-1 responses both fixed and unfixed J16 cells were used. In these studies unfixed 
J16 cells synergised more greatly with LPS to induce IL-lp secretion than did fixed 
J16 cells. These data suggested that LPS could not only synergise with membrane- 
derived signals but also soluble mediator signals from J16 cells. Interestingly, fixed 
J16 cells induced greater IL-lra production than unfixed J16 cells suggesting the 
possibility that membrane bound signals from J16 cells favour the induction of IL- 
lra whereas soluble mediators favour the induction of IL-lp.
In PBMCs a similar story was observed where unfixed J16 cells synergised greatly 
with LPS to induce IL-ip production but fixed J16 cells had only a modest effect. In 
this experiment, however, IL-lra production was not induced consistently by any of 
the stimuli so no synergistic effects could be described. In attempts to study T cell 
driven IL-lra experiments were established to examine the effect of LPS on resting 
and activated normal T cell stimulated THP-1 cells. Unfortunately, however, due to 
inadequacies in the T cell purification protocol any contamination of the T cell 
preparation with monocytes dramatically skewed the levels of IL-lp produced in 
response to LPS co-stimulation. As the THP-1 cells needed high levels of LPS to 
induce IL-ip and IL-lra responses if there were any blood monocytes in the T cell 
preparation they produced so much IL-ip that the THP-1 responses were swamped. 
As a result, to avoid this problem different T cell blasting protocols were tested to 
produce a population of pure activated T cells from blood PBMCs. Super antigen 
(SEA) and PDBu/Ionomycin were used to activate PBMCs. On days three, five and 
seven after stimulation T cells were taken, assessed for purity and activation via 
surface marker expression and then used for co-culture with THP-1 cells. All 
experiments showed that the T cell blasts could induce IL-ip and IL-lra production 
and that there was synergy between LPS and T cell driven IL-lp. LPS and T cell 
stimulation had an additive effect on IL-lra production. The synergy between LPS 
and T cell driven IL-ip was most marked using day seven SEA blasts. These T cells 
did not appear different according to surface phenotype but the induction of IL-ip 
was dramatic. When unfixed T cells were compared to fixed T cells for their ability 
to synergise with LPS at inducing IL-ip production it was again found that fixation
Chapter 6: T cell Monocyte co-culture - 197-
inhibited the IL-ip response. It appears that soluble, T cell derived mediators are 
dominant in the synergy between LPS and T cell stimulated IL-lp production.
Interestingly, in all experiments there was a correlation between CD69 expression 
and the induction of IL-lra production (R=0.727, P=0.024) but not IL-lp production 
(R =-0.383, P = 0.323).
Unfortunately, at this point in the co-culture studies there was insufficient time to 
further explore the phenomenon that have been described here. Due to the award of a 
Basic Science Initiative grant from Pharmacia and Upjohn further studies were 
dedicated to the investigation of whether Sulphasalazine could modulate T cell- 
monocyte co-culture responses. In some complementary studies, however, the 
PI3-Kinase inhibitor LY294002 (LY) was used to challenge the co-culture model. 
As PI3-Kinase is known to be involved in FcR signalling it was suggested that LY 
may well modulate IgG induced responses of PBMCs and THP-1 cells. To test 
whether T cell derived signals may utilise similar signalling pathways responses 
were challenged with various concentrations of LY, and IL-ip and IL-lra production 
was monitored. In PBMCs LY inhibited LPS induced IL-lra, fixed activated J16 
induced IL-lra and IgG induced IL-lra in a concentration dependent manner. The 
induction of IL-ip by all of these stimuli was unaffected by LY. Similarly, in THP-1 
cells LY inhibited LPS, IgG, J16 and T cell blast induced IL-lra but not IL-ip.
The effect of Na7K+-ATPase modulation on J16 driven PBMC cytokine production 
was also studied in two preliminary experiments. The results clearly showed that 
ouabain synergised with J16 cells to induce IL-lp production but inhibited IL-lra 
production. Stimulation with unfixed activated J16 cells synergised most greatly with 
ouabain suggesting the possibility that ouabain may modulate the production of J16 
derived soluble mediators.
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CHAPTER 7




The studies described in chapter six clearly demonstrate that T cells are capable of 
modulating the production of IL-lp and IL-lra from monocytes. The use of T cell 
fixation differentiated between signals coming solely from T cell-monocyte 
membrane interactions and those resulting from the combined effect of T cell derived 
cytokines and membrane interactions. In particular, fixed activated J16 cells strongly 
induced IL-lra production from the THP-1 ceil line in the absence of a significant 
IL-ip response. Conversely, unfixed activated J16 cells were able to synergise with 
LPS to dramatically induce IL-lp production whilst attenuating the IL-lra response. 
This evidence suggests the possibility that T cell derived soluble mediators and 
membrane antigens differentially regulate monocyte cytokine production. Evidence 
from recent literature has implied the role of several T cell surface molecules in the 
regulation of monocyte responses in co-culture. McAllister and Ellis (1996) have 
shown inhibition of T cell driven peripheral blood monocyte IL-ip production using 
antibodies that block CD2 interactions with CD58 (368). In THP-1 cells, however, 
responses to T cell stimulation have been inhibited using anti-CD69, CDlla, CDllb 
and CDllc (352,354). Using freshly isolated T cells anti-CD69 mAb in particular 
have been shown to inhibit 70% of monocyte IL-lp production. From these data it is 
apparent that no single T cell surface molecule is responsible for the induction of 
monocyte responses. It is likely that, as well as critical T cell signalling molecules, a 
complex interaction of adhesion molecules is also crucial for monocyte activation. 
The rapidly inducible nature of the activation dependent T cell membrane molecules 
combined with the anti-CD69 mAb data strongly suggested CD69 as a likely 
candidate for further investigation. The evidence presented in chapter 6 also supports 
a role for CD69 as the ability of activated peripheral blood T cells to induce D3 THP- 
1 IL-lra release correlated with CD69 expression. In an attempt to achieve the 
cleanest system for analysis of CD69 dependent monocyte activation it was decided 
to clone human CD69 in order to generate a transfected cell line. By ensuring that 
CD69 is the only T cell antigen expressed on the transfectant, clear data as to the role 
of CD69 in monocyte activation could be constructed.
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7.2: METHODS
The details of all protocols used in the cloning and transfection of human CD69 are 
detailed in Chapter 2, section 2.9. Any practical considerations relevant to the 
specific enzymes, cloning techniques and reagents used will be detailed here, along 
with the results.
7.3: RESULTS
7.3.1: Production of cDNA
Human CD69 is rapidly expressed in J16 cells upon activation with various stimuli. 
In this study, CD69 surface expression, as determined by antibody staining using 
flow cytometry, was induced with the phorbol ester PDBu and the calcium ionophore 
ionomycin. CD69 expression was monitored over a twenty-four hour time-course and 
as can be seen from figure 7.1 was readily measurable within two hours. By eight 
hours nearly the entire population of cells became CD69 positive. Using this 
evidence PDBu and ionomycin were tested at various concentrations to activate J16 
cells to induce CD69 expression. As can be seen in figure 7.2, PDBU and ionomycin 
induced CD69 expression in an additive and concentration dependent manner. 
Consequently, 5ng/ml PDBu combined with lpM ionomycin was used to induce 
CD69 mRNA production. Within two hours of stimulation the percentage of cells 
expressing CD69 was already high, at 88%. The level of protein expression was quite 
low, however, as can be determined by the magnitude of the shift in FL-1 
fluorescence. Consequently, a two-hour time-point was used for mRNA harvesting.
Messenger RNA was prepared as described in method 2.8.1 and reverse transcribed 
into cDNA as described in method 2.8.3.
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Figure 7.1: Time-course of CD69 expression induced by 5ng/ml PDBu + lpM 
Ionomycin in J16 cells.
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7.3.2: CD69 Sequence and Primer Design
The gene for CD69 is 1662 bases long, of which section 56 to 682 codes for the Type 
II transmembrane protein. Using this sequence information, shown below, CD69 
forward and reverse primers were designed.
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The CD69 primers were tested against the sequence of CD69 using the Mac Vector 
program. The data below shows the primer sequence used, the physical properties of 
the primers and their specificity for the CD69 sequence.
Human CD69 Sequence Scanned: 56 to 682
CD69 Forward: 5' GGAATCTTGAGAATAAAGATGAGC 3' 
length: 24, %GC: 37.5, Gs: 7, Cs: 2, ambiguous G or C: 0 
Tm: 46.4 °C, (Of Primer itself) 
lpg of primer is equivalent to 415.9 pmole of ends 
Primer does not form Self 3'-dimer 
Primer does not form Hairpin 
Primer does not form Self Duplex 
Primer binds at position 56 on the Top Strand (score 24)
CD69 Reverse: 5' GTTTCCTTATTATTTGTAAGG 3' 
length: 21, %GC: 28.6, Gs: 4, Cs: 2, ambiguous G or C: 0 
Tm: 36.5 °C, (Of Primer itself) 
lug of primer is equivalent to 440.6 pmole of ends 
Primer does not form Self 3'-dimer 
Primer does not form Hairpin 
Primer does not form Self Duplex
Primer binds at position 682 on the Bottom Strand (score 21)
Product details:
Product: 627 bp (56-682)
Optimal annealing temp: 49.5,
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7.3.3: Production of CD69 cDNA
The cDNA prepared from PDBu/ionomycin stimulated J16 cells was used as a 
template for PCR amplification using the CD69 forward and reverse primers 
described above. An annealing temperature range o f 49°C to 52°C was studied, 
based on the optimal temperature o f 49.5°C recommended by the Mac Vector 
software. The 627 base pair product generated was visualised on a 1% Agarose gel 
which is shown in figure 7.3. Once optimal PCR conditions had been defined they 
were used to produce a CD69 cDNA fragment which was suitable for directional 
insertion into the pCR3.1-Uni vector (Invitrogen).
CD69 (627 b.p.)
Figure 7.3: Effect of Annealing temperature on PCR amplification of CD69 
cDNA.
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7.3.4: Unidirectional Cloning
Unidirectional cloning exploits the nontemplate-dependent activity of Taq 
polymerase which adds a single deoxyadenosine (A) to the 3’ ends of PCR products. 
The vector used in this study, pCR3.1-Uni, has single 3’ deoxythymidine (T) 
residues that ligate readily to PCR products with A-overhangs. To achieve directional 
insertion of PCR products, however, the forward PCR primer is phosphorylated prior 
to amplification. The resulting PCR product is only phosphorylated at the 5’ end, 
allowing ligation into the modified vector in only one orientation.
Attempts to insert CD69 cDNA in both orientations were made in order to produce a 
control clone that did not express CD69 protein. To achieve this the CD69 forward 
and reverse primers were phosphorylated and used in separate PCR reactions. To 
phosphorylate the primer, 0.5-lpg was incubated at 37°C for thirty minutes with lpl 
10X buffer, lpl lOmM ATP, lpl T4 polynucleotide kinase (10U/pl) and sterile water 
(up to lOpl). The phosphorylation reaction was stopped by incubation at 94°C for 
five minutes and then the primer was used immediately, with the complementary un- 
phosphorylated primer, to amplify CD69 for ligation.
Insertion of fresh uni-directional PCR product was carried out as described in section 
2.9.7. The ligated vectors produced were then used immediately to transform 
TOPI OF’ cells as described in method 2.8.9.
The vector modification also rules out self-ligation in the absence of PCR fragment 
insertion improving the transformation efficiency.
7.3.5: Colony Screening for CD69 Insertion
Either side of the insertion point in the pCR3.2-Uni vector is a T7 promoter/priming 
site and a pCR3.1 reverse priming site. The primers for these sites allowed the 
transformed colonies to be screened for CD69 cDNA insertion via PCR amplification 
of the polylinker sequence. Bacteria were transferred from individual colonies to 
PCR reaction tubes and the DNA was amplified using the previously described 
reaction. Figure 7.4 shows the results from eleven selected colonies compared to 
control CD69 PCR product. CD69 positive colonies yielded a PCR product 
equivalent in size to CD69 (627 bases) plus the polylinker site (approximately 145
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bases). Lanes 3, 7, 8, 9 and 10 clearly display products o f approximately 800bp 
which represent insertion of CD69 DNA.
Colony Number
10 11





2 .0 2 7
« i l «
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Figure7.4: PCR Screen of Transformed colonies.
Lanes one to five contain DNA from colonies selected form the CD69 reverse 
ligation reactions. Low molecular weight bands represent amplification o f the 
polylinker region in the absence o f CD69 insertion. In lane three the low molecular 
weight band is replaced with an intense band at approximately 800 bp which 
represents inserted CD69.
Lanes six to eleven represent colonies from CD69 forward reactions and clearly 
display CD69 insertion in lanes seven to ten.
CD69
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7.3.6: Confirmation of CD69 DNA Orientation in pCR3.1 Vector
Even though a unidirectional cloning system was used, the positive clones identified 
above were tested for insert orientation by restriction mapping. DNA was prepared 
using the mini-prep system described in method 2.8.10 and was digested with the 
enzymes Sac 1, Nco 1 and Bst XI. Figures 7.5 and 7.6 show the restriction sites for 
these enzymes in the pCR3.1-uni vector, including CD69 DNA inserted in a forward 
and reverse reading direction respectively. The digestion fragment sizes produced are 
listed in table 7.1.
pcr3.1uni. CD69
Ncol






Figure 7.5: pCR3.1 (CD69F) Restriction map for Nco 1, Bst XI and Sac 1.










Figure 7.6: pCR3.1 (CD69R) Restriction map for Nco 1, Bst XI and Sac 1
Enzyme CD69 Forward CD69 Reverse
Fragment Size Cut From:To Fragment Size Cut From:To
Nco 1
2148 3876:385 2334 845:3178
2013 1166:3178 2148 3876:385
780 386:1165 697 3179:3875
697 3179:3875 459 386:844
Sac 1 5513 719:593 4932
1300:593
125 594:718 706 594:1299
BstXI 5467 1344:1172 5140
1344:845
171 1173:1343 498 846:1343
Table 7.1: DNA fragment sizes for pCR3,l containing CD69 DNA in a forward or
reverse direction.
DNA from six o f the transformed colonies was digested with each o f the three 
restriction enzymes. Three o f the CD69F insert positive colonies identified in figure 
7.4 (lanes 7-9) were used as were three CD69R colonies. O f the three CD69R
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colonies only one had been identified in as being insert positive (lane 3) the other 
two were fresh mini-prep products from colonies transferred from new colonies. The 
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Figure 7.7: pCR3.1-CD69 Restriction Digests
Orientation o f CD69 insert DNA was assessed using the restriction enzymes Nco 
1, Sac 1 and Bst XI.
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As can be seen in figure 7.7 test samples one to six and control pCR3.1 circularised 
vector all show clear bands of coiled and supercoiled DNA in the undigested lanes. 
The lower bands in lanes one to three and five also appear to be retarded indicating 
the presence of the insert. All of the digestion reactions can be seen to have linearised 
the DNA tested due to the absence of the bands present between 3,500 bp and 6,500 
bp in the controls. In the case of BstXI, the linearised plasmid DNA can be 
visualised at about 5,000 bp. Bst XI digestion also liberated low molecular weight 
fragments from samples in lanes one to three indicating that the CD69 is indeed 
orientated in a forward direction. These data is complemented by the Nco 1 
digestion, which results in bands at 697 bp and 780 bp for the samples in lanes one to 
three. Finally the Sac 1 digestion confirms that the plasmids in lanes one to three 
contain CD69 DNA in the forward orientation due to the intense bands at 125 bp and 
the retardation of the higher molecular weight band which is 5467 bp. Out of the 
three CD69 reverse samples tested only the one in lane five appears to contain insert. 
The insert, however can clearly be seen to be in the reverse orientation due to the 
digestion fragments observed with all enzymes used (i.e. 498 bp with BstXI, 459 bp 
with Nco 1 and 706 bp with Sac 1).
7.3.7: Transfection of CD69 into COS-7 Cells
Plasmid DNA containing the CD69 DNA was prepared from the screened colonies 
via the maxi-prep system described in method 2.8.10. Transfection via 
electroporation was carried out as described in method 2.8.11 and transient 
expression was assessed after thirty-six hours. The electroporation conditions were 
varied in respect to voltage and capacitance and the cells plated out on separate petri- 
dishes. The FACS analysis results for transient expression can be seen in figure 7.8. 
The cells which displayed the highest degree of transient surface expression of CD69 
(15%) were then selected via immunomagnetic positive retention and cultured on for 
several days until confluent. Ten days after transfection the magnetic bead sorted 
cells were stained again for CD69 and as can be seen in figure 7.8 expressed a low 
level of stable CD69. These cells were selected again using magnetic beads and re­
cultured until a population that was suitable for FACS sorting had developed. After 
twenty-four days the surface expression of CD69 can be seen to have risen to about 
45%.
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Figure 7.8: CD69 expression in transfected COS cells
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7.3.8: Fluorescence Activated Selection of CD69 Positive cells
The cells that had been selected with immunomagnetic beads and determined to be 
45% positive for CD69 expression were sorted using flow cytometry. After a single 
sort, populations o f cells which were 70-80% positive for CD69 expression were 
recovered, as can be seen in figure 7.9. Various other populations were also 
recovered, cultured on and then frozen down for storage. The populations with the 
highest expression o f CD69 were used for co-culture experiments to determine the 
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Figure 7.9: CD69 Surface Expression on COS69 line 2
7.3.9: Effect of CD69 Stimulation on D3 THP-1 Production of IL-1(3 
and IL -lra
D3 THP-1 cells were prepared as described in section 2.6.1 and plated out at a 
density o f lx l0 6/ml in 100pl volumes of RPMI-1640. To these were added lOOpl o f  
COS-69 cells that had been fixed with 0.025% glutaraldehyde and resuspended at 
5x l06/ml in RPMI-1640. Untransfected COS-7 cells that did not express CD69 were 
used as controls. In some experiments D3 THP-1 cells were co-stimulated with LPS 
as well as membrane bound CD69.
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In all experiments cells were cultured for forty-eight hours and then secreted IL-lp 
and IL-lra concentrations were determined via ELISA of the supernatants (Method 
2.7). Preliminary results are shown in figure 7.10. It must be stressed that at this 
point the COS-69 cells used for co-culture had varying levels of CD69 surface 
expression. In an attempt to repeat experiments some unsorted transfectants were 
used so the data displayed are merely a preliminary observation as to whether CD69 
may have any effect of monocyte activation. As can be seen in the graphs, CD69 
appears to synergise with LPS to induce high levels of IL-lp production from D3 
THP-1 cells. COS cells transfected with CD69 were significantly better at 
synergising with LPS to induce IL-lp release from THP-1 cells than control COS 
cells (P<0.05). Control COS cells also had a positive effect on IL-ip production 
(P<0.05) but this could be due to the fact that COS cells express certain surface 
molecules that have sequence homology to human adhesion molecules. Interactions 
between COS cells and THP-1 cells could cause weak activation due to non-specific 
adhesion. The effects of CD69 on IL-lra responses are less marked but these data 
needs to be improved.
7.4: SUMMARY
The main goal of this chapter was to produce a transfectant cell expressing human 
CD69 on its surface. Antibody binding studies using flow cytometry have clearly 
shown this to have been achieved. As to the role of CD69 in T cell driven monocyte 
cytokine production, this question will have to remain. Preliminary data suggest that 
CD69 is able to synergise with LPS to induce high levels of IL-lp production but 
more studies, with more refined transfectants, will be needed to confirm this.
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Figure 7.10: Effect of Membrane-bound CD69 Stimulation on D3 THP-1 
Cytokine Production.
Panel A: IL-ip production from D3 THP-1 cells stimulated with LPS and fixed 
COS-69 cells for 48 hours o f  culture. Controls used untransfected COS-7 cells 
(n=3±STDEV: *=P<0.05).
Panel B: Parallel IL-lra content o f same supernatants.
Chapter 7: Generation of a CD69 Transfectant -216-
CHAPTER 8




Sulphasalazine (SPZ) is an earlyexample of rational drug design for the treatment of 
rheumatoid arthritis in that the combination of a salicylate (anti-inflammatory) and a 
sulphonamide (antibiotic) was considered ideal for an inflammatory disease of 
putative bacterial aetiology. Despite fifty years of research and clinical usage, 
however, investigators have failed to identify a specific mode of action for SPZ in 
this disease (461). The predominant process leading to cartilage degradation and 
bone erosion is believed to be mediated largely by the prolonged generation and 
activity of cytokines, including TNFa and IL-lp. These proteins are produced 
almost exclusively by monocyte-macrophage cell types in the synovial membrane 
and exert potent stimulatory effects on chondrocytes and osteoclasts. The pro- 
inflammatory actions of TNFa and IL-ip in RA appear to be inadequately opposed 
by other cytokines that may be generated to limit inflammatory responses under 
normal conditions. Such cytokines include IL-lra, IL-4 and IL-10. SPZ has been 
shown to inhibit cytokine production from human monocytes in vitro (518), although 
drug concentrations effective in these studies were significantly higher than plasma 
levels attained in vivo.
Relatively little is known about the cellular interactions or intracellular biochemistry 
that is associated with the imbalance of cytokine production in the chronically 
inflamed rheumatoid synovium. Recent research, however, has reported that co­
culture of monocytes with different subpopulations of T cells promotes the 
production of either a broadly pro- or anti-inflammatory cytokine profile. In 
particular, Thl cells can up-regulate IL-lp production by the monocytic cell line 
THP-1 whereas Th2 cells, which themselves produce IL-4 and IL-10, promote the 
generation of IL-lra (397). Thus, a hypothesis may be proposed that one factor 
contributing to the chronicity of the rheumatoid lesion is an inability of the patient’s 
T cells to drive macrophage cytokine production towards an anti-inflammatory 
balance. This inability could reflect either a decrease in Th2 type cytokine 
production or decreased contact between Th2 specific surface markers and the 
neighbouring macrophages. Impaired production of IL-4 (462) and IL-lra (390) have 
been reported in the rheumatoid synovium.
The aim of this chapter was to explore the hypothesis that SPZ or its metabolites 
may influence the ability of T cells to modulate the cytokine production of
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monocytic cells. As part of this work the direct effect of SPZ on T cell activation 
was studied as well as the effect of SPZ on control monocyte responses to IgG and 
LPS.
As all the studies detailed here were carried out in vitro one of the most important 
prerequisites of this work was to determine clinically relevant concentrations at 
which to use the test compounds. Consequently pharmacokinetic data compiled by 
Schroeder, H and Campbell, DES (1972) was utilised to determine median (and 
range) steady state concentrations of the parent compound and its metabolites.
Compound Molecular
Weight
[Drug] in Blood with 
4g/day dosing.
(median (range))/pg/ml
[Drug] in Blood with 
4g/day dosing.
(median (range))/pM
Sulphasalazine 398.39 12 (4.7-45) 15(5-56)
Sulphapyridine 249.29 50(18.5-46) 100 (74-185)
5-aminosalicylate 153.13 2 6
Bearing the pharmacokinetic data in mind and with advice from Pharmacia and 
Upjohn maximum concentrations used were 75 pM SPZ, 200pM SP and 25 pM ASA.
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8.2: RESULTS
This chapter examines the effects of sulphasalazine (SPZ) and its metabolites 
sulphapyridine (SP) and 5-aminosalicylate (ASA) on monocyte cytokine production 
in the previously described T cell/monocyte co-culture model. Due to the complexity 
of this model preliminary studies examined the effects of SPZ, SP and ASA in 
control monocyte and T cell experiments. Monocyte responses to LPS and IgG 
stimulation and T cell activation studies, including surface marker expression and 
proliferation assays, were carried out before the effects on T cell driven monocyte 
cytokines were examined.
8.2.1: Effect of Sulphasalazine on LPS and IgG Driven D3 THP-1 
IL-lp and IL-lra Production
l,25(OH)2-vitamin D3-differentiated THP-1 cells were used as model monocytes for 
the study of the effects of SPZ on the balance between IL-lp and IL-lra production. 
Culture conditions were repeated as detailed before in Chapter 6 and SPZ, SP, ASA 
or a combination of all drugs were incubated with the D3 THP-1 cells for thirty 
minutes prior to stimulation. The following results are presented with IL-ip 
production shown in the top panels and IL-lra production shown in the bottom 
panels for matched samples.
LPS induced responses are shown in figure 8.1. Both IL-lp and IL-lra production 
are induced in a concentration dependent manner by LPS. The IL-ip and the IL-lra 
responses to lpg/ml LPS are both mildly inhibited by SPZ alone and the 
combination of both the parent drug and its metabolites. SP displays a mild 
inhibitory effect on 1 pg/ml LPS induced IL-lra (P<0.05) but not IL-lp and ASA has 
no effect at all.
Plastic bound IgG induced both IL-lp and IL-lra production from D3 THP-1 cells in 
a concentration dependent manner (see figure 8.2). The effects of the test compounds 
on IgG induced IL-lp were marginal, with SPZ alone and the combination of all 
compounds only slightly inhibiting protein secretion. SP and ASA alone had no 
effect on IgG induced IL-lp production. In contrast, the large induction of IL-lra 
stimulated by IgG was blocked by approximately fifty percent by SPZ. SP alone had
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a weak inhibitory effect against 200fig/ml IgG induced IL-lra and ASA had no effect 
against either concentration of IgG. Interestingly the combination of all the 
compounds had a much less effect against either concentration of IgG compared to 
the parent compound alone.
8.2.2: Effect of Sulphasalazine on LPS and IgG Driven Normal 
PBMC IL-ip and IL-lra Production
In contrast to D3 THP-1 responses, PBMCs are much more sensitive to LPS 
stimulation. However, whilst LPS is a potent inducer of PBMC IL-lp production its 
effects on IL-lra production are inconsistent. In D3 THP-1 basal IL-lra release is 
very low, at levels of approximately 400pg/ml and LPS induces IL-lra secretion in a 
dose dependent manner, reaching levels of up to lOng/ml. In PBMC cultures, 
however, basal IL-lra release often reaches levels of 6000-8000 pg/ml, perhaps due 
to adherence activation. In some experiments LPS has been seen to augment the 
release of IL-lra from PBMCs but in others inhibition occurs.
Figure 8.3 displays the effect of SPZ and its metabolites on LPS induced IL-ip and 
IL-lra production from normal PBMCs. In this experiment, LPS potently induced 
IL-ip production but inhibited IL-lra release. In contrast to D3 THP-1 responses, 
SPZ had no effect on LPS induced IL-ip in normal PBMCs. SP, however marginally 
inhibited LPS induced IL-lp. As LPS did not induce IL-lra in this experiment it is 
difficult to interpret the effect of SPZ under these conditions. Basal release of IL-lra 
is mildly inhibited by SPZ alone and SP alone but ASA has no effect. The small 
inhibition of IL-lra release induced by LPS in this model is augmented slightly by 
SPZ and even more so by SP. ASA has no effect on the IL-lra responses to LPS. The 
combination of all compounds has no greater effect on IL-lra responses to LPS than 
SP alone.
PBMC responses to IgG are more consistent than those to LPS. In all studies carried 
out in this thesis IgG has minimal effects on IL-ip release but strongly induces IL- 
lra production. Consequently, IL-lra production is considered a more important 
feature of IgG stimulation than IL-lp production. The IL-ip and IL-lra levels 
produced in response to IgG are, however, displayed in parallel for comparison.
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Figure 8.4 shows the very slight induction of IL-ip production seen only with 
50pg/ml IgG. As the levels of IL-ip secretion are so low the slight effects seen with 
the test compounds are insignificant. IgG induced IL-lra synthesis, however, did 
appear to be sensitive to inhibition. SPZ alone and especially SP alone inhibited IgG 
induced IL-lra production but ASA had no effect. The combination of all three 
compounds had no greater effect than SP alone.
8.2.3: Effect of Sulphasalazine on LPS and IgG Driven IL-lp and 
IL-lra Production from PBMCs Harvested from Sero-positive 
Rheumatoid Arthritis Patients Receiving Sulphasalazine Treatment
The effect of long-term sulphasalazine treatment was studied by measuring the 
responses of patient PBMCs to LPS and IgG stimulation, results being displayed in 
figures 8.5 and 8.6 respectively. The possibility of cumulative effects of SPZ 
treatment on ex-vivo responses to SPZ and its metabolites was also considered by 
challenging LPS and IgG responses with the test compounds. Interestingly, although 
lng/ml LPS induced IL-lp was not affected by any of the test compounds SPZ and 
to a similar extent SP markedly inhibited lOng/ml LPS induced IL-lp. Again, 
however, the combination of all compounds did not give an inhibition of LPS 
responses that exceeded that of the single compounds.
In these experiments LPS had an unusual effect on IL-lra production. Basal IL-lra 
production was comparable to levels seen in other PBMCs but was markedly 
elevated upon stimulation with lng/ml LPS. Interestingly, although lOng/ml LPS 
also up-regulated IL-lra production it was not as potent as the lower concentration of 
LPS. Basal IL-lra levels were mildly inhibited by both SPZ and SP. Responses to 
lng/ml and lOng/ml LPS induced IL-lra, however, were slightly inhibited by SPZ 
but markedly inhibited by SP. The potent inhibition of SPZ against lOng/ml LPS 
induced IL-lp was not paralleled with an equivalent effect against IL-lra production. 
ASA demonstrated no effects against LPS induced IL-ip or IL-lra.
The responses of PBMCs from SPZ patients to IgG were very similar to those 
described for normal PBMCs. As can be seen from figure 8.6 the IL-ip induced by 
IgG is again very low, and although the test compounds appear to have effects the
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concentrations of IL-ip that are involved are so low that no conclusions are derived 
from these experiments. However, the IL-lra induced by IgG stimulation is inhibited 
by SPZ but more markedly so by SP. Combining the compounds had no additive 
effect and ASA alone had no effect on IgG induced responses.
8.2.4: Effect of Sulphasalazine on LPS and IgG Driven IL-ip and 
IL-lra Production From PBMCs Harvested From Sero-positive 
Rheumatoid Arthritis Patients
As a control for the effects of SPZ on the responses of PBMCs from SPZ patients 
samples were also taken from rheumatoid patients who were not receiving second- 
line treatment.
As can be seen from figure 8.7, the effects of SPZ and its metabolites on LPS 
induced responses were comparable to those seen in normal PBMCs. In contrast to 
SPZ-patient PBMCs, control rheumatoid PBMCs showed very low sensitivity to SPZ 
or its metabolites. LPS induced IL-ip was not affected by any of the test compounds 
except a small inhibition with SP. LPS did not greatly modulate IL-lra responses and 
only SP seemed to have any affect, resulting in a slight reduction in IL-lra release.
The effects of SPZ and its metabolites on the IgG responses of rheumatoid PBMCs 
are shown in figure 8.8. In comparison to both the normal PBMCs and the SPZ- 
patient PBMCs the rheumatoid PBMC responses to IgG were less sensitive to SPZ 
or its metabolites. IgG induced IL-ip responses were comparably low and again the 
effects of SPZ, SP and ASA were not really significant. IgG induced IL-lra 
responses, however, appeared to be less sensitive to inhibition by both SPZ and SP.
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Figure 8.1: Effect of SPZ on LPS Stimulated Cytokine Release from D3- 
Differentiated THP-1 Cells
Panel A: Shows the IL-lp release from Differentiated THP-1 cells stimulated 
with 0.1 and lpg/ml LPS for 48 hours (n=4-8 ±SEM: *=P<0.05).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.2: Effect of SPZ on IgG Stimulated Cytokine Release from D3- 
Differentiated THP-1 Cells
Panel A: Shows the IL-lp release from Differentiated THP-1 cells stimulated 
with plastic-bound IgG for 48 hours (n=4-8 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.3: Effect of SPZ on LPS Stimulated Cytokine Release from Normal 
PBMCs
Panel A: Shows the IL-ip release from normal blood PBMCs stimulated with 1 
and lOng/ml LPS for 48 hours (n=6 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.4: Effect of SPZ on IgG Stimulated Cytokine Release from Normal 
PBMCs
Panel A: Shows the IL-lp release from normal blood PBMCs stimulated with 
plastic-bound IgG for 48 hours (n=6 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.5: Effect of SPZ on LPS Stimulated Cytokine Release from SPZ 
Patient PBMCs
Panel A: Shows the IL-lp release from SPZ patient PBMCs stimulated with 1 
and lOng/ml LPS for 48 hours (n=5 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.6: Effect of SPZ on IgG Stimulated Cytokine Release from SPZ 
Patient PBMCs.
Panel A: Shows the IL-ip release from SPZ patient PBMCs stimulated with 
plastic-bound IgG for 48 hours (n=5 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.









□ CTRL 1SPZ IS P  LHASA 1  ALL












Figure 8.7: Effect of SPZ on LPS Stimulated Cytokine Release from Control 
SPRA Patient PBMCs.
Panel A: Shows the IL-ip release from sero-positive RA patient PBMCs 
stimulated with 1 and lOng/ml LPS for 48 hours (n=7 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.8: Effect of SPZ on IgG Stimulated Cytokine Release from Control 
SPRA Patient PBMCs.
Panel A: Shows the IL-lp release from sero-positive RA patient PBMCs 
stimulated with plastic-bound IgG for 48 hours (n=7 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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8.2.5: Effect of Sulphasalazine on T cell Activation
Having established control monocyte responses to LPS and IgG and studied the 
effect o f SPZ, SP and ASA under these conditions consideration was given to direct 
effects o f the test compounds on T cells. T cells can regulate monocyte functions via 
direct cell-cell contact and also through the production o f various cytokines. In the 
co-culture model that has been developed as part o f this thesis the main focus has 
been on T cell surface molecule derived signals and how these vary under different 
states o f activation. Consequently, SPZ and its metabolites were assessed for their 
ability to modulate basic T cell proliferation responses and surface activation marker 
expression. For the study o f the effects o f SPZ on T cell driven monocyte cytokines 
the predominant model was to be that which utilised fixed activated T cells. 
Therefore the effects o f SPZ on T cell derived cytokines was not considered here.
8.2.6: Effect of Sulphasalazine and its Metabolites on PDBu and 
Ionomycin Induced Activation Marker Expression in J16 cells
The PKC activator PDBu was used to activate J16 cells in a way that mimicked 
down-stream signals from TCR ligation. The calcium ionophore, ionomycin, was 
combined with PDBu in certain experiments to deliver a second intracellular calcium 
signal. In order to cover the broadest range o f activation states PDBu and ionomycin 
concentration response curves were constructed, measuring the induction o f the 
surface activation marker CD69. As CD69 is so rapidly induced the induction of 
surface expression was monitored over three time-points, two hours, four hours and 
twenty-two hours, to maximise the possibility o f observing effects with SPZ. The 
effect o f SPZ on PDBu and ionomycin induction o f J16 CD28 expression was also 
monitored over a similar time course. CD28 is also regulated during T cell activation 
and is involved with interactions between T cells and monocytes.
J16 cells were suspended at lx l0 6/ml in RPMI-1640 and cultured with SPZ (75 pM), 
SP (200pM), ASA (25pM) or a combination o f all three for thirty minutes prior to 
receiving the activation stimuli. After activation the J16 cells were removed from 
culture at two hour, four hour and twenty-two hour time-points and washed ready for 
staining with anti-CD28 and CD69 antibodies. Care was taken to halt the metabolic 
activity o f the cells by carrying out all staining procedures at 4°C. In this way
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activation induced trans-location o f surface antigens to the cell membrane would be 
halted and the stain would reflect the surface expression at the time o f cell harvest. 
Surface antigen expression was analysed by flow cytometry using a FITC conjugate 
and therefore measured as an increase in FL-1 fluorescence. Figure 8.9A shows a 
typical histogram trace for PDBu and ionomycin induced CD69 expression after 
twenty-two hours o f culture. PDBu alone induces CD69 expression in a 
concentration dependent manner and synergises with ionomycin to further enhance 
expression o f CD69. As can be seen from figure 8.9B neither SPZ nor its 
metabolites had any effect on J16 CD69 expression induced by the maximal 
concentrations o f PDBu and ionomycin after twenty-two hours.
To simplify presentation, the rest o f the data for FACS analysis o f surface marker 
expression is displayed in table format. The degree o f surface expression was 
monitored as an increase in Mean Fluorescence Intensity (MFI) o f the whole cell 
population. As CD69 and CD28 induction in J16 cells involves gradual up- 
regulation o f surface expression in the entire population rather than the development 
o f a separate antigen positive population, the MFI is an accurate representation o f the 
degree o f surface expression. I f  a fluorescence level was defined as indicating 
positively stained cells and the percent o f the population that became antigen- 
positive monitored instead o f the total MFI, intricacies o f changes in surface antigen 
expression on cells that have low molecule numbers would be lost. Percentage 
positive gating is most effective in monitoring surface expression in a heterogeneous 
population o f cells but in this case, however, MFI measurement is the most accurate 
way of displaying data.
CD28 expression in J16 cells was not greatly induced by PDBu or ionomycin. Basal 
levels o f CD28 expression were found to be unaffected by SPZ or any o f its 
metabolites. Consequently, the data presented here in tables 8.1, 8.2 and 8.3 only 
represents the effects of SPZ on activation induced CD69 expression after two, four 
and twenty-two hours o f stimulation respectively. PDBu and ionomycin induced a 
time and concentration dependent increase in surface expression o f CD69 but SPZ, 
SP and ASA had no effect.
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8.2.7: Effect of Sulphasalazine and its Metabolites on PDBu and 
PDBu/CD80 Induced Activation Marker Expression in Normal T 
cells
Surface expression o f CD28, CD69 and CD95 was assessed after stimulation with 
5ng/ml PDBu, either alone or in combination with CD80 co-stimulation from CHO- 
CD80 transfectants. T cells were prepared from the blood o f healthy volunteers as 
described in m ethod 2.2.6 and suspended at lx l0 6/ml in RPMI-1640. The cells were 
then cultured with SPZ (75pM), SP (200pM), ASA (25pM) or a combination o f all 
three for thirty minutes prior to receiving the activation stimuli. CHO-CD80 cells 
were fixed prior to use and cultured with the T cells at a ratio o f 1:3.
The MFI o f cells stained with anti-CD28, CD69 and CD95 is displayed in tables 8.4, 
8.5 and 8.6 respectively. Each table contains data for cells harvested at two, five and 
nineteen hours after stimulation, giving an indication o f early and late activation 
marker expression. PDBu alone and in combination with CD80 had little effect on 
CD28 expression in the conditions used here. Basal CD28 expression climbed 
slightly over the nineteen-hour time-course and if  anything there was a trend for 
CD80 to down-regulate this slightly. None o f the test compounds had any effect on 
CD28 expression over the course o f this study. Likewise, CD95 expression was not 
modulated by either o f the activation stimuli, except for a slight elevation at the 
nineteen-hour time-point. Again, SPZ, SP and ASA had no effect on CD95 
expression. In contrast, PDBu rapidly induced CD69 expression and the addition of 
CD80 augmented this induction. At the two-hour time-point SPZ, SP and ASA had 
no effect on either basal or activation induced CD69 expression. At the five-hour 
time-point, however, although statistically insignificant SPZ and SP caused a slight 
down-regulation o f PDBu induced CD69 expression. Any effects o f the test 
compounds were lost by nineteen hours when surface CD69 expression was at its 
maximum.
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Figure 8.9: Effect of SPZ on 22 H our Activated J16 Surface CD69 Expression.
Panel A: Effect of various stimuli on J16 CD69 expression assessed by FACS 
analysis.
Panel B: Effect o f SPZ on 5ng/ml PDBu + lpM  Ionomycin induced CD69 
expression.
Data displays the FL-1 fluorescence o f entire anti-CD69 stained population and is a 
typical representative o f three experiments.
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Table 8.1: Effect of SPZ on 2 hour Activated J16 CD69 Expression (Data 
Represents Mean Fluorescence Intensity (MFI) of Whole Population: n=3)
Type and Duration of 
Stimulation CTRL SPZ SP 5ASA ALL
2 hour control 6.32 6.41 7.10 6.70 6.11
0.5ng/ml PDBu 7.13 7.43 5.96 6.39 8.46
5ng/ml PDBu 8.90 9.04 10.24 8.85 9.22
luM  Ionomycin 7.17 7.65 6.97 7.57 7.72
0.5ng/ml PDBu/I 8.74 13.59 13.14 14.30 12.88
5ng/ml PDBu/I 23.81 25.40 22.13 25.81 24.99
Table 8.2: Effect of SPZ on 4 hour Activated J16 CD69 Expression (Data 
Represents Mean Fluorescence Intensity (MFI) of Whole Population: n=3)
Type and Duration of 
Stimulation CTRL SPZ SP 5ASA ALL
4 hour control 8.37 8.54 7.93 9.08 9.18
0.5ng/ml PDBu 8.83 8.74 8.07 8.73 10.26
5ng/ml PDBu 14.25 14.20 11.65 15.54 16.69
luM Ionomycin 10.63 10.13 8.62 10.59 11.86
0.5ng/ml PDBu/I 14.41 15.35 11.88 15.69 16.80
5ng/ml PDBu/I 27.75 36.02 30.50 30.25 32.13
Table 8.3: Effect of SPZ on 22 hour Activated J16 CD69 Expression (Data 
Represents Mean Fluorescence Intensity (MFI) of Whole Population: n=3)
Type and Duration of 
Stimulation CTRL SPZ SP 5ASA ALL
22 hour control 6.51 7.30 7.40 6.49 6.72
0.5ng/ml PDBu 8.43 9.76 8.89 8.58 7.99
5ng/ml PDBu 34.15 37.17 35.93 35.88 34.36
luM  Ionomycin 16.95 15.66 15.77 17.42 15.39
0.5ng/ml PDBu/I 29.70 28.64 25.36 28.14 25.40
5ng/ml PDBu/I 86.49 72.33 76.01 76.03 87.92
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Table 8.4: Effect of SPZ on Normal T cell Surface CD28 Expression (MFI n=2)
Type and Duration of 
Stimulation CTRL SPZ SP ASA ALL
2 hour Ctrl 9.41 9.91 10.61 9.84 9.37
5ng/ml PDBu 11.22 10.9 12.17 11.71 10.48
5ng/ml PDBu + CD80 8.97 8.55 8.725 8.63 9.94
5 hour Ctrl 9.28 9.48 10.56 9.43 10.16
5ng/ml PDBu 11.14 10.49 10.90 9.56 11.37
5ng/ml PDBu + CD80 7.98 9.01 9.23 16.6 7.73
19 hour Ctrl 14.32 13.01 12.41 12.62 11.53
5ng/ml PDBu 14.47 13.6 13.23 15.76 14.46
5ng/ml PDBu + CD80 9.90 9.75 9.55 9.64 9.67
Table 8.5: Effect of SPZ on Normal T cell Surface CD69 Expression (MFI n=2)
Type and Duration of 
Stimulation CTRL SPZ SP ASA ALL
2 hour Ctrl 6.27 6.33 6.03 6.65 6.07
5ng/ml PDBu 17.95 18.1 18.57 19.2 17.45
5ng/ml PDBu + CD80 19.5 19.46 20.63 20.8 20.69
5 hour Ctrl 7.28 6.99 7.20 6.96 7.16
5ng/ml PDBu 33.55 26.08 24.12 28.55 24.33
5ng/ml PDBu + CD80 31.77 31.54 25.14 32.88 30.62
19 hour Ctrl 20.65 14.17 12.4 12.37 13.2
5ng/ml PDBu 39.16 36.54 40.89 45.47 38.14
5ng/ml PDBu + CD80 45.49 37.32 36.72 39.18 36.78
Table 8.6: Effect of SPZ on Normal T cell Surface CD95 Expression (MFI n=2)
Type and Duration of 
Stimulation CTRL SPZ SP ASA ALL
2 hour ctrl 10.32 9.31 9.85 9.05 9.08
5ng/ml PDBu 10.50 10.00 8.13 8.85 8.65
5ng/ml PDBu + CD80 9.915 10.05 10.65 11.11 9.35
5 hour ctrl 11.95 12.61 10.67 11.79 10.91
5ng/ml PDBu 10.17 9.725 9.30 9.97 10.35
5ng/ml PDBu + CD80 10.71 10.97 10.57 10.45 11.45
19 hour ctrl 15.79 15.66 15.08 14.73 15.36
5ng/ml PDBu 16.96 16.14 17.11 17.60 16.27
5ng/ml PDBu + CD80 18.53 16.82 15.54 17.51 16.21
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8.2.8: Effect of Sulphasalazine and its Metabolites on T cell 
Proliferation
As can be seen in figure 6.9B J16 cells are a very rapidly growing cell line and 
consequently were not suited for studies on proliferation induction. The effects o f 
SPZ and its metabolites on T cell proliferation were, therefore, only studied in 
normal T cells. T cell proliferation assays were carried out as described previously in 
section 6.2.4 and method 2.2.8. Control stimulations were characterised using PDBu 
and aggregated anti-CD3 antibody either alone or in combination with CHO-CD80. 
Cells were stimulated for seventy-two hours and 3H-thymidine incorporation was 
monitored over the last eighteen hours. Typical control proliferation responses are 
shown in figure 8.10, displaying synergistic induction o f proliferation with 
CD3/CD80 and PDBu/CD80.
The T cells were cultured with SPZ (75pM), SP (200pM), ASA (25pM) or a 
combination o f all three for thirty minutes prior to receiving the activation stimuli. 
CHO-CD80 cells were fixed prior to use and cultured with the T cells at a ratio of 
1:3.
As well as activation induced proliferation, basal T cell proliferation was also 
monitored in order to check for cytotoxic drug effects. As can be seen in figure 
8.11 A, none o f the compounds alone had any effect on basal T cell proliferation. The 
combination o f all three compounds, however, mildly suppressed basal proliferation 
but with the low number o f experiments carried out this proved to be insignificant. A 
similar trend was observed with CD3/CD80 stimulation (figure 8.1 IB) with only the 
combination o f all three compounds having any effect. In contrast, PDBu/CD80 
induced proliferation was most resistant to modulation by any o f the test compounds 
with not even the combination o f drugs being effective (figure 8.12 A).
Interestingly, it appeared that any effects of the test compounds on T cell 
proliferation were seen in the combination group only. Both basal proliferation and 
the CD3/CD80 stimulation were mildly inhibited but the more aggressive 
pharmacological induction o f proliferation using PDBu was unaffected. It is possible 
that the more physiological type proliferation induced by CD3 stimulation was more 
sensitive to inhibition by the combination o f SPZ and its metabolites. 
Complementary data was also observed in three experiments when it was noticed 
that CD80 stimulation alone induced a mild proliferation. In these CD80 responders
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SPZ, SP and even ASA had a marked effect on proliferation, inhibiting 3H thymidine 

















Figure 8.10: Control Proliferation Responses of Normal T cells
Normal T cells were stimulated with 5ng/ml PDBu or lpg/ml anti-CD3 with or 
without CHO-CD80. Cells were cultured for seventy-two hours and the 
incorporation o f 3H thymidine was measured over the last eighteen hours (Data 
represents the mean o f four experiments ± STDEV).
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Figure 8.11: Effect of SPZ, SP and ASA on Normal T cell Proliferation 
Panel A: Effect o f SPZ on basal proliferation o f resting T cells.
Panel B: Effect o f SPZ on CD3/CD80 induced T cell proliferation. Normal T 
cells were stimulated with lpg/ml anti-CD3 and CHO-CD80. Cells were cultured 
for seventy-two hours and the incorporation o f 3H thymidine was measured over 
the last eighteen hours (Data represents the mean o f four experiments ± STDEV).
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Figure 8.12: Effect of SPZ, SP and ASA on Normal T cell Proliferation 
Panel A: Normal T cells were stimulated with 5ng/ml PDBu and CHO-CD80 
(Data represents the mean o f four experiments ± STDEV).
Panel B: Normal T cells were stimulated with CHO-CD80 alone (Data represents 
the mean o f three experiments ± STDEV).
Cells were cultured for seventy-two hours and the incorporation o f 3H thymidine 
was measured over the last eighteen hours
Chapter 8: Effect of SPZ on monocyte derived cytokines -241 -
8.2.9: Effect of Sulphasalazine on T cell Driven Monocyte IL-lp  and
IL-lra Production
Fixed activated J16 cells were used to stimulate cytokine production in D3 THP-1 
cells, normal PBMCs, SPZ-patient PBMCs and control rheumatoid PBMCs. Fixation 
o f the J16 cells ruled out any contribution o f soluble factors and thus the “ T cell” 
stimulus was defined as a membrane interaction only. The test compounds, SPZ, SP 
and ASA were pre-incubated with the monocytes for thirty minutes prior to 
stimulation with the J16 cells.
Figure 8.13 shows J16 induction o f IL -lp  and IL -lra production in D3 THP-1 cells. 
As can be seen from both panels J16 cells induced IL -ip  and IL -lra in an activation 
dependent manner, with resting J16 cells having little effect on cytokine production. 
However, neither SPZ nor its metabolites SP and ASA had any effect upon J16 
induced IL -lp  or IL -lra production from D3 THP-1 cells.
With PBMCs, fixed activated J16 stimulation resulted in a small increase in IL -ip 
production and a more pronounced increase in IL -lra production. The cytokine 
production induced in normal PBMCs is shown in figure 8.14. Similarly to IgG 
stimulation the IL -ip  response o f normal PBMCs when co-cultured with activated 
J16 cells reflects a subtle elevation in cytokine production. There is a three to five­
fold increase in IL -lp  production above that seen in controls, but this represents an 
increase in concentration o f only 100 to 150pg/ml. As a result, the interpretation of 
the effect o f SPZ and its metabolites on J16 induced IL -lp  production is difficult. 
Naturally, as this drug has been seen to be efficacious in the treatment o f RA for 
some fifty years it would be strange to expect to see a pro-inflammatory cytokine 
profile induced in monocyte cultures. However, with J16 stimulated normal PBMCs 
that is what is observed. Both SPZ and more markedly SP slightly augment J16 
induced IL -lp  production and inhibit IL -lra production. Although these effects are 
statistically insignificant there is a clear trend and the question that is left is whether 
this degree o f elevation o f IL -lp  production is truly biologically significant. If  SPZ is 
having such an effect on IL -lp  production, albeit a modest one, could it perhaps be 
due to experimental conditions or toxicity?
In contrast to normal PBMCs, PBMCs taken from SPZ patients display different 
responses to SPZ in vitro. As can be seen in figure 8.15 activated fixed J16 cells
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stimulated both IL -lp  and IL-lra production. However, a very small but equally non­
significant inhibition, rather than an augmentation o f IL -lp  production was seen with 
SPZ and SP treatment. In contrast, like in normal PBMCs SPZ and SP mildly 
inhibited J16 induced IL -lra production.
Control rheumatoid PBMCs gave another variable response to SPZ treatment when 
challenged with activated J16 cells (see figure 8.16). SP and to a similar extent ASA 
slightly augmented J16 induced IL -ip  but none of the compounds had any effect on 
J16 induced IL -lra production.
8.2.10: General Balance Between IL-lp and IL-lra Production 
Observed in the Different Patient Groups
Out o f all the observations made on the effects o f sulphasalazine in the co-culture 
models described here perhaps the most interesting is the difference between the 
basal responses o f the different patient groups. As can be seen in figure 8.17, SPRA 
patients who have received SPZ treatment display an elevated IL -lra response and 
depressed IL -lp  response to all o f the stimuli studied. At present with just an 
experimental repeat o f five for the SPZ patients these data are not statistically 
significant but the trend is clear.
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Figure 8.13: Effect of SPZ on J16 Stimulated Cytokine Release from D3- 
Differentiated THP-1 cells.
Panel A: Shows IL-ip release from D3 THP-1 cells cultured for 48 hours with 
fixed resting or activated (*) J16s(n=4-8 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.14: Effect of SPZ on J16 Stimulated Cytokine Release from Normal 
PBMCs.
Panel A: Shows IL-lp release from normal PBMCs cultured for 48 hours with 
fixed activated (*J16s) (n=6 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.15: Effect of SPZ on J16 Stimulated Cytokine Release from PBMCs 
from SPZ Patients
Panel A: Shows IL-ip release from SPZ patient PBMCs cultured for 48 hours 
with fixed activated (*J16s) (n=5 ±SEM).
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.16: Effect of SPZ on J16 Stimulated Cytokine Release from SPRA 
Disease Control PBMCs
Panel A: Shows IL-ip release from PBMCs cultured for 48 hours with fixed 
activated (*J16s). PBMCs were purified from sero-positive RA patients attending 
clinics at the RNHRD who were not taking second-line treatments (n=7, ±SEM). 
Panel B: Shows parallel IL-lra release from the same supernatants.
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Figure 8.17: Comparison of Control IL -ip  and IL -lra  Responses of SPZ 
Patient PBMCs, Control SPRA PBMCs and Normal PBMCs.
Panel A: Shows IL-lp release from PBMCs cultured for 48 hours with various 
stimuli.
Panel B: Shows parallel IL-lra release from the same supernatants.
The data highlights the balance between IL-lra and IL-lp production seen 
between the different groups.
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8.3: SUMMARY
Sulphasalazine (SPZ) and its metabolites sulphapyridine (SP) and 5-aminosalicylate 
(ASA) have been tested for their ability to modulate T cell-, IgG- or LPS-mediated 
generation o f IL -ip  and IL -lra by monocytes. Drug effects have been determined on 
healthy isolated T cells and J16 cells, as well as healthy and rheumatoid mononuclear 
cells and l,25(OH)2-vitamin D3-differentiated THP-1 cells.
No evidence has been found for an effect o f any drug, either alone or in combination, 
at relevant therapeutic concentrations on (anti-CD3+CD80)- or (PDBu+Ionomycin)- 
stimulated T cell proliferation, expression o f CD69, CD28 or CD95, or the ability to 
stimulate cytokine production by monocytes in co-culture. Similarly, little evidence 
was observed for an effect o f any drug on PBMC responses to LPS or IgG. The 
exception, however, was that SPZ (75 pM) caused a marked inhibition o f LPS 
induced IL -lp  production from PBMCs purified from the blood o f patients receiving 
long-term SPZ treatment with little effect on parallel IL -lra production. These data 
suggest that SPZ may have cumulative effects on the responses o f monocytes to ex 
vivo pro-inflammatory stimuli. Complementary to this is the observation that the 
profile o f cytokine responses from SPZ patient PBMCs, stimulated ex vivo, favoured 
the production o f IL -lra over IL -lp , when compared to normal and SPRA PBMCs. 
In response to LPS, IgG and J16 stimulation SPZ PBMCs produced higher IL-lra 
and lower IL -ip  levels than any o f the other groups.
It is perhaps possible that any in vitro effects of SPZ on the balance between pro- and 
anti-inflammatory cytokine production in normal PBMCs were not evident due to the 
short-term nature o f such studies. The evidence from the ex vivo studies o f SPZ 
patient PBMCs supports the already well known clinical evidence for the efficacy of 
SPZ in RA with data suggesting that this may be due to the balance between IL-ip 
and IL -lra production.




The outcome o f an inflammatory reaction is controlled by a complex interaction of 
infiltrating immune cells, resident tissue and inflammatory cells and cytokine 
signalling mediators. There is a fine balance between signals that control and 
suppress the inflammatory response, adapting the tissue environment to one of 
healing and repair, and those that exacerbate the host response, eventually leading to 
considerable tissue damage. A breakdown in the balance o f this regulation is seen in 
chronic inflammatory diseases such as rheumatoid arthritis, which is characterised by 
an inflammatory response levied against the joint tissues o f the host. Whether this is 
as a result o f an inappropriately directed antibody-driven immune response or as a 
consequence o f an uncontrolled inflammatory incident remains to be clarified. One 
thing that is undisputed, however, is the important role that is played by monocyte 
derived cytokines in the orchestration o f the events within the inflamed synovium 
that lead to joint destruction.
In the inflamed joint there are many possible therapeutic targets, such as the MHC 
molecule that is involved in antigen presentation to T cells, CD4+ T cells themselves 
and pro-inflammatory cytokines such as IL-1 and TNFa. Perhaps the most promising 
o f these novel therapeutic strategies has proven to be the anti-cytokine treatments 
(173,175,463,464). These anti-cytokine therapies have moved with remarkable speed 
from the laboratory to the clinic with, in some cases, less than a decade separating the 
preliminary biological investigations and the present clinical usage (465,466).
In RA it is generally accepted that no one single mediator is responsible for the 
pathogenesis o f disease, but many believe that TNFa plays a pivotal role in the 
generation o f a pro-inflammatory cytokine profile (467,468,525). Indeed anti-TNFa 
therapies are proving to be clinically efficacious as are some IL -lra and anti-IL-ip 
treatment strategies (463,469). Although these protein mediators are perhaps not at 
the apex o f the initiation o f RA, and as a result therapeutically targeting them will not 
cure disease, successful neutralisation o f their effects will effectively treat the 
symptoms o f chronic inflammation and lead to rapid disease improvement. However, 
despite the efficacy o f the anti-cytokine therapies that is currently being 
demonstrated in clinical trials the question still remains as to what is driving the 
generation o f the pro-inflammatory cytokine profile that is observed in the
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rheumatoid synovium. Perhaps an even more pertinent question would be whether it 
is the overproduction o f pro-inflammatory cytokines that is solely responsible for the 
pathogenesis o f RA or whether it is in fact inadequate production o f regulatory anti­
inflammatory mediators. Our belief, which is shared by many, is that it is the balance 
between the production o f pro- and anti-inflammatory mediators that is responsible 
for the pathogenesis of RA. O f particular interest to us is the balance between the 
production o f IL -ip  and IL-lra in the rheumatoid synovium. Both o f these cytokines 
are expressed in the rheumatoid synovium and are readily measurable in synovial 
fluid and in vitro cultures o f dissociated synovial tissue samples. Elevated levels of 
IL -lra and IL -ip  are found in RA but the ratio between their concentrations is 
insufficient for IL -lra to neutralise the effects o f IL -ip. It is our belief that an 
increased understanding o f factors that regulate the balance between monocyte 
production o f IL -lp  and IL -lra would prove invaluable to the search for successful 
therapeutic targets for the treatment o f RA.
9.1: Regulation of monocyte function in RA
Monocytes play critical roles in both the innate and adaptive immune response. In 
RA increased numbers o f activated monocytes are observed within the inflamed 
synovium and lining layer and especially within the destructive area o f the pannus 
(18,19). Blood monocytes are recruited to sites o f inflammation in response to 
chemo-attractant gradients and interactions with activated endothelial cells that line 
the blood vessels. Inflammatory mediators present in the area o f tissue injury induce 
the expression o f adhesion molecules on both the monocytes and endothelium that 
result in cell infiltration into the inflamed joint. As monocytes and promonocytes 
migrate through the tissues, mediators within the inflammatory milieu can induce 
activation and differentiation into tissue macrophages, dendritic cells and osteoblasts 
(2-4,7). Thus, within the joint there is a constant flux o f infiltrating cells of the 
monocyte/macrophage lineage as well as the already present tissue macrophages, 
dendritic cells and resident type A synoviocytes.
It has been demonstrated that in RA peripheral blood monocytes have increased 
phagocytic activity and that they secrete increased levels o f pro-inflammatory 
mediators (20,21,23,470). Thus it is possible that the infiltrating monocytes already
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display increased levels of activation prior to entering the inflamed joint due to 
stimulation within the periphery. Systemic activation may play an important role in 
RA but it is likely that the key events leading to monocyte/macrophage activation 
occur within the joint. Which stimulatory events are critical to the generation o f a 
pro-inflammatory cytokine profile within the joint and especially which factors 
regulate the balance between monocyte production of pro- and anti-inflammatory 
mediators are questions that need to be answered. The studies detailed within this 
thesis consider mechanisms of monocyte activation that are thought to be relevant to 
the pathogenesis of RA. The approach that was taken was to consider factors that 
may be responsible for inappropriate activation o f monocytes and then test how they 
influence the balance in monocyte cytokine production.
9.1.1: Biochemical regulation of monocyte cytokine release
In RA the environment in which the monocyte/macrophage resides is considered to 
be oxidative and this in itself may have grave repercussions on the state o f cell 
activation. Reactive oxygen species such as superoxide and hydroxyl radicals 
generated during the respiratory burst by phagocytic cells in the area o f inflammation 
contribute to the intracellular and extracellular reduction/oxidation (redox) balance. 
Intracellular redox potentials are involved in the stability o f ferritin/transferrin 
receptor mRNAs (471) and the activation o f transcription factors such as AP-1 (472) 
and NF-kB (473,474). More important to the studies in this thesis, however, is the 
effect o f oxidative stress on the function o f cell surface proteins such as the 
Na+/K+ATPase. The Na7K+ATPase has been described as a thiol-dependent 
oxidation sensitive enzyme by Skou 1963 (475). Dikstein (1971) showed a 
correlation between the oxidation state o f glutathione and the activity of 
Na+/K+ATPase with increased oxidation tending to inhibit Na+/K+ATPase activity 
(476). Further studies by Rohn et al (1993) have shown that the generation o f oxygen 
radicals inhibits Na+/K+ATPase activity and that this inhibition is reversed by 
deferoxamine or by the addition o f superoxide dismutase (477). The Na+/K+ATPase 
is a key ion-motive enzyme in the cell membrane and is one o f the main mechanisms 
by which intracellular cation levels are regulated. Inhibition o f Na+/K+ATPase has 
been shown to cause a decrease in intracellular K+ concentration and an increase in 
intracellular Na+ concentration that is linked to an increase in intracellular Ca2+ via
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modulation o f the Na+/Ca2+-exchanger (211,411). The oxidation o f external thiol 
groups in the Na+/K+ATPase due to oxidative stress in the rheumatoid joint could 
thus lead to profound effects on intracellular cation levels.
In this thesis the specific inhibitor ouabain was used to selectively study the effect of 
Na+/K+ATPase inhibition on monocyte cytokine production. By using ouabain to 
inhibit the Na7K+ATPase, mimicking what in the joint may be a result o f oxidative 
damage, attempts were made to assess the role o f intracellular cation levels in the 
regulation o f monocyte cytokine production. It was found that ouabain differentially 
regulated cytokine production from resting peripheral blood mononuclear cells. 
Whilst inducing the secretion o f IL -lp  and to a lesser extent TNFa ouabain had no 
effect on IL-6 and OSM release. These results are in partial agreement with previous 
findings from this laboratory that demonstrated higher basal release o f monocyte 
cytokines and more marked modulatory effects of ouabain on IL -lp , TN Fa and IL-6 
(232). In order to assess whether the findings shown here could be due to more 
quiescent mononuclear cell cultures or changes in reagents investigations were 
carried out to address the effects o f ouabain on LPS primed PBMCs. As LPS is a 
potent inducer of IL -lp, TNFa, IL-6 and OSM it presented experimental conditions 
in which to assess whether ouabain would induce the synthesis o f one or other of 
these cytokines. Interestingly, it was found that lower concentrations o f ouabain 
synergised greatly with LPS in the induction o f IL -lp  release whilst having little 
effect upon TNFa, IL-6 or OSM release. At higher concentrations, however, ouabain 
inhibited LPS induced secretion o f TNFa, IL-6 and OSM from PBMCs whilst still 
synergising greatly with LPS to induce IL -lp  secretion. These results demonstrated 
that ouabain preferentially induced IL -lp  secretion from resting and LPS primed 
PBMCs. To test whether this differential regulation o f monocyte cytokine secretion 
would extend to modulation o f anti-inflammatory cytokines the secretion o f IL-lra 
was measured in parallel to IL -lp. It was found that whilst synergising greatly with 
LPS to induce IL -lp  release, ouabain markedly inhibited LPS induced secretion and 
intracellular accumulation of IL -lra in PBMCs.
Inhibition o f the Na+/K+ATPase with ouabain leads to an increase in the intracellular 
concentration o f Na+ and a decrease in the intracellular concentration o f K+. From 
these data conclusions cannot be made as to which o f these cations is critical to the 
ability o f ouabain to stimulate IL -lp  synthesis from PBMCs. However, it is clear that
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the intracellular concentration o f these cations is in some way linked to the regulation 
o f pro- and anti-inflammatory cytokine production from monocytes. From these 
results it appears that ouabain predominantly favours the production o f IL -ip. These 
data complement previous reports that demonstrate K+ regulatory effects on the 
processing and secretion o f mature IL -ip  (234,235,249). Perregaux et al (1992) have 
shown that depletion o f intracellular K+ is linked to increased cleavage of 
intracellular proIL-ip via modulation o f the activity o f ICE. Walev 1995 maintains 
that Na+ and Ca2+ fluxes are not important to the activity o f ICE but other 
investigators have demonstrated that both the sodium ionophore, monensin 
(232,478), and the calcium ionophore A23187 (233) have modulatory effects upon 
IL -lp  secretion from monocytic cells. The data presented here cannot answer the 
question as to which cations are critical to the activation o f ICE. It does, however, 
imply that inhibition o f the Na+/K+ATPase in the rheumatoid joint due to oxidative 
stress could be an important factor in the generation o f an imbalance between IL -lp 
and IL -lra production in the synovium.
Interestingly, after the completion o f these early studies, results published by 
Matsumori et al (1997) confirmed what had been found in our laboratory. Matsumori 
showed that ouabain synergised greatly with LPS to induce IL -ip  secretion but had 
less marked effects upon IL-6 and TNFa release (479). They did not however 
comment upon IL -lra production and it appears that the evidence presented here is 
the first to show opposing effects o f ouabain upon IL -lp  and IL -lra release.
These data, however, were complicated by the observation o f monocyte specific 
cytotoxic effects with higher concentrations o f ouabain. Early studies by Walev 
(1995), Newton (1990) and Foey (1995), upon which these initial studies were based, 
and then the more recent data published by Matsumori et al. (1997) and Foey (1997) 
have all used ouabain at high concentrations to induce monocyte cytokine release and 
none have observed cytotoxic effects. It is probable that in a PBMC preparation, if  
death is monitored using trypan blue exclusion, that fluctuations in the viability of 
the monocyte population could be missed. If  the sample has a low number of 
monocytes then the increase in stained cells due to ouabain induced death is difficult 
to monitor. The effects o f ouabain induced death, however, may result in a profound 
release o f IL -lp. In these studies it has been shown that concentrations o f ouabain 
that most effectively induce IL -lp  secretion from PBMCs are able to induce death of
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monocytes. Death was monitored using flow cytometric scatter analysis and 
propidium iodide staining and apoptosis was distinguished from necrosis on the basis 
o f phosphatidylserine extemalisation. It is worth noting that IL -lp  secretion was 
measurable several hours before any signs o f monocyte death were apparent. No 
death was detectable until about eight hours after stimulation with ouabain although 
morphologically there was an apparent increase in monocyte size after three to six 
hours. By the twenty-four hour time-point concentrations o f ouabain above 0.1 pM 
induced death o f the entire monocyte population. The activation o f ICE (Caspase 1) 
has long been implicated in the process of apoptosis. In these studies if  ouabain 
induced modulation o f Na+ or K+ is responsible for the activation o f ICE it is possible 
that both death and processed IL -ip secretion may occur depending upon which 
substrates are preferentially cleaved by the activated protease. This question was 
addressed in both purified blood monocytes and the monocytic cell line THP-1. In 
blood monocytes it was found that ouabain-induced secretion o f mature IL -ip  was 
accompanied by apoptotic cell death, although further experiments with more 
sensitive apoptosis detection systems would need to be carried out to confirm the 
degree o f apoptosis. In contrast, however, ouabain only appeared to induce necrotic 
death in THP-1 cells despite secretion o f IL -ip  (data not shown). From these data it 
appears that ouabain induced activation of ICE (caspase 1) may be responsible for 
both the induction o f IL -ip  secretion and apoptosis in blood monocytes. In THP-1 
cells, however, activated ICE may process proIL-lp without inducing the activation 
o f the caspase cascade and initiating apoptosis. The absence o f apoptosis in THP-1 
cells may be due to the fact that they are a monocytic leukaemia-derived cell line that 
might not have fully functional apoptotic pathways or increased protection from 
molecules such as Bcl-2. From the initial findings o f these studies it was considered 
that necrotic death, due to an osmotic stress induced by ouabain, may greatly 
contribute to the release o f IL-lp. Recent data published by Wamy and Kelly (1999), 
however, has linked caspase activation with necrotic death as well as apoptosis. 
Using the broad spectrum protease inhibitor z-VAD they demonstrated that ouabain- 
induced necrosis in THP-1 cells was inhibited as was IL -lp  secretion (480). Also, 
physiological concentrations o f intracellular K+ (150mM) inhibited caspase-1 
activation induced by nigericin in THP-1 cells (481). Consequently it is possible that 
ouabain-induced caspase activation may selectively induce IL -lp  processing,
Chapter 9: Discussion -256-
apoptosis or necrosis depending upon substrate preference or availability. It is now 
becoming apparent that apoptosis and necrosis may be functionally linked cell death 
pathways (reviewed in (482)). Both forms of cell death involve loss o f mitochondrial 
membrane potential and osmotic homeostasis, under the control o f proteins o f the 
Bcl-2 family. It is interesting that Bcl-xL, an anti-apoptotic protein o f this family, 
forms cation-selective membrane channels and is capable o f conducting a K+ current 
(483). Recently, Bcl-xL was found to inhibit necrosis caused by inhibitors of 
oxidative phosphorylation (484). These studies provide further evidence that 
intracellular cations play key roles in both apoptosis and necrosis. Elucidating the 
mechanism by which K+ inhibits caspase activation will present a key step in the 
understanding o f the regulation o f cell death and its relationship with IL -lp 
production.
In RA it is possible that oxidative stresses within the inflamed tissues may affect 
other membrane proteins on infiltrating cells such as ion channels. Oxidation o f KATP 
channels has also been shown to regulate intracellular K+ levels in some cell types 
(485). In beta pancreatic cells oxidative control o f KATP has been linked to membrane 
depolarisation, opening o f voltage operated Ca2+ channels and subsequent regulation 
o f insulin release (486,487). Several sulhydryl reagents have also recently been 
shown to induce an increase in intracellular Ca2+ in human T cells (488). Whether 
oxidative regulation o f intracellular Na+, K+ and Ca2+ levels is an important factor in 
the generation o f pro-inflammatory cytokine levels in RA remains to be determined. 
What has been demonstrated, however, is that intracellular Na+ levels are increased in 
rheumatoid erythrocytes (412) and intracellular Ca2+ levels are increased in 
rheumatoid erythrocytes and granulocytes (489). Although not investigated here the 
consequence o f intracellular Na+ levels on IL -lp  processing has recently been 
considered by Perregaux et al. (1998) (250). Previously the impaired IL -ip  
processing observed after complete replacement o f extracellular Na+ with K+ was 
taken as evidence that increased extracellular concentrations o f K+ inhibited 
processing o f IL -lp  and linked K+ efflux with ICE activation (235,249). Using 
choline- and sucrose-based minimal media, however Perregaux has now shown that 
extracellular Na+ is also involved in the processing o f IL -ip  (250). Quite how Na+ 
contributes to processing o f IL -ip  remains to be determined but it is possibly via an 
increase in intracellular Ca2+ due to modulation o f the Na+/Ca2+ exchanger. From the
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analysis o f monocyte responses in various cation depleted media it appears that the 
involvement o f Na+ in IL -lp  processing precedes the activation o f ICE (250). Indeed, 
Foey et al. have shown that the Na+/Ca2+ exchanger inhibitor DCB inhibits ouabain- 
induced secretion o f IL -ip  and TNFa from resting PBMCs (232). It is apparent that 
modulation o f intracellular cation levels by the Na7K+-ATPase may have effects on 
several aspects o f IL -lp  production in monocytes. Interestingly, the Na+/K+-ATPase 
has recently been shown to differentially regulate the activation o f several mitogen 
activated protein kinases (MAPK) (490). The two ligands, palytoxin and ouabain 
have been shown to compete for the same binding site and differentially regulate 
activation o f MAPK’s. Ouabain favours the activation o f ERK (mitogen activated 
MAPK) and palytoxin favours activation of p38/JNK (stress activated MAPK). 
These studies, however, used ouabain at ImM so the validity o f these results might 
be questioned due to the osmotic stress the cells would be under. Regardless o f these 
doubts, however, it is interesting that the Na+/K+-ATPase can regulate such signalling 
cascades and it impresses the need for more detailed study o f how cation levels affect 
intracellular signalling processes.
In parallel studies to the investigation o f ouabain effects upon human PBMC 
cytokine release, ouabain was also tested for pro-inflammatory effects in murine 
models o f arthritis. Despite ouabain’s ability to induce a pro-inflammatory cytokine 
profile in human PBMCs it was found that ouabain was unable to modulate murine 
antigen or zymosan induced arthritis. In the antigen induced arthritis model joint 
pathology was measured as bone erosion and synovitis and at no point did ouabain 
affect either of these scores. By utilising the more sensitive assay o f proteoglycan 
synthesis in the zymosan induced arthritis model it was shown that ouabain could 
delay the recovery o f joint pathology but this effect was not reproducible. It is now 
well reported that murine Na7K+ATPase is less sensitive to the effects o f ouabain 
than the human isoform o f the enzyme. Indeed the data presented within this thesis 
have confirmed this using the ATPase assay to measure Na+/K+-ATPase activity in 
murine cell lines and peritoneal macrophages. Reports by Yuan et al (1993) however 
demonstrated long term effects upon blood pressure in rats using equivalent doses of 
ouabain to those used in these studies (417). Also, Matsumori et al. (1997) have 
recently shown that lmg/kg ouabain given shortly before a lethal dose o f LPS 
inhibits LPS induced death in BALB/c mice, possibly via inhibition o f LPS induced 
IL-6 and TNFa release (479). They found that 0.lmg/kg ouabain was ineffective in
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this model. Taking this evidence together it appears that some investigators have 
shown effects of ouabain in rodents following both long- and short-term treatment 
but that for short-term effects high doses o f ouabain had to be used. It is thus possible 
that the dosing regime used in the present studies was unsuitable to assess the role of 
ouabain in the murine models and that the results were not a true reflection of 
ouabain’s ability to modulate cytokine production by monocytes within the joint in 
vivo. It is possible that the doses o f ouabain used were too low for the short-term in 
vivo studies and that longer pre-dosing should have been used prior to disease 
induction or that a much higher dose o f ouabain should have been used.
Modulation o f the Na+/K+ATPase throughout this thesis has been carried out using 
ouabain to mimic down-regulation of Na+/K+ATPase activity, which in resident cells 
o f the rheumatoid joint may de due to oxidative damage. Another scenario that may 
be relevant to RA is the possibility that mononuclear cell Na7K+ATPase is 
modulated by endogenous ouabain. Whether endogenous ouabain has any relevance 
to inflammatory conditions such as RA remains to be seen as most research so far has 
focused on cardiovascular conditions. Endogenous ouabain may well have important 
homeostatic functions in human biology as demonstrated by the relationship between 
plasma ouabain concentration and cardiac index and mean arterial pressure (248).
Although it now appears that ouabain may have very interesting effects upon cell 
death and that IL -ip  release may be closely related to necrotic or apoptotic processes 
it was felt at the time o f the early work that the toxic effects o f ouabain were 
detrimental to the purpose o f this research. Also, due to the slow time-course of IL- 
lra  release it was feared that even though ouabain might be selectively switching off 
IL -lra release it was also likely that monocytes were dying before they were able to 
secrete significant amounts of IL-lra. This concern, however, may indeed by an 
interesting facet o f rheumatoid disease. Firestein et al. have described increased 
levels o f apoptosis in rheumatoid synovial tissues (491). The primary location of 
apoptotic cells was the synovial lining, with the predominant cell type involved the 
macrophage. Apoptotic cells within the sublining layer included some macrophages 
and fibroblasts. If  activated monocytes rapidly secrete IL -ip  in response to 
encountering stimulation in an oxidative environment and then die before being able 
to secrete IL -lra the pro-inflammatory effects o f IL -lp  would be unchecked. The 
rapid infiltration o f monocytes into inflamed areas o f the rheumatoid synovium
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would provide a constant supply o f cells that would become activated, release large 
quantities o f IL -lp  and then die.
Despite this fascinating mechanism that could be involved in the pathogenesis of RA 
the investigations detailed here intended to observe factors that might differentially 
regulate the production o f IL -ip and IL-lra. Consequently further efforts were 
concentrated upon other mechanisms that may be more pertinent to the selective 
regulation o f monocyte cytokine release in RA.
9.1.2: Selective regulation between the production of IL-lra and IL- 
lp  from monocytes
As RA is considered an auto-immune disease it would be expected that T cells play a 
decisive role in both the initiation and maintenance o f the disease process. Reports 
published by workers form the laboratory o f Dayer have raised questions about the 
ability o f T cell populations to differentially regulate monocyte production of IL-lra 
and IL-lp. In the rheumatoid joint it has been shown that T cells and monocytes co- 
localise in areas o f the pannus where great tissue destruction is occurring (345). 
Tissue infiltrating T cells in rheumatoid synovitis, however, do not display functional 
activities typically associated with an antigen driven immune response. Although the 
majority o f the synovial T cells appear to be of the activated phenotype, as indicated 
by increased expression o f MHC class II antigens, only a few also express the CD25 
component o f the high affinity IL-2 receptor (230,492). Decreased proliferative 
responses have also been described in rheumatoid synovial T cells (493) an 
observation that has also been demonstrated within this thesis as a diminished 
response o f rheumatoid peripheral T cells to stimulation with the combination of 
anti-CD3 and CD80. Moreover, data on the detection o f T cell-derived cytokines in 
rheumatoid synovial fluid and tissues are somewhat controversial. At the level of 
mRNA detection T cell-derived cytokines have been described by several 
investigators but conclusive evidence of the significant expression o f cytokine 
protein by synovial T cells remains scarce (22,49,61,494-498). More recent data 
published by Steiner (1999) suggest that increased levels o f T cell-derived cytokine 
protein are measurable in both the synovial fluid and tissue o f rheumatoid patients 
compared to OA controls (499). These data complement cytokine secretion data from
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the early description o f rheumatoid synovial T cell clones in which a definite Thl 
skewing was seen (500,501). There are a great deal o f studies that have reported 
differential effects o f T cell cytokines on monocyte production o f IL -lp  and IL-lra. 
If  T cell-derived cytokines reach biologically significant levels in the synovium then 
the predominance o f Thl type cytokines may well influence monocyte cytokine 
production in favour o f IL -ip release.
The effect o f a predominantly Thl type T cell population in the synovium has been 
elegantly considered in preliminary studies by Chizzolini et al. (1997). Neglecting 
the importance o f secreted T cell-derived cytokines they have shown that Thl cells 
can preferentially induce IL -ip  release and Th2 cells can preferentially induce IL-lra 
release from monocytes via direct cell-cell contact alone (397). In these studies 
Chizzolini et al (1997) have shown that the ratio o f IL -lra to IL -ip  secretion from 
THP-1 cells induced by contact with Th2 clones was in the range o f 60:1 to 1000:1 
and that induced by stimulation with Thl clones was between 1:1 and 12:1. This T 
cell-derived membrane-bound signal to monocytes has been shown to involve T cell 
activation markers, adhesion molecules and to correlate with cell-surface expressed 
cytokines (354,366,368). To date, however, definitive data have not been published 
as to which T cell molecules are responsible for inducing monocyte cytokine 
secretion and more importantly how Thl and Th2 cell populations differentially 
regulate the production o f IL -ip  and IL-lra through membrane interactions alone.
Consequently, it was felt that further study o f the ability o f T cell-monocyte 
membrane interactions to induce differential production of IL -ip  and IL -lra could be 
particularly relevant to RA. It was hoped that with the clinical samples available in 
Bath the work o f Dayer’s group could be extended to study a co-culture model using 
rheumatoid and normal blood mononuclear cells. Looking at a co-culture model from 
two perspectives it would be possible to firstly study whether T cells from different 
patient groups could selectively regulate monocyte cytokine production and 
secondly, whether monocytes from different patient groups would respond 
differently to a control T cell stimulus.
Before a T cell/monocyte co-culture model could be established experimental 
conditions had to be defined for the production of IL -lp  and IL -lra from monocytes. 
The difference in the kinetics o f monocyte IL -ip  and IL -lra release in response to
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LPS and ouabain provoked further investigations into the time-course o f the 
synthesis o f these two proteins. In order to achieve such a study, different stimuli had 
to be selected that would efficiently induce the production o f both o f these cytokines 
from PBMCs or THP-1 cells. Based upon published work LPS and plastic-bound 
human IgG were utilised as suitable stimuli (502,103,229,503). Although LPS is not 
a factor that is considered relevant to RA it was used for its potent ability to induce 
IL -ip  production in monocytes. LPS is also known to stimulate IL -lra synthesis but 
there are less data reported that describe this function in normal human or rheumatoid 
PBMCs. In contrast, IgG was used for its potent ability to induce IL -lra release from 
human monocytes. Binding of monocytes to plastic-bound IgG may well represent a 
stimulus that is relevant to RA, as FcR aggregation o f a similar magnitude may be 
involved during clearance of immune complexes by monocytes. Using these two 
stimuli it was hoped that a model could be defined in which control production o f IL- 
lra  and IL -lp  could be monitored and the production o f these cytokines compared in 
different cell populations.
It was found that in the THP-1 cell line responses to LPS were dependent upon cell 
surface expression o f CD 14. In order to increase CD 14 expression THP-1 cells were 
differentiated with l,25(OH)2-vitamin D3. All subsequent experiments used 
differentiated THP-1 cells (D3 THP-1) so that LPS could be used as a positive 
control for inducing the production of IL -ip. In contrast, IgG responses and FcR 
expression were comparable between resting and differentiated THP-1 cells. CD32 
and CD64 but not CD 16 are expressed on THP-1 cells but expression is limited to 
only about 15-20% of the cell population.
In normal PBMCs, purified monocytes and D3 THP-1 cells stimulation with IgG 
resulted in a marked release o f IL -lra with very little effect on IL -lp  release. In 
contrast, LPS potently induced IL -lp synthesis whilst also inducing some IL -lra 
production. The ability o f LPS to induce IL-lra production, however, varied greatly 
between cell types and individual samples. In PBMCs and purified monocytes it was 
found that adherence to plastic was sufficient to induce a marked release o f IL-lra. 
Further stimulation o f adherent PBMCs or purified monocytes with LPS had variable 
effects upon IL -lra release depending upon the basal level o f IL -lra  release. In some 
patients LPS induced IL -lra release whilst in others LPS actually suppressed basal 
IL -lra release. The IL -lra promoter has been shown to contain three LPS response
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element sites that bind NF-kB (149), PU.l (34) and GABP (34). The crystal 
structures o f these transcription factors suggest that they will not bind together and 
will compete for occupancy (151-154). It is thus possible that LPS induced signals 
will inhibit adherence induced signals via competition for binding sites on the IL-lra 
promoter. In contrast, D3 THP-1 cells produced very little IL -lra in resting culture, 
perhaps as a result o f their inability to adhere to plastic. LPS stimulation o f D3 THP- 
1 cells produced a concentration dependent increase in IL -lra release. The kinetics of 
IL -ip  and IL -lra production was quite different regardless o f cell type or stimulus. 
IL -ip  was measurable much earlier than IL -lra and levels secreted reached a 
plateaux between twenty-four and forty-eight hours after stimulation. In contrast, the 
production o f IL -lra climbed steadily even after seventy-two hours o f culture. 
Consequently, a forty-eight hour time-point was used in all further experiments in 
order to be able to compare the levels of IL -lp  and IL -lra release. The main query 
with such an experimental design is that between cell stimulation and cytokine 
determination there is a large window for complications such as feedback regulation, 
which may not be stimulus-specific. For example the varying effects o f LPS on IL- 
lra  release seen in these studies and the delayed appearance o f IL -lra  might suggest 
that IL -lra production is induced by feedback effects o f LPS induced IL-ip. 
Considering this however, as the hope was to compare stimuli that are relevant to the 
setting o f the rheumatoid joint it was felt that such non-specific feedback 
mechanisms, which may be beyond basic experimental control, would not detract 
from the information obtained from these studies. If, for example, LPS induced IL- 
lra  was in fact an artefact o f feedback effects o f IL -lp  this would easily be 
confirmed using neutralising antibodies against IL-ip.
It has been demonstrated that for IL -lra to effectively inhibit the biological activity 
o f IL -lp  that a ratio o f IL -lra:IL -lp o f at least 100:1 needs to exist. Applying this 
criterion to these studies helps to highlight the biological significance o f the stimuli 
being studied. For example in resting (cultured on plastic) PBMCs and purified 
monocytes a ratio o f IL -lra:IL -lp o f 100:1 and 700:1 respectively is achieved after 
forty-eight hours o f culture. In both these cell types stimulation with LPS reduces 
this ratio to 4:1 indicating the probable physiological dominance o f IL -ip  under 
these conditions. In contrast, although stimulation with IgG was seen to induce IL -ip 
secretion the excess of IL -lra production maintains the ratio at 120:1 in PBMCs and
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250:1 in purified monocytes. Very similar results are seen in D3 THP-1 cells, with 
LPS and IgG stimulation inducing an IL -lra:IL -lp ratio o f 3:1 and 133:1 
respectively. Thus from these studies there is no evidence to support a pro- 
inflammatory role for stimulation o f monocytes through FcR aggregation, in terms of 
the balance between IL -ip  and IL-lra release, and there is no evidence that LPS 
induced secretion o f IL -lra will have biological significance.
The ability o f FcR aggregation to induce monocyte IL -lra production questions 
whether immune complexes are in fact a pro-inflammatory stimulus in RA. Larger 
immune complexes bind complement and perhaps this cascade is more important for 
inflammatory responses to immune complexes in RA. Monocytic binding and 
phagocytosis o f immune complexes via FcR interactions may well, however, involve 
the induction o f IL -lra release that protects the local environment from an 
inappropriate inflammatory response. Such a mechanism would allow the safe 
clearance o f immune complexes in the absence o f tissue damage.
9.1.3: T cell driven monocyte cytokine production
Having established control responses for the production o f IL -lp  and IL -lra from 
monocytes these studies were extended to examine the effects o f interactions with T 
cells on monocyte cytokine secretion. A similar model has already been described by 
Vey et al. (1992) using various T cell lines and THP-1 cells (352). The studies 
described here, however, were intended to extend the application o f such a model to 
the study o f clinical samples from RA patients. It was also felt that a co-culture 
model would be pertinent for the study o f an anti-rheumatic compound such as 
sulphasalazine (SPZ), which has significant but as yet undefined clinical efficacy. 
Consequently studies were aimed at showing whether the current monocytic cultures 
would produce IL -ip  and IL -lra in response to T cells, whether such a stimulus 
would selectively induce the production o f one o f these cytokines and whether the 
balance in the production o f IL-1 p and IL-lra would be influenced by SPZ.
Using fixed resting or PDBu/ionomycin activated J16 cells it was shown that direct 
cell-cell contact was sufficient to induce IL -ip  and IL -lra production from D3 THP- 
1 cells, PBMCs and purified monocytes. The ratio between IL -ip  and IL-lra 
production from all three o f the monocytic cell types studied varied depending upon
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the activation state o f the J16 cells. In D3 THP-1 cells, resting and activated J16 cells 
induced a significant release of IL -lra but only activated J16 cells had the ability to 
induce IL -lp  secretion. Comparing these effects in respect to the levels o f IL -lra to 
IL -ip  produced, a ratio o f 60:1 was observed when D3 THP-1 cells were stimulated 
with activated J16 cells. Thus it is apparent that even though activated J16 cells 
induce the secretion o f IL -ip  from D3 THP-1 cells the parallel release o f IL -lra is 
perhaps sufficient to counteract any biological effects o f such stimulation. In PBMCs 
and purified monocytes the results o f co-culture with J16 cells are somewhat 
complicated. Resting and activated J16 cells stimulated both IL -ip  and IL -lra from 
these cell types. Resting J16 cells induced a cytokine profile that favoured biological 
effects o f IL -lp  but activated J16 cells increased the ratio in favour o f IL-lra, 
especially in purified monocytes. Despite this slight variation in responsiveness to 
J16 cells, however, it was interesting to note that PBMC responses were broadly very 
similar to those o f purified monocytes. These results thus question the role of the 
autologous T cell population that is present in the PBMC preparation. In comparison 
to IgG and LPS induced monocyte responses it was found that activated J16 cells 
induced a similar cytokine profile to that o f IgG stimulation, with IL -lra  production 
being favoured over that of IL -ip  whereas LPS favoured the production o f IL-ip.
As D3 THP-1 cells secrete very low levels o f both IL -ip  and IL -lra under basal 
conditions they are an appropriate model monocyte for the determination o f stimuli 
that induce the production o f both IL-lra and IL-lp. It was found that the ability of 
J16 cells to induce cytokine release from the D3 THP-1 cells was strongly influenced 
by their activation state. J16 cells proliferate at very high rates under normal culture 
conditions and upon stimulation with phorbol ester + ionomycin or anti-CD3 + CD80 
are seen to stop multiplying. Consequently, the activation o f J16 cells was 
determined via surface staining o f activation markers. The ability o f J16 cells to 
induce cytokine production from D3 THP-1 cells was related to the level o f CD69 
expression. The ability o f activated peripheral blood T cells to induce D3 THP-1 IL- 
lra  release was also seen to correlate with CD69 expression. These data as well as 
reports in the literature that anti-CD69 neutralising antibodies could block T cell 
induced secretion o f cytokines from monocytes (354,366,368) prompted further 
investigations into the role o f CD69 in this model. As there is no evidence to identify 
the monocyte ligand for T cell expressed CD69 there were not many further
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experiments that could be conducted to see what the involvement o f CD69 was in the 
co-culture model. Neutralising antibody experiments were felt to have an element of 
doubt due to the fact that the binding o f an antibody molecule to the cell surface may 
also inhibit the interactions of neighbouring molecules. Also, in light o f the ability of 
FcR aggregation in monocytes to induce the production o f IL -lra it is possible that 
presenting the monocyte with an activated T cell, that is covered in anti-CD69 IgG, 
could itself induce activation. Consequently, CD69 was cloned and expressed in the 
COS cell line so that a positive response to CD69 could be looked for instead o f a 
tool to inhibit a response. Preliminary data from this work support a role for CD69 in 
stimulating monocyte production o f IL-1(3. The COS cells alone, however, induced 
the production o f both IL -lp  and IL-lra from D3 THP-1 cells suggesting that the 
monkey derived cell line may possess surface markers with significant homology to 
human adhesion molecules. In these studies, however, CD69 expressing COS cells 
induced greater IL -lp  secretion from D3 THP-1 cells and this reached significant 
levels when the D3 THP-1 cells were co-stimulated with LPS. These data do not 
prove that T cell CD69 is entirely responsible for the ability o f activated T cells to 
induce monocyte cytokine secretion but they do show a contributory role.
In a study using normal purified T cells that were activated, fixed and then re­
cultured with autologous purified monocytes, similar effects were seen to those 
studies using J16 cells. The ability of activated T cells to induce monocyte IL -ip  
production correlated with the ability o f the activation stimulus to induce T cell 
proliferation. Both resting and activated T cells, however were able to stimulate 
marked IL -lra release from monocytes but the differences were marginal. In fact, the 
release o f IL -lra from monocytes co-cultured with resting T cells was so high that 
significant effects o f any o f the activated T cell groups were hard to define. 
Interestingly, it has been suggested recently that rheumatoid synovial T cells that are 
anergic due to inappropriate antigen presentation in the synovium may have the 
capacity to modulate monocyte cytokine production despite their inability to 
proliferate (Panayi, personal communication). The data presented here, however, 
suggest that cells that proliferate in response to stimuli, in this case anti-CD3 and 
CD80, express a surface phenotype that can interact with monocytes and induce the 
secretion o f IL -ip  and IL-lra. Thus it is possible that the ability o f T cells to drive 
monocyte cytokine release is more closely related to the state o f cell activation and
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not necessarily their ability to proliferate. In their resting state fixed T cells induce a 
very high level o f IL -lra release from monocytes with very little IL -lp  release. Upon 
activation fixed T cells in this study did not develop the ability to significantly raise 
IL -ip  release in relation to IL -lra release. Consequently it may be surmised that 
factors other than membrane interactions alone are likely to be required for T cells to 
be able to induce a pro-inflammatory level o f IL -lp  secretion from monocytes in the 
rheumatoid synovium.
T cell-derived cytokines clearly have regulatory roles on the secretion o f IL -lp  and 
IL -lra from stimulated monocytes. As the detection o f significant levels o f T cell- 
derived cytokines in rheumatoid synovial fluid is not universally accepted the initial 
studies detailed here were based upon the reports o f T cell membrane-restricted 
stimulation o f monocytes (351,353,354,366,368,381). Consequently, all co-culture 
studies described so far have used fixed T cells or J16 cells to stimulate monocyte 
cytokine release. To investigate the contribution o f T cell-derived soluble factors in T 
cell stimulated monocyte cytokine release co-culture assays were established using 
unfixed cells. Unfixed resting J16 cells induced significantly less IL -lra release from 
D3 THP-1 cells than fixed J16 cells. In contrast, unfixed J16 cells induced 
significantly more IL -lp  release from D3 THP-1 cells than fixed J16 cells. 
Activation o f the J16 cells had no effect on their ability to modulate the balance 
between IL -lra and IL -lp  production from D3 THP-1 cells although the actual levels 
o f cytokine released increased. When J16 cells were used to stimulate cytokine 
release from PBMCs it was again found that unfixed J16 cells induced a much 
greater production o f IL -lp  than fixed J16 cells. The effect o f fixation on the ability 
o f J16 cells to induced IL -lra release from PBMCs was masked by the already very 
high basal release o f IL-lra. These data suggest that in this model J16 cell contact 
dependent stimuli preferentially induce IL-lra release from D3 THP-1 cells and 
soluble factors override this to favour IL -ip  release from both D3 THP-1 cells and 
PBMCs. Interestingly, the addition o f LPS to this system had profound synergistic 
effects on the ability o f J16 cells to induce IL -lp  secretion from D3 THP-1 cells and 
PBMCs. In particular, stimulation of D3 THP-1 with unfixed activated J16 cells 
markedly synergised with LPS to induce the secretion o f IL -lp. In contrast, the 
combination o f J16 cell and IgG stimulation only had an additive effect upon both 
IL -lra and IL -ip  production by D3 THP-1 cells. In PBMCs a similar degree o f
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synergy was seen when unfixed J16 cells and LPS were used in combination to 
stimulate IL -ip  release, although in this case the effect was not dependent upon 
activation o f the J16 cells. A very similar synergy was observed when activated 
peripheral T cells and LPS were used to stimulate IL -ip  production from D3 THP-1 
cells. In this case, however, the degree o f synergistic IL -lp  production induced was 
dependent upon the stage of T cell activation and the activating stimulus that had 
been used. In particular, T cells that had been activated with SEA for six to seven 
days consistently synergised most potently with LPS to induce IL -ip  secretion from 
D3 THP-1 cells. Based upon such low experimental numbers it is difficult to be sure 
o f this response. Also, there was no correlation with T cell surface marker expression 
suggesting the possibility that the synergy with LPS was due to a soluble factor. 
Further work is in progress to assess the ability of LPS to stimulate soluble mediator 
production from various T cell populations. This synergy between live unfixed T 
cells and LPS in stimulating IL -ip release from monocytic cells may not be 
immediately relevant to rheumatoid disease but it does highlight that multiple signals 
may converge on the monocyte to induce a marked shift in the balance between IL- 
lra  and IL -lp  secretion. Extrapolating these data, however, it might be possible that 
other mediators that are more relevant to RA, such as TNFa, may have the ability to 
synergise with T cell stimulation o f monocytes. From these data it is difficult to say 
whether the monocyte is synergistically responding to distinct signals, one from the 
LPS and one from the T cell membrane with or without a contribution from soluble 
mediators, or whether the LPS could be modulating the T cell directly. The effects of 
LPS on T cell responses are not well documented. Tennenberg and Wellers (1996), 
however, described the ability o f LPS to induce T cell IFNy production in the 
presence o f endothelium (504) and more recently Mattem et al have shown that LPS 
and its lipid A component are potent inducers o f T cell proliferation and o f Thl-type 
cytokine production (505). Further studies by Mattem et al have also shown that the 
ability o f LPS to drive T cell proliferation is dependent upon the presence of viable 
monocytes, is MHC unrestricted but is dependent upon CD80 co-stimulation (506). 
These reports suggest that the synergistic induction o f monocyte IL -lp  secretion 
might be due to reciprocal activation o f the T cells by LPS and monocyte contact. To 
test whether LPS alone might induce the production o f pro-inflammatory cytokines 
from activated J16 cells preliminary experiments have been carried out by
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transferring stimulated J16 supernatants to culture with purified monocytes (data not 
shown). It has been found that when activated J16 cells are stimulated with LPS they 
produce a soluble factor that induces monocyte IL -lp  secretion. The level of IL -lp 
secretion induced in monocytes by the conditioned J16 medium has been found to be 
markedly higher than that induced by the concentration o f LPS relevant to that 
carried over from the J16 culture.
Interestingly, sub-toxic concentrations o f ouabain were also able to synergise with 
unfixed J6 cell stimulation of IL -lp  production from PBMCs. Ouabain at 1-1 OnM 
had no effect on fixed J16 cell induced IL -ip  secretion from PBMCs. These data 
suggest that the ability o f ouabain to modulate T cell driven secretion o f IL -lp  from 
monocytes is dependent upon T cell viability. Whether this is due to the release o f a 
T cell factor in response to ouabain or the synergy between an already present T cell 
factor and the ability o f ouabain to modulate the activity o f ICE in monocytes 
remains to be determined. The ability o f ouabain to modulate T cell activation is a 
subject that has not been investigated here and is perhaps an important area that 
could bring together important features o f RA pathology. Oxidative damage of the 
Na+/K+ATPase in both synovial lymphocytes and monocytes may well contribute to 
the development o f a pro-inflammatory cytokine profile.
The identity o f a candidate T cell-derived factor whose production is induced by LPS 
remains to be determined. The report of LPS induced IFNy production from T cells 
(504), however, would fit with this model as EFNy has been shown to up-regulate 
LPS induced IL -ip  release from monocytes (349,507-509). IFNy has recently been 
shown to potently augment activation o f NF-kB in monocytes stimulated with LPS 
and to accelerate binding o f NF-kB to DNA (510). In this same study Held et al 
(1999) also showed that LPS enhances the activation o f signal-transducing activator 
o f transcription-1 (STAT1) induced by IFNy. These data show that in monocytes 
distinct stimuli may mutually potentiate their individual effects. Other possible T 
cell-derived soluble factor candidates include IL-17 and monocyte migration 
inhibitory factor (MIF). Both of these have been shown to induce monocyte IL -ip 
secretion alone or in combination with other stimuli (511,512). As LPS is a potent 
inducer o f MIF secretion from monocytes, and MIF plays an important role in T cell 
proliferation it is possible that the LPS induced proliferation o f T cells described by
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Matem et al. (1998) (506) might involve MIF secretion. Tetanus toxoid driven 
proliferation o f T cells in the presence of autologous monocytes has been shown to 
be inhibited by anti-MIF antibodies (513). Whether MIF is involved in the synergy 
between LPS and viable T cell-derived stimulation o f monocyte IL -ip  secretion 
remains to be determined. It is possible that MIF plays an important role in 
regulation o f both monocytes and T cells in the rheumatoid joint, however, as levels 
measured in synovial fluid o f RA patients are greatly elevated (514).
Taken together, the co-culture data shown here support a role for both T cell-derived 
soluble mediators and membrane bound molecules in the induction o f monocyte 
cytokine production in RA. The T cell dependence o f monocyte activation in the 
rheumatoid synovium has recently received further support from Klimiuk et al. 
(1999) (515). They have shown, using adoptive transfer or depletion o f T cells into 
rheumatoid synovial membrane engrafted NOD-SCDD mice, that the production of 
IL -ip , TNFa and MMPS is T cell dependent. In this thesis it has been shown that 
resting and activated J16 cells or blood T cells are capable of inducing production of 
IL -ip  and IL -lra from PBMCs, purified monocytes and D3 THP-1 cells. Questions 
still remain as to the specific interactions involved but despite this the T 
cell/monocyte co-culture model appears to be sufficiently well characterised for the 
study o f modulatory compounds or clinical samples. Unfortunately, due to time 
constraints this model was not used to investigate the ability o f rheumatoid T cells to 
induce D3 THP-1 cytokine production. It is felt, however that this would be a very 
fruitful study in which it would be possible to compare the ability o f peripheral and 
synovial T cells from various patient groups for their ability to induce changes in the 
balance o f IL -lra and IL -ip  production from D3 THP-1 cells. If  the data published 
by Chizzolini (1997) using T cell clones holds to be true then it would be expected 
that normal T cells o f the Thl phenotype would also favour the induction o f IL -ip 
secretion from D3 THP-1 cells. Comparing the clinical samples to normal healthy 
samples it would be interesting to see if  increased Thl-like activity could be 
demonstrated using monocyte cytokines as a measurable outcome. D3 THP-1 cell co­
culture may offer a convenient model to show whether the predominance o f Thl-like 
activity is confined to synovial T cells in RA thus backing up evidence o f Thl 
cytokine profiles in synovial fluid.
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The co-culture model was used, however, to study the ability o f sulphasalazine (SPZ) 
to modulate T cell driven cytokine production from monocytes. In these studies 
sulphasalazine and its major metabolites were assessed for their ability to modulate T 
cell proliferation and T cell activation marker expression. Also, the test compounds 
were assessed for their ability to modulate control monocyte responses to IgG and 
LPS. Finally, using the J16 cell line the test compounds were assessed for their 
ability to modulate fixed J16 cell induced IL -ip  and IL -lra secretion from D3 THP-1 
cells, normal PBMCs, chronic rheumatoid PBMCs and SPZ treated rheumatoid 
PBMCs. Neither SPZ or its major metabolites significantly modulated any of the 
responses measured in these studies. It became apparent, however, that the PBMCs 
from the SPZ patients showed a general profile of cytokine release in response to all 
stimuli tested in which they produced higher levels o f IL -lra and lower levels o f IL- 
lp  than any o f the other sample groups. Unfortunately this finding is as yet 
statistically insignificant but further studies are underway to improve these data. The 
possibility that SPZ is regulating patient PBMC cytokine secretion could be due to 
long-term protection o f monocytes from oxidative damage. SPZ has been shown to 
scavenge ROI produced by neutrophils, monocytes and macrophages (516). By 
protecting cells from oxidative damage SPZ may inhibit damage to surface proteins 
such as Katp or Na+/K+-ATPase. From the data presented here it can be surmised that 
protection o f monocyte Na+/K+-ATPase from ROI induced inhibition could regulate 
intracellular cation levels and subsequently attenuate IL -lp  secretion. As well as ROI 
scavenging SPZ has been shown to inhibit LPS induced IL -lp , IL-6 and TNFa from 
monocytes in vitro (517) and to also inhibit IL-2 secretion from human T cells 
(518,519) possibly via inhibition o f NF-kB (520). These data support the ability of 
SPZ to affect both T cell and monocyte responses and therefore support the use of the 
co-culture model for the analysis o f mechanisms o f action o f SPZ. In some of these 
reports, however, concentrations o f SPZ used far exceeded the mean therapeutic 
levels found in patient serum with levels that were between 50- and 100-fold higher 
being used. This fact, combined with the results presented here, suggest that although 
SPZ remains a drug with valuable clinical efficacy in RA it does not appear to be 
able to modulate monocyte cytokine release in short term in vitro assays. The much 
more promising data, which is as yet still statistically insignificant, is that long-term 
treatment with SPZ may well modulate monocyte cytokine production in such a way 
as to favour IL -lra production above that of IL -ip. The mechanism by which SPZ
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might be able modulate monocyte cytokine production remains to be determined. In 
studies by Vey et al (1997) the induction o f IL -ip  and IL -lra  secretion in THP-1 
cells was shown to be differentially regulated by the serine/threonine phosphatase 
inhibitor okadaic acid (381). Inhibition o f serine/threonine phosphatases was shown 
to have no effect on basal release o f IL -ip  and IL -lra but was shown to up-regulate 
IL -ip  secretion from T cell stimulated THP-1 cells. In the preliminary studies 
detailed here it has also been shown that PI3-K may play an important role in IL-lra 
production but not IL -lp  production by PBMCs and D3 THP-1 cells in response to 
stimulation with LPS, IgG or activated T cells. The selective PI3-K inhibitor LY 
294002 was shown to potently inhibit IL -lra secretion from monocytic cells but had 
no effect on IL -ip  secretion in response to any stimuli studied. Although 
preliminary, these data suggest an important role for PI3-K in the regulation of IL- 
lra  release from both resting and stimulated monocytes. Whether SPZ could 
potentiate signalling through PI3-K or serine/threonine phosphatases remains to be 
determined.
9.2: SUMMARY AND CONCLUSIONS
The studies o f this thesis have shown that the production o f cytokines from 
monocytes, particularly IL -lp  and IL-lra are differentially sensitive to stimuli such 
as LPS, IgG, T cells and cation modulation. Inhibition o f the Na+/K+-ATPase, which 
in the synovium may be due to oxidative damage, has been shown to greatly 
contribute to the generation o f a pro-inflammatory cytokine profile from stimulated 
monocytic cells. The specific Na+/K+-ATPase inhibitor ouabain has been shown to 
increase IL -lp  processing in monocytes stimulated with LPS, or viable activated T 
cells, and to concurrently down-regulate IL -lra production. The differential response 
o f normal, early rheumatoid and chronic rheumatoid patient PBMCs to stimulation 
with ouabain alone may simply reflect increased processing o f an already present 
pool o f proIL-lp rather than differential sensitivities to ouabain. The mechanism of 
action o f ouabain in these models may well involve increased activation o f ICE due 
to K+ efflux and indeed it has been shown that increased concentrations o f ouabain 
induce a toxic reaction in monocytes that may well involve activation o f ICE-like 
caspases.
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The ability o f T cells to regulate production o f IL -lp  and IL -lra from neighbouring 
monocytes may be an important mechanism in the pathogenesis o f RA. The studies 
here have shown the successful development o f a co-culture model in which to assess 
the contribution o f different T cell populations to monocyte cytokine production. 
This model will allow improved study o f different patient T cell and monocyte 
responses and will be ideal for the study of potential anti-inflammatory compounds. 
The ability o f monocytes to secrete IL -lra under resting conditions highlights the 
regulatory role o f this cytokine in the prevention o f an inflammatory reaction. The 
models studied here have shown that fixed T cells were able to induce the secretion 
o f both IL -ip  and IL -lra from resting monocytes, perhaps due to surface CD69 
expression, but that the balance in cytokine production was not consistently driven in 
a pro- or anti-inflammatory direction. Stimulating the monocytes with viable T cells, 
LPS or a combination o f both, however, resulted in a marked swing in the balance of 
cytokine production to favour biological effects o f IL -lp. From these data it can thus 
be concluded that T cell membrane derived signals are involved in the induction of 
monocyte cytokine secretion but that soluble factors are critical to the development 
o f a pro-inflammatory response.
9.3: FUTURE WORK
The studies detailed here have asked almost as many questions as they have 
answered. As a result there are many avenues o f investigation that are now open for 
continued study. Looking back on the Na+/K+ATPase studies in light o f the more 
recent data published on the involvement of Caspase-1 (ICE) in both apoptosis and 
necrosis it would be interesting to pursue a more detailed study o f the ability of 
ouabain to induce apoptosis. I f  indeed early death o f monocytes occurs in the 
rheumatoid joint and involves K+ regulation of Caspase-1 then oxidative damage of 
ion channels or Na7K+ATPase may well be critical events in the pathogenesis o f RA. 
Similarly the presence o f endogenous ouabain in synovial fluid might play a role in 
inducing death o f monocytes and inducing a pro-inflammatory balance in the 
production o f IL -ip  and IL-lra.
The development o f the T cell/monocyte co-culture model that has been established 
here also opens many opportunities for further studies. O f immediate interest would
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be the comparison o f rheumatoid synovial and peripheral T cells for their ability to 
induce D3 THP-1 cytokine secretion. Combined with this there is a great need to 
further investigate whether membrane molecules and surface bound cytokines or T 
cell-derived soluble factors are capable of selectively inducing the production o f IL- 
lp  or IL-lra.
Also, the promising data on the ability o f SPZ treatment to favour monocyte 
production o f IL -lra above that of EL-lp needs to be clarified for publication.
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APPENDIX 1
APPENDIX 1
GROWTH MEDIUM, BUFFERS AND SOLUTIONS 
1: Dulbeccofs Minimal Essential Medium (DMEM) 
1.1: Glutamine free DMEM for CHO Cells
DMEM (IX)
FCS
Penicillin (1000IU/ml)/ Streptomycin (lOOOpg/ml)
Nucleosides (100X)




1.2: DMEM for COS Cells
DMEM was prepared as above with the addition of 5ml L-glutamine (200mM stock).
1.3: DMEM for Murine Patellae culture
DMEM was prepared as above except 0.1% BSA (w/v) was used instead of FCS. 
1.85 MBq 35S [NajSOJ (Amersham, UK) was added for the last three hours of 
culture.





Penicillin (1000IU/ml)/ Streptomycin (lOOOpg/ml)
Sodium Bicarbonate (7.5% w/v)
Glutamine (200mM)
Sodium hydroxide (10M)
3: Phosphate Buffered Saline (PBS)























0.1M bicarbonate, pH9.6 
1% BSA, 5% sucrose in PBS, pH7.4 
0.05% Tween 20 in PBS, pH7.4
0.05% Tween 20, 0.1%BSA in Tris Saline pH7.3 (20mM 
Trizma base,150mM NaCl)
0.5M H2S 0 4
5: ATPase Assay Cocktail
The assay cocktail was composed o f the following components, dissolved in milli-Q 
water and pH adjusted to 7.4:
NaCl 100 mM
KC1 20 mM
M gS04 4.5 mM
EGTA 5 mM
N a ^ T P  3 mM
PEP 1.2 mM
Trimethylamino-ethanesulphonic acid-Tris buffer (TES) 40 mM
6: Cell Lysis Buffer





To this stock the following were added on the day o f use:
DTT
PMSF








1:1000 o f stock (1 mg/ml) 
1:1000 o f stock (5mg/ml)
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